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Abstract 
Introduction. The precise aetiology of autism is unclear, however recent 
studies link autism with gastrointestinal (GI) dysfunction. Although there is no 
specific treatment, the potential to ameliorate the behavioural and GI 
problems of autistic children is of interest. This study aimed to evaluate 
inflammatory markers in faecal samples taken from autistic children with GI 
dysfunction before, during and after visceral osteopathic techniques (VOT), 
and to link these findings with contemporaneous questionnaires. These data 
assessed whether GI status could be reliably determined from a single 
sample, whether VOT affected behaviour and clinical signs, and whether 
there was any association between biochemical markers and the 
questionnaire. Methods. Faecal samples were analysed for three biochemical 
markers, calprotectin, M2-pyruvate kinase and lactoferrin. Forty nine children, 
between 3½ and 8 years old, and independently diagnosed as autistic by 
specialist professionals were recruited. Questionnaires using a 10 point Likert 
scale assessed behavioural parameters and clinical signs throughout the 18 
week study period, before, during and after VOT. Results. Due to intra-
individual biological variability, analysis of single faecal samples over time did 
not give a consistent readout of marker levels. The questionnaire showed 
significant improvement in symptoms and behaviour during treatment, 
specifically, reduction in vomiting (p<0.001), and poor appetite (p<0.05), and 
an increase in eye contact (p<0.05). Analysis of an inflammatory marker, 
together with the questionnaire, showed a highly significant association of 
‘need for a fixed routine’ (p<0.0001) and ‘constipation’ (p<0.02) parameters 
with calprotectin, and showing multivariate coefficients of 3.227 and -1.584 
respectively. Discussion and Conclusion. VOT ameliorates GI symptoms in 
these autistic children and a standardised questionnaire could include ‘need 
for a fixed routine’ and ‘constipation’ as independent predictors of their bowel 
dysfunction. This study uniquely used biochemical markers to assess 
symptomatic changes before, during and after VOT. 
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Chapter 1 - Introduction 
1.1 Autism 
Autism is a multifactorial condition with unclear aetiology and no specific 
treatment. Studies have been undertaken regarding a possible link between 
autistic behavioural dysfunction and gastrointestinal (GI) signs and symptoms. 
Some studies claim that there is a possible gut-brain axis, where the 
worsening of behavioural symptoms may possibly be due to inflammatory gut 
reactions meditated by immunological signals (Jyonouchi et al., 2005a, 
Reichelt and Knivsberg, 2009, Forsythe et al., 2010). 
Over the past 15 years an increased awareness has developed amongst 
researchers of the number of children with autism suffering from GI 
symptoms. According to Horvath et al. (1999), children with autism often 
suffer from  reflux oesophagitis (69%), chronic gastritis (42%) and chronic 
duodenitis (67%). A recent study suggests that intestinal biopsies from autistic 
children with GI symptoms display a characteristic genetic profile distinct from 
that of control, non-autistic children with similar symptoms (Walker et al., 
2013). Nikolov et al. (2009) reported a link between the worsening of 
behavioural symptoms and GI signs and symptoms, specifically diarrhoea and 
constipation. The same study also reported that autistic children suffering 
from GI problems had a tendency to present with higher levels of irritability 
and anxiety, and were more socially withdrawn compared with children with 
autism who had no GI symptoms (Nikolov et al., 2009). A consensus 
paediatric report undertaken by the Paediatric Gastrointestinal Unit in Boston, 
USA, concluded that the behaviour of children with autism may have an 
underlying medical condition, which may be GI in nature (Buie et al., 2010). 
Currently, studies suggest that the management of GI symptoms have the 
potential to assist with some of the behavioural symptoms seen in children 
with autism (Buie et al., 2010). However, there remains a lack of satisfactory 
low-invasive treatment that could potentially ameliorate the challenging 
behaviour and GI signs and symptoms of children with autism (Furuta et al., 
2012).  
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The current research aimed to investigate the effects of visceral osteopathic 
techniques VOT, a low-invasive method of manipulative treatment, on the GI 
and behavioural signs and symptoms of children with autism. GI signs and 
symptoms, such as constipation, diarrhoea, bloating, abdominal pain, poor 
appetite, flatulence and vomiting, and behavioural patterns typical in children 
with autism, were assessed before, during and after VOT treatment via 
questionnaires and the analysis of three biochemical markers.  
The rationale for the use of VOT on the abdominal area of autistic children 
suffering from GI complaints was based on evidence, new at the time of the 
start of this study, linking the amelioration of behavioural patterns in children 
with autism after medical intervention for their GI dysfunction (Horvath, 2000, 
Horvath and Perman, 2002, Buie et al., 2010, Furuta et al., 2012). Exploration 
of the use of standardised VOT on the abdominal area of autistic children 
suffering from GI problems coupled with analysis of the behavioural and GI 
signs and symptoms before, during and after its application is a novel 
approach to this problem.  
The first attempt to study the effects of VOT on GI and behavioural signs and 
symptoms of autistic children dates back to 2002 when a pilot study, by the 
same author, was performed on 13 autistic children suffering from GI 
dysfunction (Bramati-Castellarin and Janossa, 2002). The concept of the pilot 
study was developed from a lack of alternative or complementary 
interventions available focusing on the GI dysfunction of autistic children.  
Historically, positive results have been associated with application of VOT to 
the abdominal area of subjects with GI dysfunction (Ernst, 1999, Finet and 
Williame, 2000, Lamas et al., 2009, Attali et al., 2013). However, VOT has 
never before been applied specifically to autistic children. The subjects who 
participated in the pilot study in 2002 were selected from special schools for 
autistic children. All subjects were treated using VOT and a modified Secretin 
Outcome Survey (S.0.S) questionnaire was used to measure possible 
changes in the GI signs and symptoms and behavioural patterns of the 
selected children. The results of the pilot study suggested positive GI and 
behavioural responses after application of VOT. These positive results led the 
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author to develop this pilot protocol, introducing biochemical markers in an 
attempt to quantify any changes experienced by the patients.  
1.2 History of Autism  
Autism was first described in 1943 by Dr Leo Kanner, an American child 
psychiatrist at Johns Hopkins University (Kanner, 1943, Aarons and Gittens, 
1999). He employed the Greek word ‘autos’, meaning ‘self’, to describe the 
condition, which is marked by children being engrossed within their own world 
(Kanner, 1943). Later, Kanner and Eisenberg (1957), in an attempt to clearly 
define the condition, included a number of behavioural features which remain 
relevant today since they describe the condition in its classic form Table 1-1 
lists the behavioural features observed by Kanner when Autism was first 
described.  
Table 1-1: Kanner’s Classical Behavioural Features of Autism.  
 
Inability to develop relationships 
Delay in the acquisition of language 
Non-communicative use of spoken language, after it develops 
Delay echolalia - the repetition of words and phrases 
Pronominal reversal - a child rarely uses the pronoun ‘I’ 
Repetitive and stereotyped play 
Maintenance of sameness 
Good rote memory - autistic children may show remarkable feats of memory  
and rote learning 
Normal physical appearance 
(Compiled from Kanner (1943)) 
An epidemiological study undertaken in 1993 by Wing suggested that the core 
deficit in autism is social in nature (Wing, 1993b). This study indicated that the 
difference between an autistic child and another with learning impairment is 
that autistic individuals have an observable social impairment. The study also 
suggested that there is no clearly defined limit to the disorder. Consequently, 
clinicians may encounter individuals who do not conform to the classical 
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description of autism as described by Kanner (Wing, 1993b). Wing highlighted 
three areas of social difficulty that an autistic individual may display, and 
described these as forming ‘the triad of impairments of social interaction’ 
which she divided into three areas: relationships, communication and 





                      
Figure 1-1: The triad of impairment of social interaction 
Since autism was first described, researchers have tried to establish criteria 
with which to clearly diagnose the condition. The original diagnostic criteria 
were based on the nine requisite points defined by Kanner (see Table 1-1). If 
a child presented with only eight out of these nine requisite features, then 
he/she would not be diagnosed as autistic (Kanner, 1943, Aarons and Gittens, 
1999). 
1.3 Current Classification and Definition 
Autism or autism spectrum disorder (ASD) is classified as a pervasive 
developmental disorder (PDD), with abnormal or impaired development in 
reciprocal social interactions, abnormal or impaired social communication, 
and social imagination (Wing, 1993a, Aarons and Gittens, 1999). This 
classification is utilised in both the Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition (DSM –IV) and the International Statistical of Diseases 
and Related Health Problems, 10th edition (ICD-10), that describe the 
international standardised classifications for psychiatric diseases and 






Both classifications define autism as a PDD and not a ‘child schizophrenia or 
psychosis’ as suggested in the past (Treffert, 1970). These classifications are 
used as a diagnostic tool, yet they do not explain either the causes or the true 
nature of the disorder neither of which are clearly understood.  
Researchers use DSM IV and the ICD10 as criteria to classify autistic 
individuals who possess a deficit in verbal communication and non-verbal 
behaviour, such as eye contact, facial expression, body posture and gestures, 
thereby making general and sustained social interaction difficult. Individuals 
who have verbal skills may lack the ability to initiate or sustain a conversation 
with others (Wing and Wing, 1971, Wing, 1993a, Waterhouse et al., 1996, 
Aarons and Gittens, 1999, Kent et al., 2013). Speech may present with 
echolalia, the repetitive use of language regardless of meaning, as well as 
abnormal pitch, intonation, rate and rhythm. Older children or adults, who 
have gained some interpersonal interactions, may still show a disturbance in 
their comprehension of language, and demonstrate an inability to understand 
questions, directions or jokes (Wing, 1998). 
Imaginative play is often absent and a child will not engage in games or 
routines of early childhood (Wing, 1993b) but instead may perform repetitive 
mimicking actions, for example by copying the actions of television 
commercials and repeating them over and over again. Individuals may insist 
on following a specific routine or sequence and show resistance or distress 
over trivial changes to this routine. Autistic individuals present with a failure to 
develop relationships, and have little or no interest in establishing friendships 
(American Psychiatric Association, 1994), indeed they may show a lack of 
emotion and reciprocity, and therefore, an individual with this disorder may not 
notice another person’s distress (Wing, 1993b). 
Individuals typically demonstrate restricted, repetitive and stereotyped 
patterns of behaviour, interest and activity, and repetitive motor mannerisms 
are characteristically present (e.g. clapping of hands, finger flicking or rocking, 
dipping and swaying the whole body) (Wing, 1993b). Similarly, they may show 
a fascination for spinning objects, opening and closing doors, or they may 
become fixated on some inanimate object. Relatively normal development is 
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sometimes reported during the first two years of life, although parents of 
autistic children usually report regression in language development after the 
child has acquired five to ten words (Wing, 1993b). 
1.4 Diagnosis  
No single test has been developed that clearly diagnoses autism, thus a gold 
standard for diagnosis is yet to emerge (Matson et al., 2012). Currently, the 
diagnosis of an ASD is determined via a series of parental interviews and 
diagnostic observation scales, following the DSM-IV and ICD-10 diagnostic 
criteria (American Psychiatric Association, 2000, World Health Organization, 
2004). 
The observational schedule and structured interview currently used are the 
Autism Diagnostic Schedule (ADOS) and the Autism Diagnostic Interview 
Revised (ADI-R) respectively, the latter being a complement to ADOS (Le 
Couteur et al., 1989, Lord et al., 1994, Lord et al., 2000, Gotham et al., 2007, 
Luyster et al., 2009). Both instruments are used to recognise patterns of 
behaviour present early in life, usually before the age of 36 months. 
A revised diagnostic description of autism and autism-related disorders, 
encompassing them under a single umbrella description, was published in 
May 2013 (American Psychiatric Association, 2013). This revised version 
replaces the DSM-IV. According to the American Psychiatric Association, the 
classification of mental disorders, and also of autism, have been modified 
(American Psychiatric Association, 2013), and the new criteria employed will 
create a better link between DSM-5 and the ICD. ICD-10 is currently in the 
process of being revised and the 11th edition has a provisional publication 
date of sometime in 2014. According to Swedo et al. (2012), classifying 
autism as a neurodevelopmental disorder may encourage earlier diagnosis; 
however, other studies disagree with this change in classification. McPartland 
et al. (2012) suggested that the specificity of the new diagnostic criteria for 
ASDs, at 60%, is quite high, whilst the sensitivity of the new diagnostic criteria 
for ASD subgroups, such as Asperger’s and PDDs not otherwise specified 
(PDD-NOS), and cognitive ability is very low, raising questions concerning the 
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validity of the new ASD classification by the scientific community (McPartland 
et al., 2012). Swedo et al. (2012) were highly critical of the comments made 
by McPartland et al. (2012), and the Neurodevelopmental Work Group 
supports the decision to alter the diagnostic checklist in the latest edition of 
the DSM (Swedo et al., 2012). At present, there is a lack of research using the 
new diagnostic criteria and therefore it is not yet possible to draw a conclusion 
on its validity. 
Although the American Psychiatric Association has announced changes in the 
classification of PDDs, the current study used the DSM-IV and ICD-10 as the 
standard for the classification of diseases as these were in use at the time the 
study was designed and the data collected.  
1.5  Current treatment and/or Management of Autistic 
Symptoms 
As yet, there is no defined protocol in place for treatment and/or management 
of autism. However, in 2014, NICE released the quality standard 51 (NICE, 
2014), an updated quality standard recommendation for the assessment, 
diagnosis and treatment of children, young people and adults diagnosed as 
autistic. The document follows the criteria of the Autism Act released in 2009 
which requires that each local authority in England and Wales creates 
provision in health and social care for individuals diagnosed as autistic (NICE, 
2014).  
NICE (2014) quality standard 51 recommends that individuals diagnosed as 
autistic should receive personalised care developed and implemented by the 
individual’s carer, their family, and the autism team. The needs of autistic 
individuals vary according to where they fall within the autistic spectrum. 
Some individuals require a wider range of support than others. Hence, quality 
standard 51 was developed to ensure the best outcome possible for 
individuals diagnosed as autistic, based on their personal needs. 
Over the past 15 years, the increased awareness of and research into autism 
has helped broaden the intervention modalities to help with managing 
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symptoms associated with the condition. However, there is not yet a cure and 
no specific treatment developed for autism. At the present time, there is little 
empirical evidence to support the effectiveness of any treatments and/or 
management modalities used to help minimise the symptoms of autism.  
1.5.1  The Current Approach to Treatment of Autism 
Psychological interventions are usually implemented in a variety of settings. 
Some children have intervention in educational settings where behavioural 
therapy aims to implement strategies of socialisation and integration as well 
as focusing interpersonal skill development, acquisition of language, play and 
other skills (Hess et al., 2008). 
The private sector also offers group and individual treatment programmes for 
autistic children where positive reinforcement is used to promote attention and 
behavioural imitation especially in non-verbal autistic individuals (Levy et al., 
2009). 
According to Ingersoll et al. (2007), parental mediated interventions have also 
demonstrated to be an important aspect of behaviour management. It is 
suggested that parents become positive collaborators in the intervention as 
long as they learn how to apply the method suggested to their autistic child. 
1.5.1.1 Behavioural Intervention Methods  
The Early Start Denver Model (ESDM) (Rogers et al., 2003, Rogers et al., 
2006, Rodger et al., 2010) is an early intervention approach for children age 
12 months to 48 months of age. This intervention has been developed 
specially for young children, toddlers and preschool autistic children and aims 
to focus on individual profiles of strengths and weaknesses and on play-based 
routines to improve parent-child and teacher-child relationships as well as 
language (Rogers et al., 2006, Dawson et al., 2010). The ESDM model has 
been shown to have positive results in ASD children after 12 months of 15-25 
hours of therapy weekly (Vivanti et al., 2014). Dawson et al. (2010) also 
suggests a significant improvement in cognition, language skills and adaptive 
abilities in autistic children after ESDM intervention. 
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Applied Behaviour Analysis (ABA) (Foxx, 2008) is another type of behavioural 
intervention that uses positive reinforcement, such as a reward, as a tool to 
aid behavioural changes. ABA can be applied in different settings such as 
schools and everyday situations (Foxx, 2008, Mohammadzaheri et al., 2014). 
Mohammadzaheri et al. (2014) compared the effects of ABA and Pivotal 
Response Treatment (PRT) and suggested that PRT is more effective in 
improving social communication. PRT is a behaviour intervention similar to 
ABA therapy; however it uses preferred toys and activities as stimuli rather 
than the artificial stimuli such as cards that are used in ABA. 
Mohammadzaheri et al. (2014) suggests that the use of natural stimuli, 
creating a more interesting teaching environment, may possibly be the reason 
why PRT is more effective than ABA. Treatment and Education of Autistic and 
Communication Handicapped Children (TEACCH) (Schopler, 1994, Panerai 
et al., 2002) recognises autism as a lifelong condition. It aims to help 
individuals with autism to live a more independent life, focusing on an 
individual’s strengths and abilities (Schopler, 1994, Panerai et al., 2002). 
1.5.1.2 Occupational Therapy 
The objective of occupational therapy for autistic individuals is the same as for 
any other patient who needs help in performing daily tasks and personal care. 
The treatment is patient centred and varies according to their needs but is 
usually focussed on enhancing sensory processing issues, behaviour and 
motor coordination (Rodger et al., 2010, Ashburner et al., 2013, Ashburner et 
al., 2014).  
1.5.1.3 Medication 
Medication may be prescribed to autistic individuals either to address co-
morbid symptoms such as attention-deficit-hyperactive disorder, and including 
anxiety and depression or as an adjunct to educational, behavioural and 
developmental treatments. Recently ‘Risperidone’ and ‘Aripiprazole’, both 
antipsychotic antidepressant drugs approved by the U.S. Food and Drug 
Administration, have been used in the treatment of irritability in ASD patients 
(Jesner et al., 2007, Robb et al., 2011). However, as irritability is not a core 
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symptom of autism, researchers have not yet come into a consensus with 
regard to the effectiveness of these drugs (Jesner et al., 2007, Robb et al., 
2011, Rossignol and Frye, 2014). Other medical symptoms experienced by 
ASD children such as seizures and tics are usually treated with appropriate 
medication.  
1.5.2 Complementary and Alternative Approaches to Treating Autism  
According to Hanson et al. (2007), parents often use complementary and 
alternative medicine (CAM) to treat autistic symptoms because of concerns 
about the safety and efficacy of the standard prescription medicines; even 
though medication has only a minor role in the treatment of autism (Wong and 
Smith, 2006).  
Wong and Smith (2006), investigated the use of CAM therapy in autistic 
children as compared with typical unaffected developing children. The study 
found that 52% (p=0.024) of the parents of autistic children reported using, or 
had used, at least one CAM therapy. Parents of autistic children use CAM 
therapy to treat a variety of symptoms such as: general symptoms (35%), 
concentration or attention (19%), relaxation (23%), GI problems (15%), sleep 
disorders (12%), communication/speech (12%), tactile sensitivity (4%), and 
also to maintain general health (8%) (Wong et al., 2006). 
CAM therapies encompass a wide range of philosophies and beliefs. The 
National Centre for Complementary and Alternative Medicine (NCCAM) 
defines CAM as ‘a group of diverse medical and health care system practices 
and products that are not presently to be part of ‘conventional medicine’. 
NCCAM divided CAM therapies according to the following categories: 
alternative medical systems (e.g. acupuncture), biological based therapies 
(e.g. diets), manipulative and body based therapies (e.g. osteopathy and 
chiropractic) (Wong et al., 2006, Hanson et al., 2007). Examples of these 
therapies employed during management of ASD are given below. 
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1.5.2.1 Acupuncture  
Acupuncture has been reported to be effective on some of the symptoms of 
ASD. Acupuncture may influence the neuroplasticity of the brain and thereby 
have a therapeutic role (Hong et al., 2014, Li et al., 2014). 
According to Wong (2010) acupuncture to the tongue may improve language, 
social communication and cognition in autistic children after one or two 
courses of treatment. The same author suggests that electro-acupuncture 
also has a beneficial effect on autistic symptoms (Wong et al., 2014). 
However, there is no consensus as to the effects of such therapy on autism; 
necessitating the need for more controlled trials.  
1.5.2.2 Massage and/or Touch Therapy 
A typical symptom experienced by autistic children is sensory hypersensitivity. 
Silva et al. (2007) showed improvement in social skills in 13 autistic children 
of 3-6 years old through following a series of Qigong massage treatments.  
Silva and Schalock (2013) also demonstrated that tactile sensitivity improved 
after a series of Qigong massage treatments and Cullen et al. (2005) 
demonstrated that touch therapy improved the ability of autistic children to 
accept touch.  
To date, there are no published research papers regarding the effects of other 
manipulative CAM therapies such as osteopathy and chiropractic on the 
management of autism.  
1.5.2.3 Diet 
ASD children may have feeding difficulties and/or may be very selective when 
choosing what to eat; raising concerns with parents (Williams and Seiverling, 
2014). Food allergy and/or sensitivity may be a contributory cause of this food 
selectivity or avoidance (Shattock and Whiteley, 2002, Shattock et al., 2004).  
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According to several studies (Elder et al., 2006, Alpert, 2007, Elder, 2008, 
Hsu et al., 2009, Pennesi and Klein, 2012), a gluten/casein free diet may 
improve some of the core symptoms of autism. 
1.5.2.4 Hyperbaric Oxygen Chamber - Non CAM Therapy  
A randomized double-blind controlled trial has been conducted (Rossignol, 
2007, Rossignol et al., 2007), and confirmed the positive effects on autistic 
individuals of hyperbaric oxygen therapy previously reported in anecdotal 
studies and in studies without adequate controls.  
Rossignol et al. (2009) also suggests that 40 sessions of oxygen treatment in 
a hyperbaric chamber results in the amelioration of receptive language, eye 
contact and sensory cognitive awareness. Even though the results of the 
studies are promising, more randomized controlled trials should be performed 
to validate the effectiveness of this therapy.  
The NCCAM do not accept hyperbaric oxygen chamber therapy as part of 
CAM, even though parents refer to it anecdotally as an alternative or 
complementary therapy.  
1.6 Gastrointestinal Problems in Autistic Children Compared 
with Unaffected Developing Children 
A recent research paper compared the frequency of GI problems between 
autistic children, children with developmental delay and typically developing 
children (n=960) (Chaidez et al., 2014). The research suggests that there is a 
higher frequency of GI symptoms in autistic children and developmentally 
delayed children, compared with unaffected developing children (Chaidez et 
al., 2014). The research also suggested a correlation between frequency of GI 
symptoms and maladaptive behaviour. The lack of research on the frequency 
of GI symptoms in typical developing children was also highlighted by 
Chaidez et al. (2014) 
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A national health survey performed between 2006 and 2010 by the Center for 
Disease Control and Prevention in the United States concluded that children 
with learning disability (LD) had a higher prevalence of medical conditions 
compared with children without LD (Schieve et al., 2012). The LD population 
included both autistic children and children with concurrent medical 
conditions, such as GI problems. The study concluded that children with 
autism were 70% more likely to suffer from colitis/diarrhoea compared with 
the intellectual disability group, twice as likely to suffer from GI dysfunction 
than the attention deficit hyperactivity disorder (ADHD) group and seven times 
more likely to experience GI dysfunction compared with typical developing 
children (Schieve et al., 2012).  
1.6.1 General Paediatric Population: Guidelines for Management of 
Commonly Encountered Gastrointestinal Symptoms  
GI symptoms can be distressing for both children and parents, resulting in 
anxiety and inability to cope with everyday tasks. 
The American Academy of Paediatrics (AAP), NICE, the North American 
Society for Pediatric Gastroenterology, Hepatology and Nutrition and the 
British Society of Gastroenterology have formulated guidelines for 
management of paediatric GI symptoms. The guidelines attempted to clarify 
common misconceptions, inadequate knowledge or insufficient knowledge 
amongst professionals. The recommendations formulated to date have been 
based on individual GI symptoms such as abdominal pain, chronic 
constipation, acute diarrhoea and oesophageal reflux (American Academy of 
Pediatrics Subcommittee on Chronic Abdominal Pain, 2005, The British 
Society of Gastroenterology, 2005, NICE, 2010, NICE, 2014).  
1.6.1.1 Abdominal Pain 
The American Academy of Pediatrics Subcommittee on Chronic Abdominal 
Pain (2005) state that:  
‘In clinical practice, it is generally believed that pain that exceeds 1 or 2 
months in duration can be considered chronic’.  
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Although abdominal pain may be distressing for the child and the parents, it is 
usually benign in nature. According to the AAP, most children displaying 
abdominal pain suffer from functional abnormalities in the enteric nervous 
system (ENS) also known as 'gut brain' (American Academy of Pediatrics 
Subcommittee on Chronic Abdominal Pain, 2005, Forsythe et al., 2010). ENS 
interacts with the central nervous system (CNS) in a bidirectional fashion and 
regulatory loss of this circuit plays an important role in the pathogenesis of the 
abdominal pain (Forsythe et al., 2010). Research suggests that abdominal 
hyperalgesia may be the result of changes in the intraluminal pressure, as 
well as to inflammatory processes in the gut that may cause sensitization of 
the afferent nervous system (Mertz, 2002, American Academy of Pediatrics 
Subcommittee on Chronic Abdominal Pain, 2005, Jyonouchi et al., 2005b). 
In the opinion of AAP the most common cause of chronic abdominal pain is 
functional in nature (American Academy of Pediatrics Subcommittee on 
Chronic Abdominal Pain, 2005). Pain can be categorized as functional 
dyspepsia, irritable bowel syndrome, abdominal migraine or functional 
abdominal pain syndrome. Treatment is recommended to attempt to establish 
normal gut function. Medications such as antispasmodic agents, smooth 
muscle relaxants and laxatives may be prescribed for a short period of time 
and the effect on the pain monitored. According to AAP (2005), parental 
education and stress reduction play an important role in the treatment of 
functional abdominal pain (American Academy of Pediatrics Subcommittee on 
Chronic Abdominal Pain, 2005). 
1.6.1.2 Chronic Constipation  
The diagnosis of constipation in the general paediatric population is based on 
clinical signs and symptoms and is defined as a delay or difficulty in 
defecation, present for more than two weeks. Constipation is a common 
childhood problem and the prevalence is dependent upon the diagnostic 
criteria used at the time of the diagnosis. Therefore, the reported incidence 
may vary between 5 and 30% of the paediatric population (NICE, 2010). The 
aetiology of constipation is not fully understood but contributory factors are: 
pain, fever, dehydration, diet and fluid intake, psychological issues, toilet 
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training, medication and family history. According to NICE (2010) clinical 
guideline 99, the signs and symptoms of childhood idiopathic constipation are: 
infrequent bowel activity, foul smelling, excessive flatulence, irregular stool 
texture, passing enormous stool or frequent small pellets, withholding or 
straining, soiling, abdominal pain, distension, discomfort, poor appetite, lack of 
energy, unhappy, angry or irritable mood and malaise. NICE (2010) clinical 
guideline 99 suggests that autistic children, and those with cerebral palsy and 
Down’s syndrome are more likely to develop chronic constipation. 
It is recommended that management of chronic constipation is undertaken 
according to the severity of the case (Constipation Guideline Committee of the 
North American Society for Pediatric Gastroenterology and Nutrition, 2006, 
NICE, 2010). In cases of impacted stools with no red flags, use of medication 
such as laxatives is advised. Dietary modification and adequate fluid intake 
are also recommended. If, after going through the recommended guidance, 
the child is still suffering from symptoms of chronic constipation, enema is the 
last recommended treatment option (Constipation Guideline Committee of the 
North American Society for Pediatric Gastroenterology and Nutrition, 2006, 
NICE, 2010). 
1.6.1.3 Acute Diarrhoea/ Gastroenteritis 
The British Society of Gastroenterology (2005) compiled guidelines on the 
diagnosis, treatment and management of chronic diarrhoea. According to 
these guidelines, chronic diarrhoea may be defined as: 
 ‘the abnormal passage of three or more loose or liquid stools per day for 
more than four weeks and/or daily stool weight greater than 200g/day’.  
The patients should be screened for infections via blood testing and stool 
analysis. Patients should also undergo investigation for laxative abuse, and, 
according to the guidelines, this should be part of the early investigation. 
Intervention should follow the investigation and rehydration is an important 
part of management (Sandhu et al., 2001, The British Society of 
Gastroenterology, 2005).  
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1.6.1.4 Irritable Bowel Syndrome (IBS) - Functional Gastrointestinal 
Disorder 
The ROME Committee (ROME III, 2006) defines IBS in children as abdominal 
discomfort or pain that improves with defecation and its onset is associated 
with frequency of stool and with change in faecal form. These symptoms must 
not be associated with evidence of inflammatory, anatomic, metabolic or 
neoplastic processes. Diagnosis is reached through taking a careful case 
history; not only from the patient but also from the parents or carers. 
1.6.1.5 Reflux  
Reflux is the passage of gastric contents into the oesophagus. Clinical 
manifestation in the paediatric population includes the following symptoms: 
poor weight gain, vomiting, dysphagia, abdominal or substernal pain, 
oesophagitis and respiratory disorder (Rudolph et al., 2001). Diagnosis of 
reflux through physical examination of infants and older children and taking a 
case history is sufficient to initiate management of the condition; according to 
the North American Society for Pediatric Gastroenterology and Nutrition 
(2001). Management may be complicated by anatomical abnormalities such 
as pyloric stenosis, hiatus hernia and oesophageal stricture. Management of 
straightforward cases may involve dietary changes and sleep repositioning 
with elevation of the head and chest in a supine position in infants or left side 
positioning in case the older children. Acid suppressants may be 
recommended such as proton pump inhibitors (PPIs). Surgery may be 
necessary in the case of anatomic abnormalities (Rudolph et al., 2001). 
1.6.1.6 Inflammatory Bowel Disease – IBD 
The guidelines formulated by the British Society of Paediatric 
Gastroenterology Hepatology and Nutrition (BSPGHAN) on inflammatory 
bowel disease (Crohn’s disease (CD) and ulcerative colitis (UC)) in the 
paediatric population (Sandhu et al., 2010) provide a consensus based on 
evidence of the diagnosis, treatment and management of the condition. 
Guidelines advise that laboratory investigations such as blood tests, stool 
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culture and levels of biochemical markers, such as calprotectin and 
lactoferrin, may become important tools for diagnosis and monitoring of the 
condition. BSPGHAN advocate investigations such as endoscopy and 
colonoscopy to confirm the diagnosis in children suspected of having CD and 
UC.  
The treatment for IBD consists of enteral nutrition and administration of 
corticosteroids to induce and maintain remission. 
1.6.2 Autistic Paediatric Population: Recommendations for Management 
of Commonly Encountered Gastrointestinal Symptoms  
In 2010, the American Academy of Paediatrics issued recommendations for 
primary care providers for the management of GI problems in ASD children 
(Buie et al., 2010). These recommendations were compiled after collating the 
suggestions of clinical paediatric gastroenterologists with experience in caring 
for autistic children. This was an attempt to raise awareness of the 
management of GI conditions in the paediatric autistic population (Buie et al., 
2010). However, evidence based guidelines for management and treatment of 
GI conditions in autistic children are yet to be formulated.  
The quality standard 51 (NICE, 2014) recommends that people who are 
referred for autistic diagnostic assessment are also assessed for coexisting 
health and mental conditions. This is to avoid coexisting conditions going 
unrecognised and/or untreated. Quality standard 51, recommends that 
physical assessment of autistic individuals should include consideration of GI 
conditions such as constipation, altered bowel habits and faecal incontinence 
that could potentially trigger challenging behaviours in this population. 
The recommendations for management and treatment of GI problems in 
autistic children have been divided into four main categories; chronic 
abdominal pain, constipation, chronic diarrhoea and oesophageal reflux (Buie 
et al., 2010). The primary care practitioner can evaluate GI disorders in 
autistic children. However, assessment and diagnosis may be challenging. 
Unpredictable behaviour displayed by some autistic individuals, along with 
lack of verbal communication and aggressive behaviour such as biting, 
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pushing spiting and screaming are limitations to the examination process 
(Buie et al., 2010).  
1.6.2.1 Chronic Abdominal Pain  
In cases where verbal communication is a limitation factor, the care provider 
should be aware of behaviours that may indicate abdominal discomfort; such 
as pressing or tapping on the abdominal area. Changes in sleep patterns, 
self-injurious behaviour and aggression may also be indicative of pain. 
Parental education is an important factor on management of chronic 
abdominal pain and parents should be informed that, although pain is real, it 
may not be indicative of serious disease (Buie et al., 2010). 
The recommendations for autistic children with alarming abdominal pain 
follow the same advice as the guidelines for unaffected developing children 
with similar pain. Further testing is advised in cases of involuntary weight loss, 
deceleration of growth, significant vomiting and chronic or severe diarrhoea.  
1.6.2.2 Constipation  
Sensory processing abnormalities may cause stool withholding in ASD 
children. Buie et al. (2010) states that autistic children may suffer from stool 
retention, unnoticed by parents, teachers or carer, as well as to determine 
whether the condition is functional or organic, a thorough case history should 
be taken in conjunction with a physical examination of the abdomen (look for 
distension, palpable liver or spleen and palpable mass) and the rectum (check 
the rectum tone for stool impaction). Challenging behaviour displayed by 
some ASD patients means that a rectal examination may not be feasible. 
Therefore, the rectal tone may not be assessed to help identify stool retention 
and occult mass. In these cases, it is recommended that an X-ray of the 
abdominal area be taken. However, a systematic review by Reuchlin-Vroklage 
et al. (2005) yields conflicting results regarding the use of radiography to 
diagnose stool impaction. Pharmacotherapy for treatment of constipation in 
ASD patients is generally the same as for unaffected children. Behavioural 
management such ABA, TEACH or ESDM may also be useful as a 
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therapeutic tool for the treatment of constipation in ASD children. See section 
1.5.1.1- Behavioural Intervention Methods.  
1.6.2.3 Chronic Diarrhoea 
There are, as yet, no clinical guidelines for the evaluation and treatment of 
chronic diarrhoea in ASD children. The standard paediatric approach is used 
for ASD children. Food allergies, celiac disease, parasites and IBDs (CD and 
UC) are the most common causes of chronic diarrhoea. Relevant diagnostic 
tests should be performed. In an attempt to raise awareness of the incidence 
of GI issues in the autistic population, Buie et al. (2010) recommends that 
clinicians should exercise particular care in clinical judgement when treating 
ASD patients with chronic diarrhoea.  
1.6.2.4  Gastroesophageal Reflux Disease (GERD)  
The same clinical and practical guidelines used for the general paediatric 
population suffering from GERD are recommended for ASD children. The 
differences lie in the behavioural changes seen in ASD children when in pain. 
ASD children may express discomfort through erratic, aggressive and/or self-
harming behaviour. Clinical examinations such as barium enema and 
endoscopic examination using a nasal probe are challenging for ASD 
children. Such investigations should therefore, be carried out under general 
anaesthesia. In the case of strictures, mal-rotation or oesophageal cancer, 
treatment of ASD children should follow the same guidelines as have been 
put in place for the general paediatric population.  
1.7 Epidemiology 
Epidemiological studies show that the concordance in monozygotic twins is 
significantly greater than that in dizygotic twins, and it is a significant genetic 
factor in diagnosing infantile autism. The published ratio of male to female 
cases ranges from 2:1 to 4:1 (Wing, 1993b), and the total prevalence of 
autism ranges from 2 to 5 per 10,000 individuals (Aarons and Gittens, 1999), 
although this number can vary from 3 to 16 per 10,000 according to the 
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diagnostic criteria used within a study (American Psychiatric Association, 
1994). It is suggested that an improvement in the diagnostic procedure and a 
greater awareness of the condition may have influenced this reported 
increase (Kurita, 2006, Williams and Brayne, 2006), although the considerable 
rise in incidence cannot be explained by improved diagnostic criteria alone 
(Hertz-Picciotto and Delwiche, 2009).  
A review to clarify the reasons for the differences in reported findings was 
undertaken in 1993 by The Centre for Social and Communication Disorders 
(CSCD) in Kent. The CSCD gathered information from 16 epidemiological 
studies over a 25 year period, which used Kanner and Rutter’s diagnostic 
criteria and the 3rd edition of the DSM (Wing, 1993b). These sets of criteria for 
the diagnosis of infantile autism have commonalities as they include social 
interactions and communication, and repetitive stereotyped behaviour as 
essential factors. Each of the 16 studies also covered geographically defined 
populations. The conclusion of the CSCD study revealed a strong possibility 
that individual interpretations of the diagnostic criteria may have caused 
discrepancies affecting the epidemiological results. According to the CSCD 
study, it was not possible to determine either precise male to female ratios or 
the prevalence of ASDs per 10,000 individuals (Whitehouse, 2013). This 
finding may reflect an implied geographical or socio-economic influence in this 
condition (van der Ven et al., 2013).  
1.8 Clinical Features of Autism  
1.8.1 Onset  
According to the DSM-IV (American Psychiatric Association, 2000) and the 
majority of clinicians and researchers, the abnormal development of autistic 
individuals is most apparent before the ages of 30 - 36 months (Wing, 1993b, 
Wing, 1998, American Psychiatric Association, 2000). The severity of the 
symptoms may become less immediately obvious during the pre-school years 
and resistance to being touched and held may decrease with age. Even so, 
the inability to play reciprocally, to treat humans as humans rather than 
objects, and distant behaviour may persist into adulthood (Seltzer et al., 
2003). 
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1.8.2 Behaviour  
The Centres for Disease Control and Prevention (CDC) advocate that children 
should be screened to assess their natural development using a series of 
normal milestones that are classified into four areas: social and emotional; 
language and communication; cognitive and movement/physical development 
(Council on Children With et al., 2006). Studies suggest that children are 
equipped with primitive responses that help them integrate into society from 
birth (Farroni et al., 2002, Simion et al., 2007, Vouloumanos et al., 2010) and 
problems in these primitive areas can be classified as delayed or abnormal. 
One of the most apparent symptoms in autism is the failure to reach social 
and emotional milestones, resulting in the adoption of abnormal behaviours. 
Several studies describe the main behavioural symptoms of autistic children 
as the failure to develop eye contact, the failure to develop social interaction, 
and the failure to develop communication skills (Gillberg and Coleman, 1992, 
Wing, 1997, Wing, 1998, Tanguay, 1999, American Psychiatric Association, 
2000, Wing, 2002, World Health Organization, 2004).  
1.8.3 Communication  
Individuals who fit the DSM-IV and ICD-10 diagnostic criteria for autistic 
disorders may experience delayed onset in speech development (Gillberg and 
Coleman, 1992, American Psychiatric Association, 2000, World Health 
Organization, 2004). Subjects may present with communication abnormalities; 
such as echolalia (parrot-like copying of other people’s speech) or delayed 
echolalia (repetition of words in a stereotyped way) (Wing, 1997). The rhythm 
and melody of speech may also be altered, with the intonation of the voice 
being high-pitched or monotonous ('robotic' speech) (Wing, 1998). Some 
autistic children develop a large vocabulary, and whilst this may not be used 
for conversation with other people, they may learn to follow instructions given 
in a familiar social context (Wing, 1997); however, they may not understand 
the same instruction if the social context is changed. Autistic individuals may 
become confused with personal pronouns and frequently there is the 
substitution of ‘I’ for ‘you’ (Rapin and Dunn, 1997, American Psychiatric 
Association, 2000, World Health Organization, 2004). They may also have 
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difficulty interpreting other people’s tone of voice, body posture and facial 
expression during a conversation (Tanguay, 1999), and may fail to initiate, 
pursue, or terminate conversations (Rogers et al., 2003). 
Some children demonstrate a compromised ability to decode verbal stimuli; 
resulting in verbal auditory agnosia, meaning that they do not understand 
verbal languages and thus fail to acquire speech (Klein et al., 2000). A recent 
study suggested that a deficit in communication may appear in infants who 
are later diagnosed as autistic as early as six months of age (Shic et al., 
2014). According to Shic et al. (2014), autistic children may not be able to 
regulate their responses to social stimuli and they present with a marked 
reduction in attention to social facial expression, either static (non-verbal) or 
dynamic (verbal). This lack of attention may later affect the normal 
development of communication skills.   
1.8.4 Impairment of Imagination and Repetitive Stereotyped Activities 
Autistic children do not develop ‘pretend’ play and imaginative activities in the 
same way as normal children; toys are purely objects that provide a physical 
sensation (Wing, 2002). Children may appear to be engaged in imaginative 
activities but prolonged observation reveals that they are repeating the same 
sequence of events over and over again, and at times are merely repeating 
games from a television programme or stories that have been read to them 
(Rapin and Dunn, 1997, Wing, 1997, Wing, 1998, Wing, 2002). Other forms of 
repetitive activity involve staring at lights, twisting and turning objects, and 
switching lights on and off (Gillberg and Coleman, 1992). 
1.8.5 Sensory Motor Symptoms  
Ming et al. (2007) assessed the prevalence of motor impairment in 154 ASD 
children of between 4 and 18 years old, and suggested that motor impairment 
is more frequent in ASD children compared with children developing normally. 
Autistic individuals may also present with a deficit in sensory motor control, 
with a delay in movement execution, joint laxity, hypotonia, clumsiness and 
apraxia (the inability to make skilled movements with accuracy) (Stoit et al., 
2013).  
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Reduced sensory motor control features in ASD may include abnormal 
posture and reduced coordination of the upper limbs, as well as clumsiness 
and a lack of balance. The unstable gait of autistic individuals is due to a lack 
of symmetry and a reduced stride length (Gillberg and Coleman, 1992, Page 
and Coleman, 1998, Jansiewicz et al., 2006). The prevalence of sensory 
motor symptoms as described by Ming et al. (2007), range from toe walking, 
finger flicking, flapping of arms and hands, running in circles and self-injurious 
behaviour (e.g. head banging and biting), all of which become more apparent 
when a child becomes excited. Ming et al. (2007) found hypotonia to be the 
most common symptom, affecting 51% of the cohort studied; however, this 
symptom was less apparent in older autistic children, suggesting that 
hypotonic symptoms may improve over time.  
1.8.6 Epilepsy 
Epilepsy is the abnormal discharge of neurons within the brain and it occurs 
more frequently among autistic and mentally handicapped children than in the 
general population (DeLong, 1999, Besag, 2002). About a third of autistic 
children will have at least two unprovoked epileptic seizures before reaching 
adulthood (Rapin and Dunn, 1997), and their onset in autistic individuals may 
be suggestive of brain dysfunction and intellectual compromise (Tuchman and 
Cuccaro, 2011, Robinson, 2012). The frequency of epileptic fits may increase 
at puberty, possibly due to hormonal changes, possibly resulting in the 
regression of developmental features already acquired (Brooks-Kayal, 2010, 
Tuchman and Cuccaro, 2011). 
1.8.7 Gastrointestinal Symptoms  
Patients with an autistic disorder may present with GI symptoms, such as 
abdominal distension and pain, constipation, chronic diarrhoea, foul-smelling 
stools and/or flatulence (Shattock and Savery, 1996, Lewis, 1998, Jyonouchi 
et al., 2005a, Jyonouchi et al., 2011). Recent studies suggest that a cognitive 
deficit in autistic children may be linked to these GI symptoms (Horvath, 2000, 
Horvath and Perman, 2002, Koves et al., 2004, Valicenti-McDermott et al., 
2008). Nikolov et al. (2009) reported a link between the worsening of 
behavioural symptoms and GI symptoms, specifically diarrhoea and 
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constipation. The same study also reported that autistic children suffering 
from GI problems have a tendency to present with higher levels of irritability, 
anxiety, and are more socially withdrawn compared with autistic children 
without GI symptoms (Nikolov et al., 2009). A consensus paediatric report 
undertaken by the Paediatric Gastrointestinal Unit in Boston, USA, concluded 
that the behaviour of children with autism may have an underlying medical 
condition, that could be GI in nature (Buie et al., 2010).This issue will be 
discussed in greater detail in section 1.10, Autism and the Gastrointestinal 
Link. 
1.8.8 Toxicity or Allergic Symptoms  
Food containing gluten and/or casein appears to be the main allergen 
affecting autistic children (Lewis, 1998, Shattock and Whiteley, 2002, 
Shattock et al., 2004). A recent report comparing autistic individuals (with or 
without GI complaints) with aged matched healthy controls suggested that 
autistic individuals (with or without GI symptoms) possess increased levels of 
IgG antibodies to gliadin; therefore, this does not exclude the possibility of an 
increased prevalence of celiac disease amongst autistic individuals (Lau et 
al., 2013).  
Some authors suggest that autistic individuals may present with abnormal gut 
permeability, leading to ‘leaky gut syndrome’ and behavioural disorders 
(Shattock and Savery, 1996, Shattock and Whiteley, 2002, Shattock et al., 
2004, Jyonouchi et al., 2005a, Jyonouchi et al., 2005b). It is suggested that 
peptides derived from gluten and casein containing foods may ‘leak’ through 
an abnormally permeable gut epithelium and then enter the central nervous 
system (CNS), thereby generating abnormal physiological symptoms, such as 
behavioural changes, mood swings and GI symptoms (Shattock and Whiteley, 
2002, Shattock et al., 2004, Jyonouchi et al., 2011). See summary of autism 
symptoms Table 1-2. 
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Table 1- 1-2: A Summary of the Symptoms of Autism  
 
Behaviour  Failure to develop eye to eye contact; failure to develop 
social interactions; failure to develop communication skills; 
lack of pretend play and imaginative activities; repetitive 
stereotyped activities (staring at lights, twisting and turning 
objects and switching lights on and off over and over again). 
Communication Echolalia (parrot-like copying of other people’s speech); 
altered rhythm and melody of speech; high-pitched or 
monotonous speech, confusion over use of personal 
pronouns (substitution of ‘I’ for ‘you’); failure to initiate, 
pursue, or terminate conversations; difficulty interpreting 
other people’s tone of voice, body posture and facial 
expression during a conversation; failure to acquire speech. 
Sensory  
Motor 
Joint laxity and hypotonia; clumsiness and apraxia (inability 
to make skilled movements with accuracy); toe walking; 
finger flicking; flapping of arms and hands; running in circles; 
self-injurious behaviour. 
Neurologic A third present with epilepsy 
Gastrointestinal Abdominal distension and pain; constipation; chronic 
diarrhoea; foul-smelling stools; and gaseousness. 
Toxic/Allergic Food intolerance; sensitivity to food containing gluten and/or 
casein. 
Compiled from (World Health Organisation, 1992, American Psychiatric Association, 1994, 
Wing, 1997), Tanguay (1999). 
1.9 Aetiological Hypothesis 
Several theories concerning the cause of autism have been suggested. A 
controversial aetiological hypothesis defining autism in psychological terms 
was first proposed by Kanner and Eisenberg (1957). Kanner initially 
suggested that autism was a primary response to a lack of maternal warmth, 
but this hypothesis is unsubstantiated and has not been supported (Kanner, 
1943).  
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A more recent study hypothesises that there are two forms of autism. The first 
is as a result of bilateral brain damage during early life, possibly involving the 
temporal lobes and resulting in dysfunction in language, social skills, and 
organised activity. The second is an idiopathic form, based on Kanner’s 
original description of autism, that is also related to familial psychopathology 
and low serotonin levels in the left hemisphere of the brain, resulting in 
symptoms such as irritation, anxiety, withdrawal from social contact, 
diminished cognition and attention (DeLong, 1999). According to DeLong 
(1999), a high functioning autistic individual may have a disease process 
affecting only one hemisphere, whilst a low functioning individual may have 
low serotonin synthesis in the left hemisphere, resulting in a wide functional 
deficit of cortical association areas and thus causing a profound cognitive 
disability (DeLong, 1999).  
1.9.1 Genetics  
The sibling recurrence figures of autism are between 2% and 5% (Aarons and 
Gittens, 1999), and this percentage has led to investigations into the 
possibility of the condition having a genetic cause. One genetic study has 
claimed an association between chromosomal abnormalities and an autistic 
phenotype (DeLong, 1999), involving a duplication and deletion of the 15q 
chromosomal region (Waterhouse, 2000). Cook et al. (1998) suggested that 
there is disequilibrium between an autistic disorder and the GABRB3 155CA-2 
gene, that is located on chromosome 15q11-13. However, a further study that 
recruited a large number of families with at least two children diagnosed as 
autistic, gave conflicting results (Rish et al., 1999). This later study, used the 
DSM-IV diagnostic criteria and did not identify a chromosomal region with 
significant evidence of linkage, but instead indicated that the most likely 
location for some genetic abnormality would be on chromosome 17q (Rish et 
al., 1999). Wang et al. (2009) analysed 10,000 subjects with European 
ancestry and identified genetic variants on chromosome 5p14.1, which affects 
the morphology and function of the brain, possibly resulting in the clinical 
features of autism. There is clearly a need for more studies in this area to 
clarify whether or not autism has a genetic component. 
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1.9.2 Allergies  
Ongoing investigations are looking at a possible link between allergies and 
autism (Shattock and Savery, 1996, Shattock and Whiteley, 2002, Shattock et 
al., 2004, Jyonouchi et al., 2005b, Valicenti-McDermott et al., 2006, Valicenti-
McDermott et al., 2008, de Theije et al., 2014). The theory of allergy-induced 
autism focuses on testing various family members of autistic individuals who 
have a history of asthma, eczema, hay fever and migraines (Srinivasan, 2009, 
Lyall et al., 2013), and autistic behaviour is considered to be the result of an 
intolerance to certain foods and/or chemicals (Shattock and Savery, 1996, 
Shattock and Whiteley, 2002, Shattock et al., 2004). Such food intolerances 
may bring on symptoms such as bad catarrh, diarrhoea, bloating, stomach 
pains, asthma and possibly petit mal epilepsy and deterioration of behaviour. 
There is evidence that children suffering from autism have a lack of the 
enzyme phenol sulphur transferase (PST) (Alberti et al., 1999, Harris et al., 
2000). This enzyme is involved in the metabolism of hormones, 
neurotransmitters and a range of toxic molecules (Alberti et al., 1999, Harris 
et al., 2000), and a lack of PST may lead to leaky gut syndrome, where 
improperly metabolised proteins could escape into the bloodstream (Shattock 
and Savery, 1996, Shattock and Savery, 1997, Shattock and Whiteley, 2002, 
Shattock et al., 2004). Other studies support this hypothesis and add that, if 
PST is dysfunctional, then the body would accumulate abnormal levels of 
serotonin, dopamine and noradrenaline (Rimland and Baker, 1996). In 
addition, phenolytic compounds, which are present in foods containing 
artificial colourings, preservatives and salicylates, can disrupt metabolic 
processes resulting in physical symptoms that are also associated with 
autism, such as excessive thirst, night sweating, facial flushing and reddened 
ears (O'Reilly and Waring, 1993, Alberti et al., 1999). Each of these metabolic 
disruptions may lead to abnormal biochemical actions, particularly in the brain 
(O'Reilly and Waring, 1993, Rimland and Baker, 1996).  
Le Couteur et al. (1988) and Shattock and Savery (1996) supported the 
hypothesis that autism may be the consequence of the action of opioid 
peptides of exogenous origin, which affect neurotransmission within the CNS, 
disrupting cognition, mood and behaviour. Whiteley et al. (1999) claimed that 
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increased levels of peptides may be the result of the incomplete breakdown of 
foods containing gluten (found in wheat, barley, rye, etc.) and casein (found in 
milk and dairy products) (Shattock and Savery, 1996). Together with an 
increased permeability of the gut wall, it is possible that opioid peptides cross 
into the bloodstream, and these toxic metabolites may easily reach the CNS 
and possibly cross the blood brain barrier, resulting in the abnormal behaviour 
demonstrated by autistic individuals (Gillberg, 1995, Shattock and Savery, 
1996, Shattock and Savery, 1997, Shattock and Whiteley, 2002, Shattock et 
al., 2004).  
1.9.3 Environmental Toxicity  
A recent meta-analysis suggested a potential association between ASDs and 
environmental toxins (Rossignol et al., 2014). Rossignol et al. (2014) 
supported the idea that some individuals may be more susceptible to genetic 
and environmental factors during periods of neurodevelopment, which in turn 
may contribute to the development of ASDs. However, this systematic review 
demonstrated that several of the studies were poorly designed, thereby 
prompting the need for more and better epidemiological studies to be 
conducted.  
1.9.4 Gastrointestinal  
One study analysed the structure and function of the upper GI tract of 36 
patients with autism who also presented with GI symptoms (Horvath et al., 
1999). Of the cases studied, 25 showed signs of reflux oesophagitis, 15 
chronic gastritis, and 24 chronic duodenitis. Twenty-two of the 25 children with 
reflux oesophagitis also had symptoms such as night-time awakening, with 
irritability and signs of abdominal discomfort (or pushing on the abdomen), 
similar to those typically reported by non-autistic children suffering from reflux 
oesophagitis. Fifteen of these children also presented with chronic 
inflammation of the gastric mucosa and 21 had low levels of carbohydrases, a 
possible cause of flatulence and diarrhoea. The study concluded that these 
findings may contribute to the evidence of GI involvement in behavioural 
problems of non-verbal autistic subjects (Horvath et al., 1999). 
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An interesting anecdotal case study has led to a new avenue of research into 
ASDs and further evidence of GI involvement. An autistic boy, who was non-
responsive, non-verbal, not toilet trained and sleeping poorly, was referred for 
endoscopy to investigate the cause of his stomach problems (Rimland and 
Baker, 1996, Rimland, 1998). Within days of the procedure the boy showed 
remarkable signs of recovery, such as an improvement in eye contact, calmer 
behaviour and improved sleeping and continence (Rimland and Baker, 1996, 
Rimland, 1998). The only explanation for both the behavioural and GI 
symptom changes was postulated to be the pharmacokinetics of the 
anaesthetic used during the procedure (Rimland and Baker, 1996, Rimland, 
1998). The anaesthetic contained the hormone ‘secretin’ extracted from 
porcine pancreas. The boy’s response to the endoscopy procedure led 
researchers to investigate further the effects of intravenous secretin infusion 
on children suffering from ASDs.  
This dramatic improvement in behavioural symptoms in the boy who received 
the dose of anaesthetic containing secretin may be explained by the 
relationship of secretin to its biochemical family members, particularly 
vasoactive intestinal peptide (VIP) (Bayliss and Starling, 1902). Studies have 
suggested that increased levels of secretin in the bloodstream stimulate VIP 
binding site receptors within the brain. This activation may produce a positive 
effect and regulate energy levels in memory-forming neurons. However, while 
a single case is insufficient to establish a direct behavioural and GI response 
link to secretin infusion, nevertheless, a series of studies using secretin 
infusion in autistic children have transpired.  
One such study compared three ASD children with non-autistic children 
following intravenous administration of secretin (Horvath et al., 1998). The 
study reported that, within five weeks of the secretin infusion, there was an 
increase in pancreaticobiliary fluid and amelioration of GI symptoms, social 
behaviour and communication in the children with ASD, Horvath et al. (1998) 
suggested that the GI symptoms and a physiological lack of secretin possibly 
play a role in the pathogenesis of the disease, whilst conversely, Owley et al. 
(2001) reported a lack of efficacy for secretin infusions on the behaviour of 
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ASD children after a randomised placebo-control trial. Williams et al. (2012) 
reviewed 16 randomised studies with placebo groups on the use of secretin 
infusion in ASD patients. These studies found no evidence that either single 
or multiple secretin infusions ameliorated the symptoms of ASD.  
Although autism has been the focus of many investigations over recent 
decades, it remains a disorder with no clear aetiology and no effective 
treatment. Some hypotheses focus on the possibility of autism being linked 
with GI abnormalities (Horvath et al., 1999, Horvath and Perman, 2002, Chen 
et al., 2010, Chen et al., 2011), whilst others have claimed that the underlying 
GI dysfunction in autistic children is characteristic of the immunological and 
inflammatory dysfunctions seen in patients suffering from inflammatory bowel 
disorders (IBDs) (Horvath et al., 1999, Furlano et al., 2001, Torrente et al., 
2002). Jyonouchi et al. (2005a) confirmed this in their study which indicated 
that there was an intrinsic defect of the innate immune response suggesting a 
possible link between GI and behavioural symptoms mediated by immune 
responses. There is growing awareness of the possibility of a link between gut 
metabolic reactions and abnormal behaviour, indicating that the ‘gut-brain 
axis’ may be central to neural development (Reichelt and Knivsberg, 2009). 
These studies provide a basis for further research into the relationship 
between the brain and the GI system, the so called ‘brain-gut’ or ‘gut-brain’ 
axis and its role in neurological disorders.  
Autism remains a syndrome with no clear aetiological explanation, although 
there have been attempts to determine the cause of the disorder by different 
professional groups. Psychologists are tempted to explain the disorder based 
on their understanding of the mind, geneticists rely on their understanding of 
human genes, whilst similarly, nutritionists, physiologists, neurologists, 
paediatricians and GI specialists all seek explanations pertaining to their own 
field. Specialists have given noteworthy insights into the disorder, but a 
satisfactory aetiological explanation of the condition still remains beyond our 
current understanding. Perhaps, a more holistic approach, using combined 
professional expertise, may facilitate the formulation of an accurate 
aetiological theory. 
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1.10 Autism and the Gastrointestinal Link 
Anecdotal reports from parents of autistic children with GI abnormalities in 
have been reported for some time; however, it was not until the late 1990s 
when D'Eufemia et al. (1996) published a paper suggesting an association 
between GI abnormalities and autism that the research community began to 
study a possible link. It has since been suggested that imbalances or 
abnormalities in the GI system may possibly have a direct influence on the 
abnormal behaviour of children diagnosed as autistic (D'Eufemia et al., 1996, 
Horvath et al., 1999, Ibrahim et al., 2009, Nikolov et al., 2009).  
The mechanism of this connection is not yet clear, although it has been 
suggested that the enteric nervous system with its neuro-regulatory pathways 
may play an important role in this intrinsic puzzle (Furness, 2000).  
1.10.1 The Brain-Gut axis Anatomy 
Neural information travelling from the brain to the gut and from the gut to the 
brain use the terms “gut-brain” and “brain-gut” interchangeably.  
The GI system has its own nervous system, the enteric nervous system 
(ENS), consisting of a complex web of neurons connected to the CNS via the 
vagus nerve. The vagus nerve contains sensory and motor fibres and is the 
longest cranial nerve. It exits the skull via the jugular foramen and passes 
through the neck, thorax and abdomen to synapse with the ENS (Powley, 
2000, Drake et al., 2010). It is suggested that the complex ENS neuronal 
circuit may affect CNS operations via vagus afferents creating a bidirectional 
circuit, that may also flow from the CNS and affect the ENS (Powley, 2000, 
Mayer, 2011).  
The ENS is part of the autonomic nervous system and can operate 
independently of the brain and spinal cord; it has been referred to as a 
‘second brain’ (Bayliss and Starling, 1899, Gershon, 1999). The neurons of 
the ENS are divided into two types: the myenteric plexus and submucosal 
plexus (Furness, 2000). The myenteric plexus is located between the circular 
and longitudinal layers of the muscularis externa and contains both 
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parasympathetic and sympathetic nerve fibres that regulate motility of the GI 
tract (Furness et al., 1999, Furness, 2000, Snell, 2010). The submucosal 
plexus is located in the submucosa, between the circular muscular layers of 
the muscularis mucosae and has a secretory controlling function (Furness, 
2000, Clerc et al., 2002). 
The ENS operates as a parallel circuit regulating somatic, autonomic, 
neuroendocrine, and pain associated with stress and emotional states (Mayer 
and Tillisch, 2011).  
1.10.2  ENS Neurons 
The intrinsic primary afferent neurons (IPANs), the interneurons and the motor 
neurons are a set of neurons responsible for the coordinated autonomic 
activity of intestinal motility (Furness et al., 1999, Furness, 2000, Bornstein et 
al., 2004, Lomax et al., 2005). 
1.10.2.1 IPANs  
IPANs are neurons embedded within the gut wall that generate intrinsic 
reflexes, resulting in the propulsive movements of the gut muscles, changes 
in the blood flow of the gut and modulation of the secretion of water and 
electrolytes (Furness, 2000, Clerc et al., 2002). IPANs react to three types of 
stimuli; chemical changes in the intestinal lumen, mechanical distension of the 
mucosa, and mechanical force in the external musculature via muscle stretch 
or contraction (Kunze et al., 1999, Clerc et al., 2002).  
1.10.2.2 Interneurons  
Interneurons are responsible for the propulsive reflexes within the gut, and 
transmit ascending and descending information within the ENS (Bornstein et 
al., 2004).Enteric motor neurons can be divided into four types; excitatory 
muscle motor neurons, inhibitory muscle motor neurons, motor neurons to the 
muscularis mucosae and motor neurons to the striated muscle of the 
oesophagus (Furness, 2000). 
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1.10.3 The ENS or ‘Second Brain’ 
The vagus nerve provides a steady transmission of signals between the brain 
and the gut, and signals from the gut to the brain maintain homeostasis and 
allow responses to changes caused by disease. The gut sends warning 
information to the brain regarding contaminated foods, chemical poisoning, 
allergens and pathogens, and the brain responds with well-known symptoms, 
such as nausea, abdominal pain, dizziness and vomiting (Gershon, 1999). 
Visceral pain is poorly localised through small diameter unmyelinated fibres 
and thinly myelinated fibres that convey both visceral and somatic pain 
sensations via the dorsal horn to the spinal cord, resulting in viscero-somatic 
reflexes. Information from the viscera also travels to the CNS via the vagal 
visceral afferent pathway (Grundy, 2004). These afferent signals regulate gut 
motility, secretion and blood flow.  
This well-orchestrated system is part of the integrated physiology for the 
maintenance of health; however, it is not yet fully understood which of these 
‘brains’ is leading the signalling information. According to some studies, 
conditions such as an ulcer may have their root cause within the CNS, as 
anxiety could potentially influence GI function and its effects may result in 
damage to the lining of the gut (Mayer et al., 2006, Goehler et al., 2007). 
Psychological stresses may potentially threaten GI homeostasis by affecting 
the gut-brain axis, consequently becoming a precursor of functional GI 
diseases, such as IBDs and IBS. Konturek et al. (2011) state that several 
areas of gut physiology could be affected by stress, including gut mobility, GI 
secretion, gut permeability, blood flow in the gut mucosa, and visceral 
sensitivity. These factors were also implicated in a study on the effects of 
stress on functional dyspepsia, where the authors suggested that 
psychological distress is directly linked to GI symptoms (Aro et al., 2009). 
According to Blomhoff et al. (2001), the co-morbidity of the GI system and 
anxiety has a direct effect on severity and duration of IBS symptoms, possibly 
explaining the mind and body relationship. Blomhoff et al. (2001), showed that 
increased activity in the gut-brain axis affects the ENS and the CNS nerve 
receptors and it seems that phobic anxiety hyper-activates the visceral frontal 
region of the cortex influencing IBS symptomatology (Blomhoff et al., 2001). 
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The gut-brain axis has also been proposed in a recent study where 
depression-like symptoms were induced in mice. According to Park et al. 
(2013), symptoms of depression alter both colonic motor activity and the 
microbial profile, most likely via the hypothalamic-pituitary axis. 
A variety of psychological symptoms have been reported, such as changes in 
mood and cognition that may be a result of ENS imbalances; consequently, 
the root cause of some behavioural disorders could potentially be the GI 
system rather than the CNS. Infection and inflammation of the GI system may 
also affect mood (Goehler et al., 2007); therefore, it is possible that epigastric 
symptoms resulting from pathogens could generate anxiety, rather than the 
other way round (Gershon, 1999, Goehler et al., 2007). A study using a 
mouse model suggested that alteration in microbial composition through 
dysbiosis, may potentially contribute to psychiatric disorders. The study 
suggested that changes in the normal microbial balance in healthy mice may 
alter their brain chemistry, thus altering their behaviour. The authors further 
suggested that the gut-brain axis influences the brain biochemistry in mice 
and is directly linked to behavioural changes (Bercik et al., 2011). The same 
observation has also been described in other studies using animal models 
that have implicated infection and inflammation of the gut in behavioural 
changes, such as anxiety; which is mediated via vagal sensory neurons 
(Goehler et al., 2005, Lyte et al., 2006). Anxiety may be a warning signal of a 
GI infective state in mice Goehler et al. (2007). 
The information emanating from the brain to the GI and from the GI to the 
brain is very much interconnected, and imbalances within this bi-directional 
axis may disrupt the ENS and the CNS, resulting in GI and behavioural 
dysfunction (Mayer, 2011). However, the mechanism of this gut-brain 
intercommunication and the potential effects of its imbalance is, as yet, poorly 
understood. Some studies suggest that the constant passage of information to 
or from the ENS may sensitise specific nerve fibres to targeted organs and 
induce neuroplastic changes. In turn, these sensitised pathways may be 
induced by psychological stresses, such as mood changes, stress and 
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anxiety, leading to chronic symptoms, even though no pathogen is present 
(Mayer and Tillisch, 2011).  
Understanding the neuroplasticity of the ENS may help clarify the 
pathophysiology of GI diseases and guide therapeutic mechanisms (Vasina et 
al., 2006). According to Lomax et al. (2005), neuroplasticity is a feature of 
inflammation and is also of paramount importance in the restoration of gut 
function. It may be possible that the adaptive changes within the neural circuit 
can be set to help the body to regain its homeostatic balance. A review by 
Mawe et al. (2009), shows that neurophysiological changes are only part of 
the picture in the alterations that occur within the gut during inflammation. 
However, understanding the neuroplastic changes within the ENS may help to 
identify therapeutic means with which to restore gut function (Katsui et al., 
2009, Mawe et al., 2009).  
1.10.4 Autistic Behaviour and the Connection to the Gut  
Resonating with the research outlined above, recent studies have 
demonstrated a strong connection between the ENS and autistic behaviour. A 
recent report suggested that the disturbed behaviour of autistic children may 
have an underlying medical condition, including GI disorders (Buie et al., 
2010). The report recommended conducting a systematic GI investigation in 
autistic children similar to that used in non-autistic individuals when they 
present with GI symptoms (Buie et al., 2010).  
D'Eufemia et al. (1996) published one of the first papers to suggest that 
autistic children have an imbalance in intestinal permeability. Follow up 
studies suggested a possible interaction between the damaged gut and the 
brain of an autistic individual. Such an interaction occurs through lymphocytes 
and cytokines crossing the damaged lining of the gut into the circulation and 
then passing across the brain-blood barrier into the brain itself (Furlano et al., 
2001, Torrente et al., 2002, Ashwood et al., 2003, Lau et al., 2013). ENS 
neurons and the enteric glial cells are important for the motility of the gut and 
also essential in maintaining the homeostatic balance, and influencing motility 
and inflammatory processes (Bassotti et al., 2007). According to de Theije et 
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al. (2011) the gut-brain axis interconnection is via an inflammatory process 
that may change the neural homeostasis and result in the exacerbation of the 
severity of autistic behaviour.  
The so called ‘gut-brain axis’ within autism has been reviewed by White 
(2003), who suggested that the GI pathology may be central to the aetiology 
of autism. Another study concluded that GI symptoms may be a co-morbidity 
of autism, and some of the autism behavioural symptoms may be the result of 
the interaction between the brain and GI function (Valicenti-McDermott et al., 
2006). The bidirectional axis that has been suggested between the brain and 
gut could potentiate or even generate behavioural symptoms in autistic 
children. In turn, this could influence neuroplastic changes in either the CNS 
or non-neuronal elements (Gershon, 1999, Dong and Greenough, 2004, 
Vasina et al., 2006). The possibility of a gut-brain axis co-morbidity in autism 
has only recently been postulated but it is receiving increasing research 
attention. 
1.11 Markers used to Assess Gastrointestinal Inflammation 
1.11.1 Faecal Markers Selection 
Kings College Hospital, a centre of excellence for measuring faecal 
biochemical markers, was approached by the researcher to discuss the use of 
gastrointestinal markers. Several meetings took place with the senior 
consultant biochemist, Professor Roy A Sherwood, prior to the selection of 
appropriate faecal markers that could be used as outcome measures.  
The research was granted collaboration with the King’s College Hospital (see 
letter Appendix 10) and was provided with facilities and high level expertise in 
measuring faecal inflammatory markers.  All biochemical analysis of samples 
was performed by a senior Biomedical Scientist in the Department of Clinical 
Biochemistry’s at King’s College Hospital. 
Following discussions with Professor Sherwood, calprotectin was selected as 
the main marker and M2-PK and lactoferrin as adjuncts. All three markers are 
stable and show good reproducibility and have high levels of specificity and 
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sensitivity for detecting gastrointestinal anomalies (see sections 2.19; 2.20 
and 2.21) (Bunn et al., 2001, Summerton et al., 2002, Fagerberg et al., 2003, 
Kane et al., 2003, Szarszewski et al., 2003, Koss et al., 2005, Loughlin et al., 
2005, Ahmed et al., 2007, D'Inca et al., 2008, Langhorst et al., 2008, 
Gonzalez-Chavez et al., 2009, NICE, 2013). In faecal samples calprotectin 
and lactoferrin indicate GI inflammation whilst M2PK indicates cell 
proliferation but is also used as a marker for IBDs and IBS (see table 1-3). 
These markers are reliable indicators of IBDs and IBS (Bunn et al., 2001, 
Kane et al., 2003, Fagerberg et al., 2005, Chung-Faye et al., 2007, Langhorst 
et al., 2008). 
Table 1-3 - Faecal Biochemical Markers Reliability 
Faecal Biochemical Markers  Calprotectin  M2-PK   Lactoferrin 
Diagnostic Sensitivity  80% 81% 77% 
Diagnostic Specificity 100% 50% 85% 
Legend to the table 1-3: Represents levels of sensitivity and specificity of calprotectin, M2-PK 
and lactoferrin (Bunn et al., 2001, Fagerberg et al., 2003, Kane et al., 2003, Fagerberg et al., 
2005, Chung-Faye et al., 2007, Langhorst et al., 2008).   
Faecal calprotetin is used to assess IBDs and non IBDs (IBS) in ASD children 
(Sandhu et al., 2010, NICE, 2013). According to the NICE diagnostic 
guidance 11, lower bowel symptoms are more often related to IBS. According 
to the ROME criteria III (ROME III, 2006), IBS is a functional bowel condition 
which can affect quality of life although it does not develop into a serious 
pathology (see section 1.6.1.4). Alternatively, persistent lower bowel 
symptoms for more than 6 weeks may potentially be the result of a more 
serious condition, such as IBD, which requires careful investigation (see 
section 1.6.1.6).  
This research was not designed to investigate IBDs but used calprotectin only 
as a marker to assess and follow any inflammatory change during application 
of VOT, so the premise for adherence to the NICE further 
investigation/treatment guidelines was not met. According to guidance 11 
(NICE, 2013), raised levels of calprotectin require further investigation such as 
blood tests, i.e. C-reactive protein and full blood count. Also, if the symptoms 
38 
are persistent for more than 6 weeks and calprotectin analysis is positive then 
the recommendation is an exploratory colonoscopy.  This diagnostic and/or 
treatment strategy was not part of the current study so the Ethics Committee 
neither considered nor approved any such course of action in this study 
population. 
1.11.2 Calprotectin  
Calprotectin, also known as MRP8/14, is a heterodimer of two calcium binding 
protein elements that belongs to the S100 protein family (see Figure 1-2) and 
it is found abundantly within the cytoplasm of neutrophils (Striz and 
Trebichavsky, 2004, Stroncek et al., 2005). Within neutrophils it constitutes 
approximately 30% to 60% of the total cytosolic proteins (Olafsdottir et al., 
2002, Stroncek et al., 2005). It is found in lower amounts (~1% of total 
cytosolic proteins) in some monocytes (Yui et al., 2003, Stroncek et al., 2005) 
and may also be occur in macrophages at sites of acute infection (Stroncek et 
al., 2005).  
It is known that high levels of calprotectin exist within the intracellular fluid 
during various inflammatory processes (Striz and Trebichavsky, 2004, 
Lundberg et al., 2005), and upon its release it can be detected within serum 
and other body fluids as a useful marker of inflammatory processes, such as 
UC, CD and IBD (Striz and Trebichavsky, 2004, Lundberg et al., 2005, 
Stroncek et al., 2005). 
It has been reported that the plasma concentration of calprotectin can be 10 
fold higher in patients suffering from rheumatoid arthritis (RA) and blood 
calprotectin levels are often elevated in patients suffering from CD, cystic 
fibrosis, multiple sclerosis, and in patients who have undergone major surgery 
(Yui et al., 2003). A significant increase in calprotectin concentration has been 
found to be present in extracellular fluid from local inflammatory sites, which 
has either been secreted from stimulated neutrophils or released as a result of 
cell death (Yui et al., 2003). A further example of a high extracellular 
concentration of calprotectin is in the faeces of patients suffering from an IBD 
such as CD or UC (Lundberg et al., 2005, Stroncek et al., 2005), where the 
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median calprotectin level in subjects suffering from CD is 31 mg/L (normal 
range 0.5 mg/L – 50 mg/L) and in subjects suffering from UC is 116 mg/L 
(normal range 0.5 mg/L – 50 mg/L) (Summerton et al., 2002). 
 
Protein Data Bank (http://www.rcsb.org/), DOI:10.2210/pdb1xk4/pdb 
Table 1-4 Calprotectin reference ranges for healthy and diseased patients  
Healthy subjects 0.5 – 50 mg/L 
Active IBD   500 – 50,000 mg/L 
Non-active IBD 150 – 500 mg/L 
IBS  1 – 150 mg/L 
 
Legend to table 1-4: Table representing the ranges of calprotectin for healthy subjects, IBD 
and IBS subjects (Lundberg et al., 2005). A result of > 50mg/l is considered a positive 
calprotectin analysis. 
The calprotectin enzyme-linked immunosorbent assay (ELISA) has been 
viewed as a very good diagnostic tool, since an elevated calprotectin level 
correlates with an inflammatory disease state (Bunn et al., 2001). Faecal 
calprotectin has high levels of specificity (100%) and sensitivity (80%) for 
children with GI disorders (Bunn et al., 2001); therefore, detecting the level of 
calprotectin in faeces can be used as a non-invasive screening test for 
identifying organic diseases of the small intestine or large bowel. The faecal 
Figure 1-2 - Crystal structure of human calprotectin 
40 
calprotectin ELISA has proved to be a valuable tool compared to more 
invasive GI tests, especially in young children (Bunn et al., 2001, Fagerberg et 
al., 2005). 
Calprotectin is remarkably stable in stools, and samples can be kept in a 
suitable container at room temperature for up to seven days (Lundberg et al., 
2005), although long-term storage until analysis should be at -18 °C or below. 
Exposure to temperatures greater than 30°C should be avoided (Buhlmann 
Laboratories, 2011).  
The main applications of the calprotectin ELISA are (Tibble et al., 2002) :  
 Differentiation between organic IBD and irritable bowel 
syndrome (IBS).  
 The detection of a decrease in faecal MRP8/14 concentrations 
during successful therapy for IBD. 
 The detection of an increase in faecal MRP8/14 as a short term 
indicator for IBD relapses.  
1.11.3 Tumour M2 Pyruvate Kinase  
M2-PK, a dimeric isoform of pyruvate kinase (see Figure 1-3), has been 
identified as a metabolic marker for various tumours, such as colorectal 
(Loughlin et al., 2005), pancreatic, GI, lung and breast amongst others 
(Allocock, 2004, Ahmed et al., 2007, Oremek et al., 2007). It is a novel marker 
that reflects metabolic activity of tumours and has become a useful tool in 
diagnosis and detection of a range of tumours (Eigenbrodt, 2001). M2-PK can 
be measured from both blood or stool samples and analysis of stools for M2-
PK has been used primarily to screen and detect colorectal cancer. It is a very 
stable marker, can be stored at 25°C for 48 hours and even very small 
amounts can be easily detected (Allocock, 2004, ScheBo® · Biotech AG, 
2011).  
A recent study has reported that faecal M2-PK as a marker has a sensitivity of 
92% for the detection of colorectal cancer, 60% for the detection of large 
polyps and 25% for the detection of small polyps. M2-PK specificity in all of 
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these cases was 92% (Koss et al., 2005). Faecal M2-PK is an enzyme that is 
released by the tumour itself and its detection has been used increasingly as 
a tumour marker. Ultimately, detection of M2-PK may replace more invasive 
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Figure 1-3 M2-PK Formation. Schematic illustrating the Tumour Metabolome-Metabolic 
Database (www.metabolic-database.com) 
A recent report from King’s College Hospital suggested that faecal M2-PK 
could be used as a non-invasive marker to differentiate IBD from functional 
bowel disorders (Chung-Faye et al., 2007). This report postulated that dimeric 
M2-PK that occurs in tumour cells would be increased in IBD owing to the 
rapid cell turnover (cell proliferation) and so the study aimed to determine the 
value of M2-PK for UC, CD and functional bowel disorders (Chung-Faye et 
al., 2007). It was found that faecal M2-PK has a sensitivity of 81% and 
specificity of 50% in the detection of IBD and the values for the different 
diseases ranged from34.3 to 62.6 U/mL for UC27.3 to 59.9 U/mL for CD and 
1.4 to 20.8 U/mL for functional bowel disease (e.g. IBS) 
The study concluded that faecal M2-PK is a novel marker that can be used to 
differentiate IBD from functional bowel disorders and that it correlates well 
with calprotectin measurements that are already validated. 
1.11.4 Lactoferrin  
Lactoferrin is a 703-amino acid iron binding glycoprotein present in mucosal 
secretions and in the secondary granules of neutrophils and its structure is 
shown in   
 (Levay and Viljoen, 1995, Walker et al., 2007). Is has been suggested that 
lactoferrin is a possible marker for assessing IBD activity, and therefore is a 
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potentially non-invasive marker of IBDs such as CD and UC, and a 
discriminative marker between IBD and IBS (Sidhu et al., 2010a).  
 
Figure 1-4: Structure of the recombinant N-terminal lobe of human lactoferrin 
Protein Data Bank (http://www.rcsb.org/), DOI:10.2210/pdb1lct/pdb  
Lactoferrin can be detected in mucosal secretions, such as saliva, tears, 
vaginal secretions and breast milk, all of which are in contact with 
environmental pathogens (Walker et al., 2007, Gonzalez-Chavez et al., 2009). 
In addition, several studies have claimed that faecal lactoferrin is a surrogate 
marker for IBD and a non-invasive marker for UC and CD (Walker et al., 
2007, Sidhu et al., 2010a). Lactoferrin has the ability to respond to several 
changes in the homeostatic balance, with its biological functions ranging from 
anti-bacterial, anti-viral, anti-parasitic and anti-fungal to anti-inflammatory 
(Gonzalez-Chavez et al., 2009, Jenssen and Hancock, 2009). Laboratory 
analysis of tissue from the intestinal lumen of subjects diagnosed with IBDs 
shows the accumulation of polymorphonuclear neutrophils (Baveye et al., 
1999). The innate immune response of the activated intestinal lumen is to 
release pro-inflammatory proteins, and one of these released proteins is 
lactoferrin (Levay and Viljoen, 1995). 
A recent study evaluated lactoferrin levels in faecal samples from 170 
children, mean age 13.4 years, in order to assess IBD disease activity. The 
study suggested that faecal lactoferrin testing is a non-invasive reliable 
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marker within the paediatric population (Walker et al., 2007). Over the last 
decade, several studies have suggested that lactoferrin has high levels of 
specificity and sensitivity for distinguishing between IBDs and IBS. A study by 
Kane et al. (2003) suggests that faecal lactoferrin was 90% sensitive for 
diagnosing active IBD and 100% specific in discarding IBS as a potential 
diagnosis, whilst Langhorst et al. (2008) found that lactoferrin sensitivity was 
85% and specificity was 77% for IBS patients.  
One study analysed the specificity and sensitivity of lactoferrin in CD 
compared to the use of capsule endoscopy, a novel wireless imaging device, 
as a form of diagnosing IBD, and suggested there was a correlation between 
faecal lactoferrin levels and capsule endoscopy (p=0.03). Lactoferrin 
sensitivity and specificity was reported to be 71% and 100%, respectively. 
However, only seventeen patients were recruited for this study (Sidhu et al., 
2010a). A further study by Sidhu et al. (2010a) analysed the sensitivity and 
specificity of faecal lactoferrin in differentiating between IBD and IBS, and 
recruited 137 subjects with IBS, 126 with UC, 104 with CD and 98 healthy 
subjects. This study suggested that lactoferrin has a higher discrimination for 
IBD sufferers compared to IBS with 67% sensitivity and 96% specificity. 
Faecal lactoferrin is stable in stools and can be stored at room temperature 
for seven days before being frozen for later analysis (TechLab®, 2008).  
1.12 Questionnaires 
Questionnaires are useful data collection tools to analyse a patient’s 
perception of health (Rattray and Jones, 2007). The current study used a 
validated standardized questionnaire to measure the parents’ perception of 
their autistic children before, during and after application of VOT. Benefits of 
using questionnaires for data collection include the relatively low 
administration costs, ease of response and simplicity of data analysis (Rattray 
and Jones, 2007).  
The health community usually uses a Likert-type or frequency scale 
questionnaire designed to measure attitudes or opinions. In this study, 
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parents completed a questionnaire regarding their assessment of the GI and 
behavioural symptoms of their children using a 24 parameter, ten point Likert 
scale, based on the Autism Research Institute Secretin Outcomes Survey 
Form – “S.O.S Form”. This is a validated and standardized questionnaire 
(Rimland, 1998, Brudnak et al., 2002, Unis et al., 2002, Esch and Carr, 
2004a, Erickson et al., 2005b, Sturmey, 2005, Williams et al., 2005). 
The Likert scale assumes linearity of the data, measuring, for example, 
parameters from strongly agree to strongly disagree. It is important to 
demonstrate the reliability of the questionnaires used for studies. The most 
common test to analyse internal consistency and reliability of a multiple Likert 
scale questionnaire or survey is the Cronbach’s α statistic. Cronbach’s 
α scores above 7 are considered acceptable for reliability (De Vellis, 2003, 
Field, 2009).  
1.13 Visceral Osteopathic Manipulation and the 
Gastrointestinal Tract 
The lining of the GI tract is regarded as a sensory organ similar to the skin, 
and it contains three types of sensory detectors that are controlled and/or 
monitored by the ENS: neurons, local endocrine cells, lymphatic cells 
(Furness et al., 1999, Smid, 2008).  
Constant signals from the enteric plexus are sent locally to the lining of the GI 
tract to control motility, secretion, tissue defence, and vascular perfusion, and 
also to other digestive organs, such as the stomach, gall bladder and 
pancreas, and to the CNS (Willard, 1997, Furness et al., 1999). This 
integrated system responds to changes in the GI luminal content (Furness et 
al., 1999). Usually this system protects the body against bacteria, toxic 
substances or harmful entities that may enter the digestive system via food 
intake; however, the system’s response is not always well adjusted which may 
cause disease or dysfunction. 
‘The enteric nervous system is composed of two ganglionated plexus. The 
larger myenteric plexus, situated between the circular and the longitudinal 
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layers of the muscularis externa, contains the neurones responsible for 
motility and for mediating the enzyme output of adjacent organs. The smaller 
submucosal plexus contains sensory cells to the motor neurons of the 
myenteric plexus, as well as motor fibers that stimulate secretion into the gut 
lumen.’ (Gershon, 1999) 
1.13.1.1 The Neurons  
There are three levels of sensory information that are necessary for proper 
functioning of the GI tract. Sensory afferent neurons are responsible for local 
reflexes in the gut wall, and form a short loop interconnecting the gut mucosa, 
submucosa or muscle to the enteric ganglia. Afferent neurons from the gut 
mucosa to the pre-vertebral ganglia along the aorta (Willard, 1997) participate 
in the intra-abdominal reflex arcs. Finally, the third level involves sensory 
neurons that project from the gut wall to the brainstem via the vagus nerve or 
to the spinal cord via the thoracic, lumbar and pelvic splanchic nerves 
(Willard, 1997, Furness et al., 1999, Gershon, 1999).  
The first level of sensory neurons responsible for local reflexes in the gut are 
the IPANs (Furness et al., 1999, Gershon, 1999, Smid, 2008), and these have 
the important task of generating reflex responses to the intestinal content. 
These reflexes cause mixing and propulsive movements of the gut muscles, 
local changes in the blood flow and modulation of the secretion of water and 
electrolytes. A study using the ileum of guinea pigs has shown that IPANs 
also respond to tension in the muscles of the gut wall, and it is suggested that 
these types of neurons are stretch-sensitive with activation occurring in 
response to muscle stretching (Furness et al., 1999, Kunze et al., 1999, Clerc 
et al., 2002, Smid, 2008). Thus, either passive or active stretching of the 
muscles of the gut wall seems to result in the firing of the IPANs. This 
information is then conveyed to other neurons of the ENS, and the information 
integrated resulting in appropriate changes in mixing and propulsive activity of 
the gut, water and electrolyte transport, local blood flow, and possibly 
endocrine secretions. Dysfunction of the GI system may cause disruption to 
this integrated system; however, visceral manipulation techniques may 
stimulate the IPANs via the stretch reflex and consequently may help to 
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rebalance the function of its integral parts, including the second and third 
levels of sensory afferent neurons (Furness et al., 1999, Gershon, 1999). 
Other fibres that may be involved are the peripheral afferent fibres of the 
vagus nerve. The intramuscular arrays and intraganglionic lamina endings 
have a mechano-sensory function and respond to muscle tension elicited via 
passive muscle stretching. Intramuscular arrays are sensory receptors and 
the intraganglionic lamina endings are suggested to be associated to 
connective tissue that responds to sheering forces generated from stretching 
during muscle contractions (Grundy, 2002, Grundy, 2004). 
1.13.1.2 Endocrine Cells 
The endocrine system is directly dependent on the cardiovascular system for 
hormonal transport to distant sites; delivering control mechanisms for the 
secretion of hormones; and hormone concentrations which influence the 
magnitude of effect at the site of action (Furness et al., 1999). Alterations in 
blood flow at a site responsible for hormonal release may cause disruption to 
the hormone secretion rate; therefore, the function of hormone target cells 
may be compromised causing an imbalance in the entire body system. For 
this reason, increasing blood flow to a dysfunctional area may result in a 
change in the functional regulation of an endocrine cell (Furness et al., 1999, 
Stone, 1999).  
1.13.1.3 Lymphatic Cells 
The most important functions of the lymphatic system are to maintain fluid 
balance and to protect the body from potential infection (Kuchera and 
Kuchera, 1994). Whenever injury occurs, the subsequent inflammation brings 
about an increase in vascular perfusion, capillary filtration, and lymph 
production to the area. The greater the lymphatic flow through the body, the 
greater the contact between body defences and toxins (Kuchera and Kuchera, 
1994, Wallace et al., 1997, Huff et al., 2008). Movements of the internal 
organs, such as through respiration and abdominal peristalsis, have a positive 
effect on the pumping action of the lymphatic system, thereby enhancing its 
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function (Huff et al., 2008). This can be achieved via direct pressure on the 
lymphatic channels via visceral soft tissue manipulation, resulting in increased 
lymphatic flow (Wallace et al., 1997, Finet and Williame, 2000, Huff et al., 
2008).  
Inadequate lymphatic drainage results in the development of tissue oedema 
which compresses lymphatic channels, the vascular tree, and adjacent 
neurological structures, potentially reducing their function (Kuchera and 
Kuchera, 1994, Finet and Williame, 2000). Increased congestion leads to the 
stasis of interstitial fluids and changes in tissues, further compromising 
function. Visceral osteopathic manipulation may promote decongestion in an 
organ or region of the body (Wallace et al., 1997). A clinical trial undertaken 
on the effects of osteopathic lymphatic pump treatment involving patients 
suffering from pneumonia suggested that manual stimulation of the pulmonary 
area may reduce infection by enhancing immunity (Huff et al., 2008). 
Osteopathic lymphatic pump treatment increases the circulating leukocytes, 
resulting in the attenuation of bacteria within the lung tissue, and may 
therefore enhance the lymphatic system (Huff et al., 2008).  
It is important for professionals in manual therapy to recognise the importance 
of the enteric system. The function of this network of neurons, lymphatic cells 
and endocrine cells may be the clue to formulating an effective visceral 
treatment protocol for functional bowel disease. 
‘Three systems for detecting changes in the tissues are located in the wall of 
the intestine: neural, endocrine and immune detecting systems. Neural 
sensations are conveyed by extrinsic and intrinsic primary afferent neurones. 
Endocrine messages are in the form of hormones released from cells in the 
mucosal epithelium. The hormones enter the circulation and thus act at 
remote sites, but they also act locally, on nerve endings, epithelium, 
microvasculature, and cells of the immune system. Immune messages are 
conveyed by local activation of lymphocytes and augmented by circulating 
lymphocytes that are activated by antigens from the lumen.’ (Furness et al., 
1999) 
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1.13.2 Rationale for the Use of VOT 
Visceral osteopathy is used to optimise blood and lymphatic supply to the 
internal organs. The viscera are a collection of organs in the abdominal cavity 
that generally respond to the internal physiological motion guided by the 
involuntary movement of the diaphragm in respiration; the internal motility of 
the viscera such as peristaltic movement; cardiac movement and blood and 
lymph circulation; and via skeletal movement such as walking, running or 
exercising. This motion and motility and the influence on the viscera is 
constantly present throughout life (Barral and Mercier, 2006). 
The internal visceral physiological balance may be disrupted or impaired by 
internal adhesions and/or fixation that, according to the basic concepts of 
visceral osteopathy, could result in visceral functional impairment (Bove and 
Chapelle, 2012, Chapelle and Bove, 2013). VOT aims to help restore a 
visceral physiological balance via low invasive techniques to the abdominal 
area (Barral and Mercier, 2006).  
A recent study, using rats, analysed the effects of visceral manipulation after 
abdominal surgical intervention (Bove and Chapelle, 2012). The aim of the 
study was to determine the effect of visceral manipulation in preventing and 
managing post-surgical visceral adhesions. Thirty rats were assigned to one 
of three different groups; the lysis group, the preventative group and the 
control group. Rats from each group were given caecal abrasion surgery. In 
the lysis group, rats received one visceral manipulation at day 7 post-surgery 
and were then euthanized. In the preventative group, rats received visceral 
osteopathic manipulation post-operatively once a day until euthanasia at day 
7. The control group received no visceral treatment and were also euthanized 
on day 7. Bove and Chapelle (2012) suggest that there were no changes in 
the number of adhesions between the three groups of rats, however the 
severity of the adhesions, measured on a scale from 0-4 by a blinded 
assistant, showed a significant decrease between the lysis and preventative 
groups where the severity of the lysis scores was reduced from 1.9 to 0.6 
respectively (p<0.01). The authors hypothesised that the effect of visceral 
manipulation improved fluid movement and inhibited fibroblast migration, thus 
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reducing adhesion formation at the injury site (Bove and Chapelle, 2012). This 
study suggests a positive post-surgical effect of visceral osteopathic 
manipulation.  
Another study on the effectiveness of visceral osteopathic techniques (VOTs) 
was performed on IBS patients, again with positive results. Attali et al. (2013) 
considered 31 IBS patients in a randomized cross-over placebo controlled 
study. The qualitative effects of depression, constipation, diarrhoea, 
abdominal distension and abdominal pain using visual analogue scales 
(VAS), and rectal sensitivity using a distension balloon, before and after 
treatment were evaluated. The treatment group received general visceral 
osteopathy sessions as well as locally applied techniques in specifically 
sensitive areas of the abdomen and gentle manipulation to the sacral area. 
The placebo group received treatment in the same areas of the abdomen with 
a light, non-therapeutic, pressure. The authors reported that VOT ameliorates 
diarrhoea, abdominal distension and pain as well as rectal sensitivity. The 
positive effects of the therapy were long lasting and the symptom scores 
continued to be low at one year follow-up with no further treatment. 
The positive effects of VOT on IBS patients were also suggested by 
Hundscheid et al. (2007). This study randomised patients into two groups, the 
standard care group and the osteopathic group assigning 19 and 20 patients 
respectively. Patients allocated to the osteopathic group reported a 68% 
improvement in overall symptoms with one patient (5%) being completely pain 
free after the intervention. The symptomatic changes between the groups 
showed a statistically significant improvement in the osteopathic group 
(p<0.006). Bove and Chapelle (2012) indicated that visceral massage 
attenuated post-operative ileus. The treatment significantly increased GI 
transit, augmented cumulative faecal pellet discharge, and shortened the time 
interval of first faecal discharge post-surgery. According to the authors the 
positive effect of the massage may possibly have improved peristaltic activity. 
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1.13.3 Non-Specific Effects of VOT  
One of the challenges of VOT is to produce measurable isolated effects. The 
clinical nature of the technique cannot isolate specific tissues; therefore the 
application of the techniques may be postulated to affect blood supply, 
lymphatic system and organ system function. In general VOT affects motility 
and mobility, circulation fluids, sphincter and muscular spasms, hormonal and 
chemical production, immunity and the psyche (Barral and Mercier, 2006).  
1.13.4 Effectiveness of VOT in other Conditions  
According to Huff et al. (2008) the lymphatic pump technique, a type of 
visceral osteopathy applied to the thoracic cavity region and used by 
osteopaths when treating oedema patients, mobilizes inflammatory mediators 
into the lymphatic circulation. The authors tested the thoracic and intestinal 
lymph of dogs both at rest and after thoracic lymphatic pumping. The study 
suggests an increase in thoracic and intestinal influx of cytokines and 
chemokines after the application of the technique. The authors support the 
idea that the increased influx of cytokines may enhance immunity, possibly 
facilitating the clearance of infection (Huff et al., 2008). 
Another study, by the same group, (Hodge et al., 2010) has tested lymphatic 
pumping techniques in rats and measured lymphatic flux. The cisterna chyli of 
the rats were cannulated and measurements of lymph flux were taken four 
minutes pre-lymphatic pump technique (LPT) and at four minutes and ten 
minutes post-LPT. The results revealed an increased number of lymphocytes 
released into the lymphatic circulation. The group also found that gut 
lymphocytes were mobilized into the cisterna chyli and thence to the 
circulation. These studies provide experimental support for the clinical 
application of VOT. According to the authors, VOT may enhance the 
distribution of antigens and antibodies and may be clinically effective in 
treating and controlling infection. Huff et al. (2008), demonstrated that LPT is 
also effective in patients with chronic pneumonia. According to the authors 
LPT increases the circulatory leukocytes that are mobilized in the lungs, killing 
bacteria and reducing tissue damage.  
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1.14 Relevance of VOT in this Current Study  
The rationale for applying VOT to autistic children suffering from GI signs and 
symptoms rests with its holistic and low invasive approach. The use of touch 
and mobilisation of organs in an attempt to restore function has the potential 
to affect the ENS and possibly help to restore the gut-brain function (Mayer 
and Tillisch, 2011). It has been suggested that psychological stressors may 
result in GI symptoms. Autistic children are in a constant state of 'stress' 
purely due to the nature of the condition itself. Any positive effect of VOT on 
intestinal function has the potential to decrease GI signs and symptoms and 
this may be translated positively into a reduction in typical autistic behaviour.  
1.14.1 Challenges of VOT Application on Autistic Children  
The major challenge of application of VOT in autistic children is the use of 
touch as a form of treatment. Autistic children are hyper-sensitive to touch. 
According to Cullen et al. (2005) disruption of the primary senses can have a 
negative effect on the world around autistic children and their parents. It can 
be translated as touch avoidance with hyper-sensitivity to touch and touch 
defensiveness resulting in challenging behaviour. 
Touch is a primary sense and it is essential to a child’s development. 
According to Escalona et al. (2001) and Field et al. (1997), massage has a 
positive role in decreasing touch avoidance in autistic children. Cullen et al. 
(2005) studied the effects of parental touch on autistic children as a form of 
therapy. Parents were trained for eight weeks to apply touch therapy to their 
child. Baseline measurements were collect via a semi-structured phone 
interview before the initiation of sessions and again at week 16 of the 
treatment period. The authors observed that autistic children dictated the 
terms of how and when they should be touched by their parents, making 
spontaneous touch a challenging experience. The parents very aware of the 
possibility that their child would not be able to cooperate during the touch 
therapy sessions, creating apprehension and further concerned at not being 
able to comfort their own child in cases of pain or distress. However, after 16 
weeks of touch therapy, autistic children and their parents reported a sense of 
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closeness. The child was able to request touch therapy at home; in turn 
creating a more positive home environment. Parents reported that the children 
were more tolerant to touch and appeared to have improved verbal 
communication and were calmer and more relaxed. In contrast to previously 
held beliefs, autistic children enjoyed the touch therapy experience. 
1.14.2 Gap in the Literature  
According to Buie et al. (2010) the management of GI symptoms in autistic 
children may improve some of the behavioural symptoms. However, to date, 
there are no known published studies on the use of a  low-invasive treatment 
that could potentially ameliorate the challenging behaviour and GI signs and 
symptoms of children with autism (Furuta et al., 2012).  
The first attempt to study the effects of VOT on GI and behavioural signs and 
symptoms of autistic children dates back to 2002 when a pilot study was 
performed on 13 autistic children (Bramati-Castellarin and Janossa, 2002). 
The concept of the pilot study was developed from a lack of alternative or 
complementary evidence in this area. Historically, positive results have been 
associated with application of VOT to the abdominal area of general 
population subjects with GI dysfunction (Ernst, 1999, Finet and Williame, 
2000, Lamas et al., 2009, Attali et al., 2013). However, VOT had not been 
applied specifically to autistic children before the commencement of this 
study. The results of the pilot study suggested positive GI and behavioural 
responses after application of VOT. These positive results led the author to 
develop the pilot protocol, with the added introduction of biochemical markers 
in an attempt to objectively quantify any changes.  
The aim of the present study attempted to address the gap in the literature by 
studying the effect of VOT on autistic children suffering from GI signs and 
symptoms using both questionnaires and biochemical marker analysis.  
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1.15 Aims and Objectives 
The aims and objectives of this research were to investigate the effect of 
visceral osteopathic techniques (VOT) on the behaviour and GI signs and 
symptoms of autistic children.  
A. GI inflammation was assessed using:  
 Levels of calprotectin as a primary biochemical marker of inflammation, 
which was assessed using stool analysis.  
 Levels of tumour M2-pyruvate kinase (M2-PK) as a second biochemical 
marker, which were then correlated with the results for calprotectin. 
  Levels of lactoferrin as a third biochemical marker, which were 
correlated with the results for calprotectin and M2-PK.  
B. Behavioural and GI activity was assessed utilising a 10 point scale 
questionnaire, ‘Autism Research Institute Secretin Outcomes Survey Form, 
the ‘S.O.S Form’, which was given to parents before and after treatment 
(Appendix 5).  
1.15.1 Null Hypothesis: 
After six weeks of VOTs autistic children will not experience: 
1. Changes in GI symptoms  
2. Changes of behavioural symptoms  
3. Measurable changes in faecal calprotectin levels 
4. Measurable changes in faecal M2-PK levels 





1.15.2 Experimental Hypothesis:  
After six weeks of VOTS autistic children will experience: 
1. Changes in GI symptoms 
2. Changes of behavioural symptoms 
3. Measurable changes in faecal calprotectin levels  
4. Measurable changes in faecal M2-PK levels 
5. Measurable changes in faecal lactoferrin levels
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Chapter 2 - Methodology 
This chapter outlines the aims and objectives of the research before moving 
to explain the research design, data collection and statistical analysis.  
2.1 Objectives of the Current Study – Brief Overview 
The objective of the current study was to investigate the effect of VOT on GI 
signs and symptoms as well as behaviour patterns in autistic children. Two 
outcome measures were used during the study, specifically questionnaires, 
given to parents to assess GI signs and symptoms and behaviour patterns, 
and three biochemical markers of inflammation present in faeces 
(calprotectin, M2-PK and lactoferrin). Each was measured before, during and 
after application of VOT. The only intervention was therapeutic VOT applied to 
the abdomen of the subjects. The methodology remained consistent 
throughout to maintain statistical power. 
Each subject was examined and screened at the start of each treatment 
session to determine whether there were any issues, contraindications or 
adverse events associated with the previous treatment or research protocol. 
The normal procedure for osteopathic care followed the Osteopathic Practice 
Standard (OPS) for the duration of the research programme. The safety and 
welfare of the subjects was always of paramount importance.  
2.1.1 Justification of Methods  
The study aimed to address the lack of low-invasive treatments to autistic 
children suffering from GI signs and symptoms. The possible connection 
between changing behaviour signs and symptoms and the gastrointestinal 
condition in these children, as well as the lack of an appropriate low-invasive 
gastrointestinal treatment led the researcher to study the possible effects of 
application of VOT in these autistic children suffering from GI signs and 
symptoms. This methodology sought to investigate a possible link between 
changing behavioural symptoms and the GI system as suggested by Buie et 
al. (2010). Several authors such as Horvath et al. (1999), Jyonouchi et al. 
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(2005a), Nikolov et al. (2009), Reichelt and Knivsberg (2009), Forsythe et al. 
(2010), Walker et al. (2013) have also suggested a possible gut-brain axis 
that could be immunological, inflammatory or genetic in nature.  
The methodology chosen for this study took into consideration the complexity 
of behavioural patterns displayed by autistic children and their strong 
preference to mantain routine and sameness (Wing, 1997, Wing, 1998, 
American Psychiatric Association, 2000).  Only a small number of quantifiable 
data collection tools are available which conform with minimal enviromental 
changes. Hence, questionnaires and faecal biochemical markers were chosen 
for this study due to their low invasive nature, the ability of producing 
meaningful data and their compliancy with the Ethics commitee constraints 
when assessing and treating autistic children.  
The questionnaires were used to measure the parent’s perception of 
behavioural and GI signs and symptoms, whilst the biochemical markers 
objectively assessed GI inflammation. The outcome measures were 
considered before, during and after application of VOT. Other data collection 
tools such as blood tests, endoscopy, X-Rays and MRI were considered to be 
higly invasive by the Ethics Commitee and beyond the financial scope of this 
research. 
Questionnaires are useful data collection tools to analyse a patient’s 
perception of health (Rattray and Jones, 2007). The current study used a 
validated, standardized questionnaire to measure parents’ perception of their 
autistic children before, during and after application of VOT. The benefits of 
using questionnaires for data collection include the relatively low 
administration costs, ease of response and simplicity of data analysis (Rattray 
and Jones, 2007).  
Following several meetings with Professor Roy Sherwood, senior consultant 
at the Department of Clinical Biochemistry, King’s College Hospital, London it 
was decided to use three faecal biochemical markers to assess GI 
inflammation in this cohort. Professor Sherwood advised the use of 
calprotectin as a main marker and M2-PK and lactoferrin as adjunct markers 
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(Sherwood et al., 2005, Chung-Faye et al., 2007, Sherwood, 2012). All three 
markers display high levels of stability and reproducibility as well as good 
sensitivity and specificity for IBDs and IBS (Kane et al., 2003, Szarszewski et 
al., 2003, Koss et al., 2005, Loughlin et al., 2005, Lundberg et al., 2005, 
Ahmed et al., 2007, Ewald et al., 2007, Oremek et al., 2007, Walker et al., 
2007, Langhorst et al., 2008, Gonzalez-Chavez et al., 2009, Sidhu et al., 
2010b, Zippi et al., 2010, Aomatsu et al., 2011, Day et al., 2012, Manz et al., 
2012, Yamamoto et al., 2013) and are therefore appropriate markers to 
assess levels of GI inflammation.  
2.2 The Development, Evaluation, Implementation and Design 
Process of the Current Study 
The Medical Research Council created guidance for the development, 
evaluation and implementation of research design for complex interventions 
resulting in the “MRC Framework for the Development and Evaluation of 
RCTs for Complex Interventions to Improve Health” (Medical Research 
Council, 2000). These guidelines are intended to advise researchers about 
choosing the appropriate methods of research when considering a complex 
research intervention to improve health. The principles originally applied to the 
current study during the development, evaluation and analysis stages are in 
accordance with ‘Developing and evaluating complex intervention: new 
guidance’ (Medical Research Council, 2006). The MRC guidance was 
published after the current study was designed and undertaken but is 
referenced to illustrate that the methodology published is a formalisation of 
basic principles previously in existence. Methodology used in the current 
study followed clear guidelines for clinical safety. The application of 
osteopathic techniques followed the principles enshrined within the OPS 
(General Osteopathic Council, 2012). Before any assessment, intervention or 
measurement was undertaken a systemic review was made to evaluate the 
viability of such a study.  
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2.2.1 Piloting and Evaluation of the Intervention 
A pilot study was performed with 13 autistic children between the ages of 3 ½ 
and 8 years. This pilot study acted as a trial for the viability of the VOT 
treatment with autistic children. In addition, this pilot study trialled the 
recruitment process, the pre-assessment questionnaires and osteopathic 
case history taking, the modified S.O.S questionnaire and the VOT procedure. 
The effectiveness of the pilot study (Bramati-Castellarin and Janossa, 2002) 
informed the design of the current study.  
The results from the pilot study informed on the effect of group size and 
variability as well as on the rate of recruitment. A refinement arising from the 
pilot study was the inclusion of biological markers to measure possible GI 
changes via objective, experimental, quantitative assessment.  
2.3 Research Design: Before and After Intervention Study of 
Effectiveness  
This research study was structured as a clinical trial employing a before and 
after treatment study of effectiveness with repeated measures design. The 
before and after treatment study was chosen due to its high sensitivity in 
measuring treatment effectiveness in each individual subject and its 
avoidance of inter-subject variability (Kabat-Zinn et al., 1992, Rosner, 2011), 
enabling the analysis to focus more precisely on treatment effects. The design 
is economical with the subjects acting as their own controls thus requiring a 
smaller total number of subjects and eliminating the necessity for additional 
ethical approval for experimentation on ‘normal’ children; the controls are 
directly related and matched to the study set.  
There are some disadvantages to this type of research design. One is the 
carryover effect of the treatment before the effect of the previous treatment 
has worn off. This design flaw was minimised by allowing a week between 
each treatment procedure in an attempt to avoid carryover effects; standard 
practice in osteopathic clinical research studies (Licciardone et al., 2013). 
Another disadvantage of this type of research design is the learning effects 
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that may possibly occur after using a measuring tool such as a questionnaire. 
Subjects may become test wise and therefore present pattern improvement. 
This is addressed in the discussion (4.3.4). 
2.4 Ethical Approval 
A proposal for a double blind controlled trial was rejected by the ethics 
committee as it was considered unethical to expose the children to a ‘no 
treatment’ or ‘sham treatment’ control. 
A modified proposal constructed as a before and after Intervention study, with 
each subject acting as their own control (baseline) was submitted to the ethics 
committee and this project structure was granted ethical approval by both the 
British College of Osteopathic Medicine Ethics Committee and by the 
University of Westminster Ethics Committee as a ‘Before and After 
Intervention Study of Effectiveness’ (see Appendix 1).  
A proposal to assess behavioural changes by an independent psychologist 
who was blind to the techniques was not feasible due to cost constraints and 
it was not, therefore, possible to use a blinded external professional to assess 
behavioural patterns before and after intervention.  
The ethical approval that was granted did influence the final study design and 
this is addressed in the discussion. 
2.5 Population  
The population for the current study was composed of male and female 
autistic children aged between 3½ and 8 years. All subjects recruited to this 
study were independently diagnosed by specialist professionals prior to their 
inclusion in the study. All the specialist professionals in England and Wales 
are required to follow the DSM-IV and ICD-10 diagnostic criteria to release a 
Diagnostic Statement. Parents were asked to provide the Diagnostic 
Statement given to them, prior to any contact with the researcher. The 
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researcher did not make any contribution to the diagnostic process, thus 
avoiding classification bias on recruitment.  
2.5.1 Inclusion Criteria 
Autistic children suffering from classic signs and symptoms, including: 
1. Abnormal behavioural symptoms characteristic of autism as recognised 
by the DSM-IV and ICD-10 diagnostic criteria. 
2. GI symptoms, including abdominal distension and/or pain, constipation, 
chronic diarrhoea, foul-smelling stools and/or flatulence. 
2.5.2 Exclusion and Withdrawal Criteria 
1. Autistic children without GI symptoms.  
2. In the event of a child being unable to cooperate or being distressed.  
3. In the event of parental withdrawal of consent to treatment. 
In the event that a child developed a condition that could put their health at 
risk, e.g. serious infections, epilepsy. 
2.6 Recruitment Sites 
The main recruitment process was via special schools for autistic children 
(see table 2-1). Ten special schools accredited by the National Autistic 
Society were randomly selected, from London and the South East of England, 
and were contacted via formal invitation of the head teacher. Of the ten 
randomly selected special schools, four accepted the invitation to be part of 
the research recruitment process. (Letters and background information 
provided in Appendix 2).  
Following the first encounter with the head teacher, the researcher was 
granted permission to give a talk to the parents during a school parent’s 
meeting to present the research background. At the presentation, the parents 
were given the research guidelines as well as the inclusion and exclusion 
criteria for the study. Parents who considered that their autistic child 
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presented with GI dysfunction were then selected to respond to an initial 
questionnaire; used to establish the fulfilment of the inclusion criteria.  
Table 2-1 Recruitment sites and subjects number  
Recruitment Site  Subject per site Percentage  subject 
per site 
School 1  8 17% 
School 2 6 12% 
School 3 4 8% 
Private Practice 31 63% 
Total  49 100% 
Subjects were also recruited in response to announcements placed in local 
newspapers and/or magazines (Angel & Urchins); Schools, Universities 
(Westminster University and The British College of Osteopathic Medicine 
clinical area) and the internet (Talk Autism website – forum for 
parents)(Appendix 4). Subjects recruited from this process were treated at a 
private practice and required to fulfil the same inclusion and exclusion criteria 
as the subjects recruited from the special schools for autistic children. One of 
the criteria for subjects recruited via these announcements was that they 
needed to be enrolled at a special school for autistic children accredited by 
the National Autistic Society. The rationale for this requirement lay in the fact 
that the special schools for autistic children in England and Wales only accept 
children who have been given a statement of special educational needs 
(which is a legal document) by the Education and Library Board (ELB) after 
being assessed by an appropriate specialist.  
The parents were required to provide a copy of the Diagnostic Statement 
together with the statement of special educational needs provided by the ELB. 
Appropriately anonymised examples of the statements provided by the ELB 
and the Diagnostic Statement are provided in Appendix 3.  
The recruitment advertisements are provided in Appendix 4. 
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2.7 Recruitment Process, Screening and Consent  
After the initial recruitment/screening questionnaire, an interview 
questionnaire (Appendix 5) was completed by parents in order to obtain a 
child’s case history and to evaluate whether osteopathic treatment was safe 
and appropriate. This interview consisted of a one and half hour conversation 
with the mother and/or father when a thorough case history was taken. The 
case history was divided into pre-natal history, pregnancy, labour, medication 
during labour, developmental stages of the child, any accidents or surgeries, 
past and present medication, when a child was diagnosed as autistic, who 
diagnosed the child, present symptoms, GI symptoms (including colour of 
stools, their frequency, consistency and smell), behavioural symptoms 
(flapping of hands, eye contact, communication, etc.) current diet and 
allergies. From this it was determined whether the subject complied with all of 
the inclusion criteria and a decision was made as to whether it was safe for 
the subject to be treated using VOT.  
Written and oral guidelines were provided explaining the research and the 
treatment procedure. 
A signed consent form authorising the child to be part of the study was 
obtained for each study participant. 
2.8 Sample Size  
In total, 64 children were recruited to the study (Figure 2-1). Ten subjects 
were excluded due either to a compromising underlying condition or to not 
presenting with GI symptoms. A further five parents of autistic children 
completed the interview but did not comply with sending the first set of stool 
samples and the questionnaires necessary to participate in the study and so 
were classified as drop outs. The final sample therefore comprised of 49 
autistic children (male and female) aged between 3½ and 8 years. Of these, 
18 subjects were recruited and treated at three different schools for autistic 
children in the London area, while the remaining 31 were treated at a private 
practice in west London. All 49 subjects were treated by the same practitioner 
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using the same range of techniques. The initial period consisted of no 
treatment (control/baseline period) in order to determine a baseline for each 
specific subject. A placebo was not used in this study; to minimise any 
potential additional challenge to the children. It was also deemed ethically 
inappropriate to use a placebo in children with a learning difficulty/disability.  
Figure 2-1 Flow chart indicating the recruitment process and final sample size 
 
2.9 Overview of the Study Periods 
The study comprised of three periods, Period I – control (baseline), Period II –
treatment, and Period III – rest and post-treatment; which were considered 
together.  
2.10 Control Period (Baseline) – Period I of the Study  
The subjects acted as their own controls; the control/baseline period covered 
six weeks during which time no treatment or intervention was given, but 
weekly questionnaires were completed and stool samples collected. During 
this control/baseline period the researcher had no contact with the subjects 
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except by text message reminders to complete the questionnaires and to post 
the stool samples. Examples of the reminders sent to the subject can be seen 
in section 2.24.  
Four questionnaires were completed during the first six weeks of the clinical 
trial; at weeks 1, 3, 5 and 6 before the treatment period commenced, in order 
for parents to become familiar with the questionnaire and to act as a baseline 
control for responses (questionnaires 1-4). At least three stool samples for 
calprotectin/M2-PK/lactoferrin analysis were collected during this period, and 
the Safeboxes™ (Royal Mail)(Figure 2-15) utilised for their transport were 
clearly labelled 1-4 to identify that the samples came from the control period.  
The baseline data generated from this period (control/baseline) were then 
compared with the results obtained during treatment (treatment period) and 
following treatment (post-treatment period). 
2.11 Treatment Period – Period II of the Study  
Four questionnaires were completed during the six week treatment period of 
the clinical trial; at weeks 8, 9, 10 and 12 of the study (questionnaires 5-8). At 
least three stool samples for calprotectin/M2-PK/lactoferrin analysis were 
collected during this period, and the Safeboxes™ utilised for their transport 
were clearly labelled 5-8 to identify that the samples came from the treatment 
period. Parents were instructed in how to collect their child’s stool samples for 
the assessment of faecal markers in the same way as in Period I. A timetable 
for stool collection (to be used for faecal marker analysis) was agreed upon 
and given to the parents before the commencement of the osteopathic 
treatment sessions.  
The intervention comprised of six osteopathic sessions, using VOT to the 
abdominal area. The interventions were a week apart.  
It was arranged for a parent to be present with the child for the physical 
osteopathic examination and follow up treatment sessions. At every treatment 
session, the parent was asked whether there were any changes in the GI 
65 
and/or behavioural symptoms of their child following the previous session. 
The parent was also asked if there had been any changes in their child’s diet 
or medication, or if any accidents or infectious diseases had occurred during 
the week following the previous session. This monitoring during every 
treatment was also designed help to highlight any trends. All of the 
information provided by the parents was recorded on the treatment notes, with 
the case history.  
2.12 The Rest and Post-Treatment Period – Period III of the 
Study 
During the five week rest/post-treatment period there was no intervention. 
During this five week period one questionnaire was collected, six weeks after 
completion of the treatment period (questionnaire 9), at week 18 of the study. 
One stool sample for calprotectin/M2-PK/lactoferrin analysis was collected 
during this period and the Safebox™ utilised for transport was clearly labeled 
9 to identify that the sample came from the post-treatment period. A summary 
of the study design is shown in Figure 2-2 and a summary of the 
questionnaire and stool collection timeline is provided in Table 2-2.  
Figure 2-2 Summary of Study Design  
 
Table 2-2: Timetable for questionnaire completion and faecal sample collection 
Study Period Weeks Questionnaire/Faecal 
sample number 
Period I. The control/baseline period  1-6 1-4 
Period II. The treatment period 7-12 5-8 
Period III. The post- treatment period 18 9 
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2.13 Visceral Osteopathic Techniques (VOT) – Intervention  
All subjects were treated using VOTs over the entire abdominal region, 
including the duodenum, ileo-caecal valve, sigmoid colon, pancreas and 
general abdominal regions. The treatment protocol was designed using 
standard osteopathic techniques. Although the treatments were performed 
over the entire abdominal area, the treatment focused on the classical regions 
of the landmarks listed in Table 2-3. It is accepted that this anatomical picture 
of the abdomen is generic and not an accurate illustration of individual 
anatomy. However, since the entire abdominal region is treated, each of the 
specific areas will be included within the treatment regimen.  
 
Figure 2-3: The nine abdominal pelvic regions 
© A.D.A.M, INC 2014 
Legend to Figure 2-3: Illustration giving a general anatomical overview of the nine regions of 
the abdomen. There is no attempt to predict the location of the abdominal pelvic organs 
accurately.  
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2.13.1 VOT Protocol  
The intervention was composed of a set of VOT techniques applied to the 
abdominal area by a single senior osteopath/researcher (the practitioner) with 
13 years of experience in osteopathic practice. Table 2.3 lists the 
standardized VOT used in the study.  Six VOT sessions were proposed for 
the study.  
Table 2-3: List of standardised VOTs used in the study 
Mobilisation Target  Abdominal Area  Position 
Ilio-caecal Valve  Between right lateral lumbar legion Supine or side lying  
Duodenum Umbilical region  Supine 
Ligament of Treitz Umbilical region Supine 
Pancreas Epigastric region Supine 
Sigmoid colon  Left lumbar region Supine or side lying  
Legend to Table 2.3: Represents a list of standardised VOTs used during the treatment 
period of the study, Period II. All techniques were applied to the abdominal area (Stone, 1999, 
Barral and Mercier, 2005, Barral and Mercier, 2007). 
The time allocated for each consultation was half an hour (30mins), timed 
from the moment the subject entered the treatment room until they left. The 
initial 10 minutes was used for meeting and greeting the patient and the 
parent as well as taking brief notes of the preceding week and to allow 
enough time for the autistic child to become accustomed to the presence of 
the practitioner. 
The practitioner spent the initial 10 minutes acclimatising the patient, with the 
intention of palpating, examining and treating the abdominal area. Patients 
often displayed unpredictable and/or aggressive behaviour towards the 
osteopath, such as spitting, biting, pushing, hair pulling and scratching and 
the nature of the treatment took these behaviours into account. All measures 
were taken to maintain the safety of both patient and practitioner. 
Each VOT session lasted 20 minutes. At the beginning of each session the 
practitioner adopted a global visceral osteopathic palpatory technique aiming 
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to treat the areas around the ileo-caecal valve, the duodenum, the ligament of 
Treitz, the pancreas and sigmoid colon.  
The visceral techniques chosen for this research project aimed to increase 
circulation, detoxification (biochemical turnover), peristalsis and gut emptying, 
in addition to aiding neuro-regulatory responses via the ENS as outlined in 
chapter one, (1.10.1) and thereby positively influencing the GI and 
behavioural function of the subjects. 
2.13.2 VOT Techniques used in the Current Study 
The VOT sequence used in this study is an illustration of the treatment 
procedure. Owing to the complexity of each case, the researcher had to adapt 
the positions and sequence of the VOT treatment to suit each patient; taking 
into account challenging behaviour exhibited by high end sufferers. Auditory, 
visual or tactile props were needed to attract a child’s attention to the 
treatment. Treatment took place variously under the couch, with the patient 
sitting on their mother’s lap, or in a standing position. Some of the subjects 
displayed distinctive behaviour, such as jumping up and down on the couch, 
flapping their hands, running in circles or needing a specific toy to play with 
during a session, as well as aggressive actions such as biting, kicking and 
spitting. A major determining factor for the sequence of the techniques was 
the individual’s behaviour, with patient and practitioner safety being of 
paramount importance. However, the techniques described in Section 2.13 
were all used in the treatment sessions, although not necessarily in any fixed 
or specific order. To date, there is no evidence to support a particular 
treatment sequence, nonetheless, in this study, the specific order of the 
sequence of treatment was noted on the case history for each subject for 
future record.  
The order of treatment was determined by the individual, for example, some 
patients had faecal impaction in the sigmoid colon and so this area was 
chosen as the starting point for treatment. It was common for children to need 
to empty their bowels urgently during treatment, which tends to support the 
treatment strategy.  
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2.13.2.1 Ileo-caecal Valve Region Technique 
The patient lies in the supine position (Figure 2-4). Using both hands, the 
practitioner will mobilise the ileo-caecal region out of the right iliac fossa. 
Gentle motion will be applied diagonally towards the patient’s left shoulder 
(see arrow in Figure 2-4). The same technique can be applied for a side lying 
or sitting position (Figure 2-5 and Figure 2-6, respectively).  




Figure 2-5: Ileo-caecal valve region technique side lying position  
 
Figure 2-6: Ileo-caecal valve region technique sitting position  
 
2.13.2.2 Mobilisation of the Duodenum – D2 Region in the Supine 
Position 
The practitioner stands by the patient’s left side, and using the right hand, 
applies an anterior posterior pressure on the ribcage of the patient thereby 
creating slack tissue (Figure 2-7). The practitioner’s left hand palpates the 
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duodenal region at the D2 level and gentle backwards and forwards motion is 
applied (see arrow in Figure 2-7).  
Figure 2-7: Duodenum region technique 
 
2.13.2.3 Mobilisation of the Ligament of Treitz Region in the Supine 
Position 
The practitioner will be at the patient’s left side and will then move his/her 
fingers across towards the patient’s right side over the ligament of Treitz 
region. With the practitioner using both hands, gentle backwards and forwards 
motion is applied (see arrow in Figure 2-8:). 
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Figure 2-8: Ligament of Treitz region technique 
 
2.13.2.4 Mobilisation of the Pancreatic Region in the Supine Position  
The practitioner is by the patient’s right side and places his/her right hand 
towards the pancreatic region. Gentle circular clockwise motion will be applied 
using both hands (see Figure 2-9).  
Figure 2-9: Pancreatic region technique in the supine position 
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2.13.2.5 Mobilisation of the Pancreatic Region in the Side Lying Position 
The same technique is applied to the pancreatic region in the side lying 
position. The practitioner is stationed behind the patient and gentle circular 
clockwise motion is applied using one hand (see Figure 2-10).  
Figure 2-10: Pancreatic region technique in the side lying position 
 
2.13.2.6 Sigmoid Colon Region Technique in Supine Position 
This technique is applied with the patient lying supine. Using both hands the 
practitioner will mobilize the sigmoid colon region out of the left iliac fossa. 
Gentle motion will be applied diagonally towards the patient’s right shoulder 
(see arrow in Figure 2-11).  
74 
Figure 2-11: Sigmoid colon region technique in the supine position 
 
2.13.2.7 Sigmoid Colon Region Technique in the Side Lying Position 
The practitioner’s position is to the side of the patient, facing their head unless 
otherwise stated, whilst the patient will lie on his/her right side. Using both 
hands the practitioner will gently mobilise the sigmoid colon region out of the 
left iliac fossa. Gentle motion will be applied diagonally towards the patient’s 
right shoulder (see arrow in Figure 2-12) the same technique can be applied 
in a sitting position (see Figure 2-13).  
Figure 2-12: Sigmoid colon region technique in the side lying position 
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Figure 2-13: Sigmoid colon region technique in the sitting position 
 
2.14 Quality Control and Fidelity  
The VOT comprises tried and tested techniques, published in classic 
osteopathic publications and used internationally by the osteopathic 
community. These techniques were used in the pilot study that preceded the 
current clinical study (Bramati-Castellarin and Janossa, 2002).   
The current study was set up as a patient centred, before and after 
intervention, study of effectiveness; using a set of VOT techniques. The 
consistency of the techniques was maintained by employing the same 
practitioner throughout the study. This study did not include an inter-rater 
reliability factor when executing the techniques since there was only one 
practitioner. The standard of techniques applied to different patients was 
consistent, as far as the subjects would allow.  
Another issue of quality control and fidelity of the procedure is stability of the 
environment throughout the study period. Subjects tested, in this current 
study, have received VOT techniques in the same room (either private 
practice or school premises) and every effort has been made to keep the 
internal environment (same room, controlled temperature, same furniture, 
controlled noise levels, same personnel present) as constant as possible 
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during each session. The two internal environments where subjects were 
treated had the same environmental control throughout the study.  
2.15 Collection of Faecal Samples and Materials Used 
Samples were collected and placed in labelled disposable polystyrene screw 
cap tubes (Figure 2-14:). The tubes were given to the parents in batches for 
each of the three collection periods.  
Figure 2-14: Disposable polystyrene screw cap tube used to collect samples 
 
www.shutterstock.com 
Period I (control/baseline); parents were given the appropriately numbered 
questionnaires, four collection tubes with numbered caps and four 
Safeboxes™ for sending the samples for analysis. Each Safebox™ was 
numbered sequentially from 1 to 4 (see table 2-4), making it straightforward to 
identify the appropriate box to be sent. Parents were asked only to date the 
sample and the form inside the Safebox™ Figure 2-15) which was coded for 
subject identification. The boxes were sent to King’s College Hospital where 
the samples were stored at -20 ºC. 
Table 2-4 Timeline for faecal sample collection 
 Study Period  Weeks Faecal Sample Lab Codes 
 Period I 1-6 1-4 1BTT -4BTT 
 Period II 7-12 5-8 1TT-4TT 
 Period III 18 9 1PTT 
Legend to Table 2.4: Laboratory sample code BTT – before treatment, TT – Treatment period 
and PTT – post treatment 
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Figure 2-15: Safebox™ 
 
(Royal Mail, 2008) 
Parents were trained in how to collect the stool samples, either from a potty or 
a nappy if the child was not yet potty trained. Calprotectin, M2-PK and 
lactoferrin remain stable at room temperature for up to seven days, allowing 
time for the sample to be posted. Parents were reminded by text message the 
day before the stool collection was due and again on the day of collection, to 
post the sample to King’s College Hospital and to send the questionnaire to 
the researcher, thus ensuring that all the samples and questionnaires 
matched with the predetermined dates.  
All laboratory analyses were undertaken by the Department of Clinical 
Biochemistry, King's College Hospital, Denmark Hill, London SE5 9RS. The 
stool samples were transported via Royal Mail, complying with the current 
postal regulations for the packaging of pathological specimens (Royal Mail, 
2008). The law requires that packaging of pathological specimens must 
comply with packaging instruction P650 and the Royal Mail supplies 
Safeboxes™ that comply with all the regulations. The Safebox™ clearly 
indicated that it was transporting human material for diagnostic purposes and 
was designated biological hazard category B, and transported under the 
auspices of UN 3373. All provisions for the health and safety of specimen 
transportation conformed with the current regulations (Health and Safety 
Executive, 2005, Royal Mail, 2008, Department of Transport UK, 2009).  
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2.16 Analysis of Biochemical Markers 
Sample analysis was undertaken at King’s College Hospital, London, a centre 
of excellence in measuring faecal markers, and strictly followed the 
manufacturer’s instructions (given below). 
2.17 Sample Requirements for Calprotectin, M2-PK and 
Lactoferrin Analysis 
Faeces are collected in a sterile screw cap container (Figure 2-14) and 
dispatched to the laboratory for analysis. Samples should not be kept at room 
temperature for more than 2 days (M2-PK) or 4 days (calprotectin and 
lactoferrin) and once received should be kept frozen at -18ºC or below until 
the time of analysis. One gram (calprotectin and lactoferrin) or 50-100 mg 
(M2-PK) of a random faecal sample is required for analysis. There are no 
dietary constraints for the subject prior to faecal collection for any of the 
markers.  
Faecal calprotectin, M2-PK and lactoferrin samples are stable for 6 months to 
1year at -18ºC. After assay, samples are stored at -18ºC or below in 
appropriately labelled bags. The assay was performed on duplicate samples.  
2.18 Sandwich ELISA (enzyme linked immunosorbent assay) 
The concentrations of faecal calprotectin, M2-PK and lactoferrin were 
measured by a sandwich ELISA and a schematic showing the steps involved 
is shown in . A sandwich ELISA is typically performed in a 96-well plate, with 
an immobilised capture antibody specific for the antigen under analysis (in this 
case calprotectin/M2-PK/lactoferrin) coating the walls of each well. The 
sample being investigated is added to the well and any protein present will 
bind to the immobilised antibody. After washing to remove any non-bound 
material, an excess of a secondary detection antibody that is labelled with an 
enzyme is added. Addition of the enzyme substrate results in a colour 
change, proportional to the amount of protein present and this can be 
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enumerated on a plate reader set to the appropriate light absorbance. See 
Figure 2.16.  
Figure 2-16: The steps involved in a sandwich ELISA  
2.19 Calprotectin 
Calprotectin EK-CAL©, from Buhlmann Laboratories, was used to detect 
calprotectin in the stool samples. Figure 2-17.  
Figure 2-17: Calprotectin EK-CAL © 
 
(Buhlmann Laboratories, 2011) 
The calprotectin assay is a quantitative ELISA using monoclonal antibodies 
for the detection of Calprotectin in the faeces. Initially, the calprotectin is 
extracted using a dissociating extraction buffer. The supernatant (after 
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centrifugation of the extraction buffer) is further diluted and used for the 
detection of calprotectin  ELISA. 
2.19.1 Calprotectin Preparation Procedure 
40-100 mg of faeces, avoiding any undigested solid material like fibres and 
seeds, were placed in a pre-weighed, empty, screw-capped tube. Pre-diluted 
buffer was added, 1:50, weight/volume, and the suspension mixed vigorously 
for 30 seconds. The suspension was then mixed for a further 30 +/- 5 minutes 
using a shaker at approximately 1000 rpm, with the loop inside the tube as an 
agitator. A small amount of the mixture (1- 2 mL) was then transferred to an 
Eppendorf tube and centrifuged at 10,000 g for 20 minutes at +4ºC. The 
supernatant was harvested and this extract used in the ELISA. A total volume 
of approximately 0.5 ml was taken and used either for the assay or stored, 
frozen. The calculations were performed by a computer linked to the ELISA 
reader, quality controls being included in each run. Stool concentration of 
calprotectin was calculated as g/g of faeces. Values above 50 g/g are 
considered a positive calprotectin test.  
2.19.2 Intra-assay precision 
The intra-assay variance of Calprotectin EK-CAL © was calculated by a 20-
fold determination of 6 samples (52.5 – 1246 g/g calprotectin/mL stool); the 
mean coefficient of variance (CV) was 5.4% (2.7 – 8.1%). 
2.19.3 Inter-assay precision 
The inter-assay variance of Calprotectin EK-CAL © was calculated with 10 
samples (18.1 – 1764 g/g calprotectin/mL stool). The aliquots were tested 
according to the assay procedure in 10 different runs. The mean CV% was 
10% (CV% 6.6 – 14.5). 
2.19.4 Sensitivity 
The detection limit of the assay is 10 g/g of faeces. 
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2.19.5 Reference range 
Faecal Calprotectin reference range 0.5 – 50 g/g of faeces is considered 
normal. 
2.20 M2-PK 
M2-PK in stool samples was detected using the Schebo®•Tumor M2-PK™ 
ELISA Stool Test from ScheBo® Biotech, according to the manufacturer’s 
instructions (Figure 2-18). 
Figure 2-18: ©Schebo®·Tumor M2-PK™ ELISA Stool Test 
 
(ScheBo® · Biotech AG, 2011) 
Faecal M2-K kit is provided by ScheBo Biotech, Netanyastr. 3 (Europaviertel), 35394 Glessen 
(Germany)(ScheBo® · Biotech AG, 2011). 
The ELISA plate is coated with a monoclonal antibody that only recognizes 
tumour from stool samples and standards. Tumour M2-PK binds to this 
antibody and a second, biotinylated, monoclonal antibody binds to tumour M2-
PK during the next incubation. The assay is completed by adding a 
streptavidin, peroxidase conjugate, followed by TMB (3, 5,3’,5’-tetra-
methylbenzidine) substrate. TMB oxidises in the presence of peroxidase, 
giving a colour change that can be measured photometrically (ScheBo® · 
Biotech AG, 2011). 
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2.20.1 Intra-assay precision 
The intra-assay variance of ©Schebo®·Tumor M2-PK™ was evaluated by a 
20-fold determination of five samples (3.8-19.7 U Tumor M2-PK/ml stool). The 
mean coefficient of variance (CV) was 5.3% (3.0-7.9%). 
2.20.2 Inter-assay precision 
The inter-assay variance of ©Schebo®·Tumor M2-PK™ was calculated with 
five samples (1.9-18.2 U Tumor M2-PK/mL stool), that were tested on ten 
different days. The mean CV was 6.8% (4.4-9.4%). 
2.20.3 Sensitivity 
This test kit allows the quantification of Tumour M2-PK from 1 to 20 units/mL 
(U/mL). Values outside this range should be specified as <1 U/mL or >20 
U/mL respectively. 
2.20.4 Reference range 
A reading of >4U/mL is considered to be a raised level of Tumour M2-PK in 
the stool and can be an indicator of colorectal polyps or colorectal cancer. 
Raised levels can also occur in acute and chronic inflammatory bowel disease 
and some other diseases of the digestive tract.  
(ScheBo® · Biotech AG, 2011).  
2.21 Lactoferrin 
Lactoferrin was detected in stool samples using the Lactoferrin IBD-SCAN® 
from TechLab®, according to the manufacturer’s instructions Figure 2-19. 
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Figure 2-19: Lactoferrin ELISA KIT IBD-SCAN® 
 
(TechLab®, 2008) 
The technical procedures were followed according to TechLab® (2008) IBD-
SCAN catalogue specifications. Faecal Lactoferrin kit is provided by Tech Lab 
Blacksburg, VA24060 USA,(TechLab®, 2008). 
The Lactoferrin test uses antibodies to human lactoferrin. The micro assay 
wells supplied with the kit contain an immobilised polyclonal antibody 
conjugated to horseradish peroxidase. In the assay, standards and serial 
dilutions of faecal samples are transferred to the micro assay wells. 
Lactoferrin present in the specimen, will bind to the immobilised antibody. 
After incubation and washing to remove any unbound protein, the antibody 
conjugate is added. The conjugate (red cap – Figure 2-19) will bind to a 
different receptor on the lactoferrin bound to the well. A second wash step is 
followed by addition of the substrate (blue cap – Figure 2-19) and the colour 
change measured is directly proportional to the concentration of lactoferrin in 
the sample.  
2.21.1 Intra-assay precision 
The intra-assay precision of the IBD-SCAN ™ test was determined by 
analysing reactions among nine faecal specimens. Five specimens had 
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elevated lactoferrin and four specimens with baseline lactoferrin. Each 
specimen was tested in quadruplicate. The mean CV was 12% (7.9-16.0%)  
2.21.2 Inter-assay precision 
The inter-assay precision was determined by analysing nine faecal specimens 
over a 3-day period. Each specimen was tested in quadruplicate. The mean 
CV was18.6% (0 - 47.7%).  
2.21.3 Sensitivity 
The detection limit of the assay is <6.25 ng/mL 
2.21.4 Reference range 
Faecal Lactoferrin reference range is 73 – 2370 ng/mL 
(TechLab®, 2008). 
A summary of technical information for each marker is presented in Table 2-5 
Table 2-5 Summary of Technical Information for each Biochemical Marker 
 Calprotectin  M2-PK  Lactoferrin  
Intra-assay (CV)  5.4% (2.7 – 8.1%) 5.3% (3.0-7.9%). 12% (7.9-16.0%) 
Inter-assay 10% (CV% 6.6 –14.5) 6.8% (4.4-9.4%). 18.6% (0 to 47.7%) 
Sensitivity  10 g/g 1 to 20 U/mL <6.25 ng/mL 
Reference range <50 g/g >4 U/mL 73 – 2370 ng/mL 
2.22  Questionnaire Structure, Design and Method of Use 
A questionnaire was used to assess GI and behaviour changes during the 
three periods of the study. Parents completed the questionnaire according to 
their assessment of their child’s GI and behavioural symptoms using a 24 
parameter, ten point scale based on the Autism Research Institute Secretin 
Outcomes Survey Form, the ‘S.O.S Form’; a validated and standardised 
questionnaire (Rimland, 1998, Brudnak et al., 2002, Unis et al., 2002, Esch 
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and Carr, 2004b, Erickson et al., 2005a, Sturmey, 2005, Williams et al., 2005). 
The different parameters used to assess symptoms are shown in Table 2-6. 
According to Jerckings (1998) the use of questionnaires in quantitative 
research has several advantages in that a large amount of information can be 
collected in a relative short period of time, validity is not compromised by 
numbers of people involved in completing them, the data generated from the 
questionnaires can easily be quantified and so can be used scientifically, data 
can be compared and correlated with other research and also, questionnaires 
can be used to measure changes before/after intervention. 
However, no scientific measuring tool is perfect and there are some known 
disadvantages of using a questionnaire to collect data for scientific research 
including reliability and accuracy of recall, level of subjectivity of perception 
when answering a question as well as omission from the questionnaire of 
questions that might have been important for the study.  
The advantages and disadvantages of using the S.O.S questionnaire in this 
current study will be considered in the discussion section 4.3.4 (Period I – 




Table 2-6: Questionnaire parameters used to assess behavioural and GI symptoms  
Social behaviour and 
communication 
1. Lack of awareness and interaction with 
parent 
2. Abnormal greeting behaviour 
3. Abnormal comfort seeking 
4. Can’t make friends 
5. Lack of awareness of social rules 
6. Lack of spontaneous speech 
7. Abnormal word utilisation 
8. Poor comprehension of verbal instructions 
9. Lack of eye contact 
Ritual and Repetitive 
Activities 
10. Abnormal repetitive gestures 
11. Need to maintain sameness 
12. Need of fixed routine 
Digestive Signs 13. Diarrhoea 
14. Constipation 




General Signs 19. Unhappy 
20. Aggressive 
21. Destructive 
22. Spaced out/Non Interactive 
23. Agitated 
24. Disagreeable 
Legend to Table 2-6: This questionnaire is a modified Autism Research Institute – S.O.S 
Form (Rimland, 1998). 
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A Likert Scale was used to assess severity of signs: 
0 = never shows this particular sign or behaviour 
1 = slight/unobtrusive 
2-3 = mild 
4-5 = moderate 
6-7 = severe 
8-9 = extreme/incapacitating 
The questionnaire parameters were collated with the contemporaneous faecal 
marker results for calprotectin, M2-PK and lactoferrin.  
The questionnaires were used during the three periods: 
 Period I: The control/baseline period. Four questionnaires were 
completed during the first six weeks of the clinical trial. Questionnaires 
1-4 were distributed at weeks 1, 3, 5 and 6 before the treatment period 
in order for parents to achieve familiarity with using the questionnaire 
and to act as a control baseline for responses.  
 Period II: The treatment period. Four questionnaires were completed 
during the six week treatment period of the clinical trial. Questionnaires 
5-8 were distributed at weeks 8, 9, 10 and 12 of the study. 
 Period III: The post-treatment period. One questionnaire was 
completed six weeks after completion of treatment, at week 18 of the 
clinical trial.  
A timetable for completion of questionnaires was agreed with the parents 
before commencement of the study (Table 2-7). Parents were provided with a 
stamped addressed envelope for each questionnaire and were reminded of 




Table 2-7: Timeline for questionnaire completion 
 Study Period Weeks Questionnaires Questionnaires Code 
 Period I 1-6 1-4 1BTT -4BTT 
 Period II 7-12 5-8 1TT-4TT 
 Period III 18 9 1PTT 
Legend to Table 2.7: Questionnaires Code: BTT – before treatment, TT – Treatment period 
and PTT – post treatment  
2.23 Measures of Outcome 
2.23.1 S.O.S Questionnaire  
To measure outcomes for the GI signs and symptoms and behaviour, the 
S.O.S questionnaires were completed, pre-treatment (control/baseline), 
during the treatment period and post treatment. 
This questionnaire has been previously validated and standardised (Rimland, 
1998, Brudnak et al., 2002, Unis et al., 2002, Esch and Carr, 2004b, Erickson 
et al., 2005a, Sturmey, 2005, Williams et al., 2005). 
2.23.2 Biochemical Markers  
To measure outcome for GI inflammation three faecal biochemical markers 
(calprotectin, M2-PK and lactoferrin) were measured in stool samples, pre-
treatment, during the treatment period and post-treatment.  
2.24 Schedule and Monitoring of Data Collection  
Parents were provided with a specific timetable for posting the questionnaires 
and the faecal samples during each period (weeks 1, 3, 5 and 6 for the 
control/baseline period (Period I); weeks 8, 9, 10 and 12 for the treatment 
period (Period II) and week 18 for the post treatment period (Period III) (See 
section 2.22 and Table 2.7). They were also provided with instructions for 
filling in the numbered questionnaires and collecting the numbered faecal 
samples as well as the procedure for posting them.  
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The patient details were entered onto a secure practice management system 
and backed up in a secure remote system, conforming to the Data Protection 
Act. All of the questionnaires and the sample collection timetable per period 
were entered in the system as well as each individual appointment for each 
VOT.  
An automated reminder text message advised the subject’s parents of the 
specific date to post the questionnaires and samples. The same system was 
utilised to monitor the appointment dates, along with informing of any 
research dropouts or did not show (DNS) for any VOT session. Drop outs and 
DNS sessions are presented in the results section of this thesis. 
Code numbered questionnaires from Periods I, II and III were entered in the 
TM2 system as received. Receipt of the corresponding Safeboxes™ was 
confirmed with the allocated laboratory assistant at King’s College Hospital. 
The questionnaires, and their corresponding Safeboxes™, were individually 
coded by period i.e. questionnaire one before treatment was coded as BT1 
and the Safeboxes™ before treatment one was coded BT1 (see tables 2-4 
and Table 2-7). 
During Period II, the parents received automated text messages to remind 
them both of appointments and to post the questionnaire, and to collect the 
faecal sample and to post the Safeboxes™. The text messages read as 
follows:  
‘This is a reminder that your next appointment for the Osteopathic Autism 
Research is tomorrow at.... time.’ 
And:  
‘This is a reminder for you to post questionnaire number X and sample 
number X by tomorrow.’  
These procedures were put in place to monitor and record any missing 
questionnaires and samples. 
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2.25 Data Management and Avoidance of any Data Bias  
Data management followed a strict procedure, outlined below, and aimed at 
avoidance of error and maintenance of data quality for analysis and 
interpretation. 
All questionnaires submitted throughout the study period were stored 
securely, in a locked cabinet, until the study had been completed. After the 
end of the Period III, an independent researcher entered the raw data 
collected from the questionnaires into a spreadsheet. All the entries were 
rechecked by an independent statistician before the statistical analysis was 
performed. The researcher was not part of this process and all the data were 
analysed only after all the entries from the questionnaires were computed as 
raw data. 
All of the samples received by Kings College Hospital were analysed by an 
independent laboratory assistant, who was not part of the study. The data 
generated from the three faecal biochemical markers (calprotectin, M2-PK 
and lactoferrin) was entered into a spreadsheet and emailed to the 
researcher. The researcher did not have any contact with the data prior to 
this, thus avoiding the risk of bias.  
The researcher then cross referenced the data generated from the 
questionnaires with the data from the biochemical markers and an 
independent statistician checked the data and computed any missing data. 
All the original data are archived, normally for five years. 
The remainder of the faecal samples submitted will be kept, frozen, at King’s 
College Hospital until June 2015.  
2.26 Pre-Statistical Analysis Testing  
A series of pre statistical testing was performed before any statistical analysis 
was completed.  
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2.26.1 Determination of the Sample Size 
One of the pre-statistical analysis tests performed for this current study 
estimated sample population and the statistic power of the study. A 
monogram (Altman, 1982, Whitley and Ball, 2002) was used for calculating 
sample sizes (Cohen, 1977). In the current study, the sample size was 
estimated at n = 52 with Cohen’s d = 0.78 with 80% power with a statistical 
significance 0.05 (p=0.05). All effort was taken to correctly identify the true 
effect size between the tested groups.  
2.26.2 Test-Retest Analysis 
The test-retest reliability is the most common measure of reliability and 
assesses the reliability between two scores using correlation analysis (Field, 
2012; Tabachnick & Fidel, 2012). The resulting correlation between the 
scores is referred as the reliability coefficient. The reliability coefficient is 
graded from 0.9 or greater (excellent), 0.9 to 0.8 (good), 0.8 to 0.7 
(acceptable), 0.7 to 0.6 (questionable), 0.6 to 0.5 (poor), and less than 0.5 
(unacceptable) (Chronbach et al. 1972; Thorndike, 1947; Nunnally, 1978; 
Field 2012). This analysis was used for Study I.  
2.26.3 Chronbach’s Alpha Analysis 
 Chronbach’s Alpha analysis, a coefficient of reliability (or internal 
consistency), was conducted on the S.O.S questionnaire to evaluate its 
reliability and the reliability of the four S.O.S questionnaire subscales 
(Appendix 7). Chronbach’s Alpha scores above 0.7 are considered acceptable 
for reliability (DeVillis, 2003, Field 2009). The overall reliability of the S.O.S 
questionnaire was 0.881 on Chronbach’s Alpha Scale suggesting a good 
internal consistency. Table 2-8 represents Chronbach’s Alpha internal 
consistency levels. More details of the Chronbach’s Alpha results for each 
questionnaire subscales are presented in the results section of this thesis. 
The evaluation of reliability of the S.O.S questionnaire was performed before 
any correlation between periods was completed. This was used for Study I.  
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2.27 Statistical Analysis  
The statistical analysis performed during Period I (control/baseline) 
established baseline levels for the three biochemical markers prior to the 
initiation of VOT. Baseline data were used to correlate the results between the 
three markers (calprotectin, M2-PK and lactoferrin) during Period I.  
The data collected from the three biochemical markers and the questionnaires 
were analysed and correlated, taking the results of Period I, Period II and 
Period III. 
The researcher had several meetings with Dr Bernardo Tura from the IDO’R 
Research Institute, Brazil and statisticians from the University of Westminster 
(Dr Clair Robertson) and from other institutions in the UK (Dr Stan Cohen). 
Moreover, Dr Andrew Dalby from Westminster University was consulted via 
the director of studies. The purpose of the meetings was to discuss the 
appropriate statistical analyses of the collected data and the specific statistical 
test used. The statisticians indicated multiple linear regression analysis as the 
most appropriate method. Multiple linear regressions were chosen due to the 
high sensitivity in measuring treatment effectiveness in each individual subject 
(Rosner, 2011). This type of analysis avoids the variability observed between 
subjects and which is often found in studies that recruit a separate set of 
individuals as controls (Stewart, 2010, Rosner, 2011).  
Cronbach’s Alpha Internal Consistency 
 α ≥ 0.9 Excellent  
0.7 ≤ α < 0.9 Good 
0.6 ≤ α < 0.7 Acceptable 
0.5 ≤ α < 0.6 Poor 
α < 0.5 Unacceptable 
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Dr Tura suggested that the data generated from the set of 8 questionnaires 
could be correlated with the results of the 8 sets of the main biochemical 
marker - calprotectin.  Each parameter from the questionnaire was analysed 
individually using a univariate model. Each parameter was analysed 
repeatedly at several points in time and corrected by patient and by sample 
and correlated to calprotectin samples. Univariate analysis is an established 
strategy to measure longitudinal data for single outcome variables (Nakai, 
2009). A mixed effect model was used to analyse the repeated observations 
for this study. In this model the analysis takes into consideration any missing 
data which could potentially have an effect on the end results, an inherent 
problem of longitudinal studies (Pan et al., 2012). The mixed effect model is 
used to correlate repetitive measures and it also measures the “within” and 
“between” subject error. This mixed effect model has been employed for the 
analysis of the data generated by longitudinal studies (Mallinckrodt et al., 
2003, Pan et al., 2012) and Dr Tura has used these statistical analyses to test 
data from his own research studies (Aguiar et al., 2010, Benchimol-Barbosa 
et al., 2013).  
Statistical tests performed on these data are outlined below.   
2.27.1 Repeated Measure ANOVA 
A repeated measure design is a sensitive model enabling predictors or trends 
to be uncovered. The advantage of this type of design is that it follows the 
same subject over a period of time enabling detection of variations in the 
tested parameters within the study population, even when the effect is small. 
(Rosner, 2011). The variability of the subjects is divided into ‘between 
subjects’ and ‘within subjects’.  
Repeated measure ANOVA is a parametric statistical test that allows several 
groups to be simultaneously tested and indicates whether there are significant 
differences between them. ANOVA was performed on the data generated 
from the three biochemical markers collected during the three study periods. 
This type of analysis compared the differences between group means and the 
variation between and within groups. It also compares the same subject on a 
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continual variable across three or more periods of time (Period I, Period II and 
Period III in this case). 
ANOVA produces an F value which is the ratio of the between-groups 
variance to the within-groups variance. See the Figure 2.19 for illustration of 
F-value.  
Figure 2-19 illustration of ANOVA F Value 
 
Between-groups variance  
(variance calculated based on the entire sample) 
F=  ___________________________________________________ 
 
Within–groups variance  
(variance calculated separately for each group) 
Repeated measure ANOVA assumes equal variances or homogeneity on a 
linear model. It assumes all errors are equal to each other, the variances are 
normally distributed and that the errors are independent. To test the equality 
of variance a Levene’s test was performed on the raw data. Levene’s test 
determines whether the variance in scores is the same across all groups. This 
means that the difference between the raw data across all groups is the 
same. The data does not violate homogeneity if Levene’s test is 0.05 or 
greater. This analysis was used for Study I; II and III.  
2.27.2 Wilk’s Lambda 
Multivariate Analysis of Variance (ANOVA) tests differences between the 
means of a group of subjects on a combination of dependent variables. The 
test is better known as Wilk’s Lambda test. This statistical test is the most 
widely used to measure the proportion of variance in a combination of 
dependent variables indicating whether or not there is a relationship between 
the independent and dependent variables This analysis was used in study. 
This analysis was used for Studies I, II and III.  
2.27.3 Bonferroni Adjustment  
The Bonferroni adjustment is obtained by dividing the significance level by the 
number of pairwise comparisons; assuming a single test performance (See 
95 
Figure 2.20). For example, if the pairwise comparison is comparing 3 groups 
the single p value should be divided by 3 ; therefore the null hypothesis would 
only be rejected if p=0.017 (0.05/3=0.017) (Bland and Altman, 1995). This 
analysis was used in study IV. 
Figure 2-20 Bonferroni Adjustment Calculation 
Significance level assuming a single test (0.05)  
Stringent p value =  ___________________________________________________ 
 
Number of pairwise comparisons  
The advantage of Bonferroni adjustment is that it is simple to compute when 
performing multiple comparisons. It is not a statistical correction but a p value 
adjustment makes it more stringent. This type of adjustment is used to reduce 
the chances of false positive results (Type I error) (Bland and Altman, 1995). 
This analysis was used for Study I.  
2.27.4 Pearson Correlation 
Pearson’s correlation is a parametric measure that indicates whether a 
statistically significant relationship exists between two variables. It also 
indicates how close the relationship is on a straight line as well as the 
direction of a linear relationship (increasing or decreasing). It is measured 
using the correlation coefficient (r) which can take any value between -1 and 
+1, the + indicating positive correlation whilst a – indicates a negative 
correlation. The perfect positive correlation is when r = +1 and perfect 
negative correlation when r = -1. Table 2-9 illustrates the value of the 
correlation co-efficient and the strength of the correlation. When the r value is 
zero, r =0, there is no linear correlation.  
Prior to performing a Pearson’s correlation, it is necessary to ascertain that 
the variables are continuous and normally distributed. There should be a 
linear relationship between variables and no significant outliers. This analysis 
was used in study I. 
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Table 2-9 The Pearson’s Correlation Co- Efficient and the Correlation Strength 
Value of correlation Co-Efficient   Internal Consistency 
1 Perfect 





0 Zero/No correlation 
Legend to Table 2-9: The Pearson’s Correlation Co- Efficient and the Correlation Strength 
according to Evan (1996) – Straightforward statistics for the behavioural science. 
2.27.5 Linear Mixed Effect Model  
A linear mixed effect model incorporates fixed and random effects in the same 
model. It takes into consideration the fixed-effect i.e. behaviour of the entire 
population and random effects which are associated with the individual 
experimental units sampled from the population. The mixed effect model is 
used to correlate repetitive measures and it also measures the within and 
between subject error. It is used to analyse the repeated observations from 
longitudinal data. In this model the analysis takes into consideration missing 
data that could potentially have an effect on the outcome; an inherent problem 
of longitudinal studies (Pan et al., 2012). A mixed effect model has been 
employed for the analysis of the data generated by longitudinal studies 
(Mallinckrodt et al., 2003, Pan et al., 2012).  
The mixed effect model has three parameters, specifically; standard deviation 
of the random effect, standard deviation of the residual effect ‘per observation’ 
and the fixed effects parameters that are labelled as intercepts. This analysis 
was used in study IV. 
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Chapter 3 - Results  
This chapter presents the detailed analysis of the data collected over the 
three periods of the research study. The results were analysed and divided 
into four studies. Figure 3.1 summarises Period I, with Study I divided into five 
parts, A, B, C, D and E. Figure 3.2 summarises Periods I, II and II for studies 
II, III and IV.  
Figure 3-1 Sample groups from the control period 
 
 










PART -B   
Analysis of 




















Figure 3-2 Sample groups from the control, treatment and post-treatment period 
 
3.1 Statistical Analysis Period I – Control/Baseline Period 
Throughout this results section, the term “Control Period” should always be 
understood to mean the “Control/Baseline Period” since the pre-intervention 
samples act as the study controls and form a baseline for comparison with the 
post-intervention results. 
The organisation of the data collected during the control period – Period I, is 
shown in Figure 3-1. 
Period I. Control period (see methodology). At least three stool samples for 
biochemical (calprotectin, M2-PK and lactoferrin) analysis were collected 
during this period. Safeboxes™ were clearly labelled 1-4 to identify that they 
contained samples from this period.  
Period I - control 
Period II - treatment 





evaluation at Period I, 





measured at Period I, 








3.1.1 Control Period Result Section 
The control period section is presented in four parts to represent the four 
component parts of Study I. Study I is divided as follows: 
Part A – Analysis of calprotectin in sequential stool samples. 
Part B – Analysis of M2-PK in sequential stool samples. 
Part C – Analysis of lactoferrin in sequential stool samples. 
Part D – Analysis of sequential S.0.S Questionnaires. 
Part E – Analysis of Correlations between calprotectin, M2-PK and lactoferrin 
from the sequential stool samples. 
3.2 Raw Data  
Raw data for collected faecal samples and questionnaires are presented in 
Appendix 7 and 8 respectively.  
3.3 Results  
Stool samples and Questionnaires were collected and the samples bio-
analysed as described methods. The resultant data was statistically analysed 
using SPSS software package, IBM® SPSS® Statistics 21, and employing the 
appropriate statistical tests described in methods.  
3.3.1 Period I – Study I (Part A) – Analysis of Calprotectin in Sequential 
Faecal Samples  
The sample size for the study was 49.  However, one patient failed to post 
samples 2, 3, and 4 and was withdrawn from this part of the study. The 
remaining 48 patients were included in the statistical analysis. All other 
participants had at least two results across the four pre-treatment measures, 
as required to calculate a mean and standard deviation (Table 3-1). 
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Table 3-1 Descriptive Statistics Calprotectin (mg/L) Concentration Scores  
 M SD 
Range 
N 
Calpro 1 46.2 92.2 26.3-511 48 
Calpro 2 76.8 240 28.6-1582 48 
Calpro 3 54.2 99.3 44.7-630 48 
Calpro 4 33.5 57.8 25.3-381 48 
Legend to Table 3-1: This table represents the mean, standard deviation and range of the 
data set (n=48) 
The range and the standard deviation have demonstrated between 
Calprotectin means 1 to 4 (Table 3-1) were variable, therefore a test-retest 
reliability analysis was performed. This test is the most common measure of 
reliability and uses correlation analysis. The reliability coefficient of 
calprotectin mean scores for the 48 subjects on four different occasions was 
calculated. The test-rest reliability, analyses the consistency of results over 
time. The test is applied to the same subject on two separate occasions (i.e. 
sample 1 collected during week one compared to sample 2 collected during 
week two) and the scores correlated to give the coefficient of reliability of that 
specific occasion. Results closest to 1 (r = 1) reflect excellent reliability, while 
results closest to 0 (r = 0) reflect unacceptable reliability between samples 
assessed on two separate occasions. (Field, 2012; Tabachnick & Fidel, 2012) 
(see methodology chapter for more information). The resulting correlation 
between the mean scores measured on two different occasions is referred to 
as the test-retest reliability coefficient for that specific point in time.  
Correlations between samples 1 and 2 reflected poor reliability (r = 0.60, p < 
0.001) while samples 1 and 3 (r = 0.30, p < 0.001), 2 and 3 (r = 0.45, p = 
0.001), and 3 and 4 (r = 0.30, p = 0.77) had unacceptable reliability. Samples 
1 and 4 had questionable reliability (r = 0.65, p = 0.001). Only samples 2 and 
4 produced excellent reliability (r = 0.90, p < 0.001) (see Table 3-2). 
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Table 3-2 Test-Retest Correlation Matrix of Calprotectin (mg/L) pre-treatment 
concentration scores (n = 48) 
 Calpro 1 Calpro 2 Calpro 3 
Calpro 2 0.60   
Calpro 3 0.30 0.45  
Calpro 4 0.65 0.90 0.30 
As the test-retest reliability only tests the correlation between two samples 
over time it could not provide a baseline to be used here and further statistical 
analysis was necessary. Prior to determining the baseline, preliminary 
statistical analysis was necessary to test the general internal consistency of 
the marker using mean scores of the four samples collected over the six week 
period of the control/baseline period. To test the general reliability of the 
marker (or general internal consistency) a Cronbach’s Alpha test was 
performed on the four mean measures of calprotectin pre-treatment. The 
result of the Cronbach’s test suggests that the overall internal consistency of 
the baseline mean values was good with a score of 0.70 (Cronbach’s Alpha = 
0.70 or 70%) and so the mean scores for calprotectin are reliable for use as 
baseline measures for this work.  
A repeated measure ANOVA was used to test the mean scores of the four 
pre-treatment samples. Since parametric analysis is highly sensitive to 
outliers, an outlier analysis was performed prior to the execution of the 
repeated measures ANOVA (see methodology information on ANOVA). For 
the analysis of the outliers a Box and Whisker plot analysis of all 48 subjects’ 
individual samples was plotted. Box and Whisker plots, provide information on 
continuous variables including mean, interquartile range and outliers and are 
widely used for outlier detection (Pallant, 2006, Field, 2007). In this study, the 
outliers were marked with an asterisk and represented values that were three 
box lengths from the edge of the box. The results of the box and whisker plot 
indicated that there were three cases with outlier values. These three cases 
were withdrawn from the 48 subjects bringing the number of subjects to 45 
(n=45) (see Figure 3-3). 
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Figure 3-3 Box & Whisker plot of calprotectin concentration (mg/L) over the control 
period for 4 sequential samples  
 
Legend to Figure 3-3: Three subjects were classified as outliers and are indicated by 
asterisks. Initial sample size, n=48, was reduced to n=45 after exclusion of outliers (patients 
39, 40 and 42) 
A repeated measures ANOVA was conducted to determine whether there was 
a significant difference in calprotectin mean scores across the four pre-
treatment concentration scores. The repeated measures ANOVA is used to 
compare the same subjects using a continuous variable (Field, 2012; 
Tabachnick & Fidel, 2012). There are three important indices that are 
produced in the results of the repeated measures ANOVA namely the Wilk’s 
Lambda (W), the F ratio (F), and the p value. Wilk’s Lambda is the product of 
the unexplained variance on each of the independent variables in the analysis 
(Field, 2012; Tabachnick & Fidel, 2012). The F ratio is where the variance in 
scores within the pre-treatment measures is compared with the variance in 
scores across the pre-treatment measures. If the p value is less than 0.05 
then there is a significant difference in mean scores between at least two of 
the four pre-treatment measures (see methodology chapter for more 
information).  
Only matching samples were included in the repeated measure ANOVA. The 
removal of the three outliers from the initial 48 (n=48) subjects resulted in 45 
subjects for the analysis. Further review of the samples revealed that there 
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were another two subjects with only two samples, rather than the maximum 
four, for calprotectin analysis. These two subjects were withdrawn from the 
repeated measures ANOVA analysis bringing the sample size to 43 (n=43). 
Means and standard deviations of the 43 subjects included in the ANOVA 
analysis of calprotectin pre-treatment concentration scores are presented in 
Table 3-3. 
Table 3-3 Descriptive Statistics Calprotectin (mg/L) Pre-treatment Concentration 
Scores (n=43) 
 M SD 
Range  
N 
Calpro 1 28.7 34.8 10-164 43 
Calpro 2 32.9 45.7 10-234 43 
Calpro 3 34.6 36.4 10-153 43 
Calpro 4 25.3 21.0 10-108 43 
Legend to Table 3-3: This table represents the mean, standard deviation and the range after 
outlier removal.  
Results of the repeated measure ANOVA indicated that there was no 
significant difference between the four pre-treatment concentration scores 
(see Table 3-4). 
Table 3-4 Repeated Measure ANOVA for Calprotectin (mg/L) Pre-treatment 
Concentration Scores 
Effect Value    F 
Hypothesis 
df Error df p 
 Wilks' Lambda 0.91 1.30 3.00 40.00 0.285 
As the rest-test reliability presented some differences when correlating two 
scores of the same subject on two different occasions (Table 3-2) it was 
necessary to assess the value for each calprotectin sample across the 
population (see Table 3-5). This analysis used the raw data presented in 
Appendix 7.This analysis included the 43 subjects who had all four pre-
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treatment samples analysed plus the 3 subjects who were considered outliers 
but also had all four samples analysed. The total subject number for this 
analysis was 46 (n= 46). 
Thirty subjects out of 46 (65.2%) had all 4 pre-treatment calproctectin 
concentration scores between 0 and 50mg/mL. Seven subjects (15.2%) had 
one concentration score above 50mg/mL, five subjects (11%) had two 
concentration scores above 50 mg/L and one (2.1%) had three concentration 
scores above 50 mg/mL. Three subjects out of the total of 46 (6.5%) had all 
four pre-treatment concentration scores above 50 mg/mL (see Table 3-5). 
Table 3-5 Weekly Calprotectin Pattern of Individual Concentration Scores mg/mL  
 N % 
All scores 50 or less 30 65.2 
One score above 50 7 15.2  
Two scores above 50 5 11 
Three scores above 50 1 2.1 
Four scores above 50 3 6.5 
Total 46 100.0  
Legend to Table 3-5: This table represents calprotectin value for 46 subjects who had all four 
samples analysed including the 3 outliers. (n=46) 
Please see table Calprotectin reference range 2.19.5, in methods section. 
3.3.2 Period I – Study I (Part B) – Analysis of M2-PK in Sequential Faecal 
Samples  
The statistical analysis of M2-PK pre-treatment concentration scores followed 
the same structure as the calprotectin pre-treatment analysis. The sample 
size for M2-PK was the same as calprotectin pre-treatment number (see 
section 3.3.1). The sample size for this analysis was 48 (n=48) (see Table 
3-6). 
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Table 3-6 Descriptive Statistics M2PK (U/mL) Pre-treatment Concentration Scores (n= 
48) 
 M SD Range N 
M2PK-1 2.6 4.2 1-19 48 
M2PK-2 2.4 4.2 1-19 48 
M2PK-3 3.6 5.1 1-19 48 
M2PK-4 2.0 2.7 1-16 48 
Legend to Table 3-6: This table represents the mean, standard deviation and range of the 
data set (n=48) 
A test-retest reliability analysis was conducted to assess the reliability of           
M2-PK concentration scores within the 48 subjects. As indicated with the 
analysis of calprotectin, (see section 3.3.1) the test-rest reliability analyses the 
consistency of the results over time. The test is applied to the same subject 
on two separate occasions. The test-retest reliability is the most common 
measure of reliability and assesses the reliability of scores using the 
correlation analysis of an individual subjects (Field, 2012; Tabachnick & Fidel, 
2012) (see methodology chapter for more information).  
Results of the 48 subjects test retest reliability analysis of pre-treatment 
samples of M2-PK indicated that the correlations between samples 1 and 2 (r 
= 0.41, p < 0.001), 1 and 4 (r = 0.46, p <= 0.001), 2 and 4 (r = 0.495, p < 
0.001) and 3 and 4 (0.393, p = 0.01) reflected unacceptable reliability. 
Samples 1 and 3 (r = 0.59, p < 0.001) and 2 and 3 (r = 0.690, p < 0.001) had 
questionable reliability (see Table 3-7). 
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Table 3-7 Test-Retest Correlation Matrix of M2PK (U/mL) Pre-treatment Concentration 
Scores (n =48) 
 M2-PK-1 M2-PK-2 M2-PK-3 
M2-PK-2 0.41   
M2-PK-3 0.59 0.69  
M2-PK-4 0.46 0.49 0.39 
As previously stated with the calprotectin analysis (section 3.3.1) the test-
retest reliability only tests the correlation between two samples over time and 
it did not provide a baseline to be used here. Further statistical analysis was 
necessary. Prior to determining the baseline, preliminary statistical analysis 
was necessary to test the general internal consistency of the marker using the 
mean scores of the four samples collected over the six week period of the 
control/baseline period. To test the general reliability of the marker (or general 
internal consistency) a Cronbach’s Alpha test was performed on the four M2-
PK pre-treatment mean measures. The results of the Cronbach’s test 
suggests that the overall internal consistency of the baseline for M2-PK pre-
treatment mean scores is 0.8 (Cronbach Alpha=0.80 or 80%). This suggests 
that the mean scores for M2-PK measures are reliable to be used as baseline 
for this thesis.  
Outlier analysis was performed on the pre-treatment M2-PK samples, as 
before (see section 3.3.1). Samples from 48 subjects were analysed and 
plotted before conducting repeated measures ANOVA. Results of the Box and 
Whisker plot analysis indicated that there were three outliers. These three 
outliers were excluded, reducing the sample size from 48 to 45                   
(see Figure 3-4). 
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Figure 3-4 Box & Whisker Plot of M2-PK concentration (U/mL) over the control period 
for four sequential samples) 
Legend to Figure 3-4: Three subjects were classified as outliers and are indicated by 
asterisks. The initial sample size (n=48) was reduced to n=45 after excluding the outliers 
(subjects 39, 40, and 45). 
A repeated measures ANOVA was conducted to determine whether there was 
a significant difference in M2-PK concentration mean scores across the four 
pre-treatment scores. Only matching samples were included on the repeated 
measures ANOVA for M2-PK. The removal of the three outliers from the initial 
48 (n=48) subjects left 45 subjects. Further analysis of the samples revealed 
that there were two subjects with only two samples, rather than the maximum 
four, for M2-PK analysis. These two subjects were withdrawn from the 
repeated measures ANOVA analysis bringing the sample size to 43 (n=43). 
Means and standard deviation of the 43 subjects included in the ANOVA 
analysis of M2-PK pre-treatment scores are presented in Table 3-8. 
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Table 3-8 Descriptive Statistics M2PK (U/mL) Pre-treatment Concentration Scores (n= 
43) 
 M SD 
Range 
N 
M2PK-1 2.25 3.64 1-20 43 
M2PK-2 2.10 3.50 1-20 43 
M2PK-3 2.69 3.63 1-20 43 
M2PK-4 2.02 2.85 1-17 43 
Legend to Table 3-8: This table represents the mean, standard deviation and the range after 
removal of outliers. 
Results from the repeated measures ANOVA indicated that there was no 
significant difference between the means of four pre-treatment concentration 
scores, W = 0.93, F (3, 40) = 0.91, p = 0.44 (see Table 3-9). 
Table 3-9 Repeated Measure ANOVA for M2-PK (U/mL) Pre-treatment Concentration 
Scores 
Effect Value    F 
Hypothesis 
df Error df p 
 Wilks' Lambda 0.93 0.91 3.00 40.00 0.44 
Similar to the calprotectin analysis the rest-test reliability presented some 
differences when correlating two M2-PK scores of the same subject on two 
different occasions (see Table 3-7) and it was necessary to analyse the value 
for each M2-PK sample across the population (see Table 3-10). This analysis 
used the raw data presented in Appendix 7. 
This analysis included 43 subjects who had all four pre-treatment samples 
analysed plus the three subjects who were considered outliers but also had all 
four samples analysed. The total subject number for this analysis was 46 (n= 
46). 
Of the 46 subjects who had at least four valid concentration scores, there 
were 32 (70%) subjects who had M2-PK concentration scores of 4U/mL or 
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less. There were seven subjects out of 46 who had one M2-PK concentration 
score above 4U/mL (15%). Six out of 46 subjects (13%) had two M2-PK 
concentration scores above 4U/mL. There were no subjects with three 
concentration scores above 4U/mL, but there was one subject (2%) who had 
4 M2-PK concentration scores above 4U/mL (see Table 3-10). 
Table 3-10 Weekly M2-PK Pattern of individual Concentration Scores (U/mL) 
 N % 
 All scores 4 or less 32 70 
One score above 4 7 15 
Two scores above 4 6 13 
Three scores above 4 0 0 
Four scores above 4 1 2 
Total 46 100.0 
Legend to Table 3-10: This represents M2-PK value for 46 subjects who had all four samples 
analysed including the 3 outliers. (n=46) 
Please see M2-PK reference range in methods, 2.20.4. 
3.3.3 Period I – Study I (Part C) – Analysis of Lactoferrin in Sequential 
Faecal Samples  
The final number of subjects who completed the study was 49 (n=49). Of 
these 49 subjects only 24 subjects had a complete set of four pre-treatment 
faecal samples analysed (n=24) for the biomarker lactoferrin. The loss of the 
subject numbers for this analysis was due to the accidental discarding of 
samples which was outside the control of the author (see Appendix 6). The 
box and whisker plot represents levels of lactoferrin samples for all the 
participants in the four sequential sample (see Figure 3-5). 
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Figure 3-5 Box & Whisker Plot of Lactoferrin concentration (ng/mL) over the control 
period sequential samples  
 
Legend to Figure 3-5: There were no subjects marked with asterisks therefore there were no 
outliers in this analysis. The final subject number was 24 (n=24) 
A test-retest reliability analysis was conducted to assess the reliability of 
lactoferrin scores for the 24 subjects. A correlation matrix was computed for 
each pair of scores. Results of the test-retest reliability analysis between pre-
treatment samples of lactoferrin indicated that the correlations between all 
sample sets had unacceptable reliability samples 1 and 2 (r = 0.18, p =0.30), 
1 and 3 (r = 0.33, p = 0.09), 1 and 4 (p= 0.25, p = 0.15), 2 and 3 (r = 0.29, p = 
0.11), 2 and 4 (r = 0.37, p = 0.18) and 3 and 4 (r = 0.26, p = 0.19) (see Table 
3-11). See methods for General Guidelines for interpreting Reliability 
Coefficient 2.26.2. 
Table 3-11 Correlation Matrix of Lactoferrin (ng/mL) Pre-Treatment Concentration 
scores (n =24) 
 Lactoferrin 1 Lactoferrin 2 Lactoferrin 3 
Lactoferrin 2 0.15   
Lactoferrin 3 0.31 0.25  
Lactoferrin 4 0.24 0.12 0.26 
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Table 3-12 represents the means and standard deviation of 24 subjects for 
the lactoferrin pre-treatment period included in the ANOVA analysis.  
Table 3-12 Descriptive statistics for lactoferrin (ng/ml) concentration in the sequential 
samples 
 M Std Dev N 
Sample 1 2100 3182 24 
Sample 2 1470 2084 24 
Sample 3 3313 4791 24 
Sample 4 1366 1361 24 
A repeated measures ANOVA was conducted to determine whether there was 
a significant difference between the means of lactoferrin concentration scores. 
Results of the repeated measures ANOVA indicated that there was no 
significant difference between the four lactoferrin pre-treatment concentration 
scores, W = 0.82, F (3, 21) = 1.45, p = 0.25 (see Table 3-13). 
Table 3-13 Repeated Measure ANOVA for Lactoferrin Pre-Treatment Concentration 
Scores 
Effect Value    F 
Hypothesis 
df Error df p 
 Wilks' Lambda 0.82 1.45 3.0 21.00 0.25 
Of the 24 subjects with data across all four pre-treatment measures, 18 (75%) 
subjects had all 4 pre-treatment concentration scores within the normal range 
(below 7.24 ng/mL). There were three subjects with one pre-treatment 
concentration score above the normal range (12.5%), and three subjects with 
two pre-treatment measures above the normal range (12.5%) (see Table 
3-14). 
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Table 3-14 Weekly lactoferrin Pattern of individual Concentration Scores (ng/mL) 
 N % 
All scores below 7.25  18 75.0 
One Score7.25 or above 3 12.5 
Two scores 7.25 or above 3 12.5 
Total 24 100.0 
Please see table lactoferrin reference range in 2.21.4, Methods section. 
3.3.4 Period I – Study I (Part-D) – Analysis of sequential S.0.S 
Questionnaire  
The statistical analyses of the four pre-treatment questionnaires were used to 
form a baseline for this thesis. The data collection was derived from four 
sequential, 24 parameters, ten point scale questionnaires based on the 
Autism Research Institute Secretin Outcomes Survey Form, the ‘S.O.S Form’. 
The measurement was done via a Likert scale as outlined in the methods 
section. 
The data analysis was performed on a total of 48 subjects (n=48). The 
statistical analyses were divided into descriptive statistics of each of the four 
sequential questionnaires and analysis of the means of the four questionnaire 
subscales that is; Social behaviour and communication, ritual and repetitive 
activities, digestive signs and general signs subscales. The results of the 
questionnaire baseline were later correlated with the results of the treatment 
and the post-treatment periods (Period II and III). Descriptive statistics for 
each questionnaire can be seen in Table 3-1. 
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Table 3-15 Descriptive Statistics Questionnaire 1 pre-treatment  
Subscales Parameters  Mean SD 
Social behaviour and 
communication 
Lack of awareness and 
interaction with parent  
2.70 2.19 
 Abnormal greeting behaviour                       3.48 2.62 
 Abnormal comfort seeking  3.82 2.52 
 Can’t make friends  5.34 3.18 
 Lack of awareness of social 
rules  
5.55 3.07 
 Lack of spontaneous speech  5.02 3.32 
 Abnormal word utilisation  4.77 3.15 
 Poor comprehension of 
verbal instructions  
4.36 2.87 
 Lack of eye contact  3.70 2.18 
Ritual and Repetitive 
Activities 
Abnormal repetitive gestures  4.65 2.96 
 Need to maintain sameness  4.54 2.71 
 Need of fixed routine  4.38 2.84 
Digestive Signs Diarrhoea  3.05 2.98 
 Constipation  4.50 3.33 
 Poor Appetite  3.23 2.85 
 Bloating 3.55 2.89 
 Flatulence  2.63 2.44 
 Vomiting  1.04 1.96 
General Signs Unhappy  2.40 2.11 
 Aggressive  2.78 2.61 
 Destructive  3.04 3.01 
 Spaced out/ Non Interactive  3.30 2.43 
 Agitated  4.36 2.56 
 Disagreeable  4.07 2.48 
    
Legend to Table 3-15: This table represents the means and standard deviation for parameters 
of the pre-treatment questionnaire 1 using a measure on a 10 point Likert scale where 0 = 
never shows this particular sign or behaviour; 1 = slight/unobtrusive; 2-3 = mild; 4-5 = 




Table 3-16 Descriptive Statistics Questionnaire 2 pre-treatment  
Subscales Parameters Mean SD 
Social behaviour and 
communication 
Lack of awareness and 
interaction with parent  
3.00 2.42 
 Abnormal greeting behaviour                       3.98 2.90 
 Abnormal comfort seeking  4.02 2.43 
 Can’t make friends  5.18 3.18 
 Lack of awareness of social 
rules  
5.41 2.92 
 Lack of spontaneous speech  4.66 3.14 
 Abnormal word utilisation  5.11 3.11 
 Poor comprehension of 
verbal instructions  
4.36 2.58 
 Lack of eye contact  3.63 2.33 
Ritual and Repetitive 
Activities 
Abnormal repetitive gestures  4.33 2.55 
 Need to maintain sameness  4.31 2.72 
 Need of fixed routine  4.18 2.52 
Digestive Signs Diarrhoea  2.56 2.80 
 Constipation  4.04 3.12 
 Poor Appetite  2.49 2.76 
 Bloating  3.27 2.66 
 Flatulence  2.54 2.46 
 Vomiting .67 1.66 
General Signs Unhappy  2.54 2.23 
 Aggressive  2.83 2.67 
 Destructive  2.78 2.83 
 Spaced out/ Non Interactive  3.35 2.82 
 Agitated  3.77 2.54 
 Disagreeable  3.78 2.69 
    
Legend to Table 2-16: This table represents the means and standard deviation for parameters 
of the pre-treatment questionnaire 2 using a measure on a 10 point Likert scale where  0 = 
never shows this particular sign or behaviour; 1 = slight/unobtrusive; 2-3 = mild; 4-5 = 
moderate; 6-7 = severe; 8-9 = extreme/incapacitating. 
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Table 3-17 Descriptive Statistics Questionnaire 3 pre-treatment  
Subscales Parameters Mean SD 
Social behaviour and 
communication 
Lack of awareness and 
interaction with parent  
3.21 2.63 
 Abnormal greeting behaviour                       3.81 2.86 
 Abnormal comfort seeking  3.62 2.61 
 Can’t make friends  5.40 2.96 
 Lack of awareness of social 
rules  
5.73 2.84 
 Lack of spontaneous speech  4.81 3.40 
 Abnormal word utilisation  4.18 3.24 
 Poor comprehension of 
verbal instructions  
4.29 2.52 
 Lack of eye contact  3.52 2.36 
Ritual and Repetitive 
Activities 
Abnormal repetitive gestures  
4.20 2.77 
 Need to maintain sameness  4.07 2.63 
 Need of fixed routine  3.78 2.64 
Digestive Signs Diarrhoea  1.63 2.30 
 Constipation  3.95 3.27 
 Poor Appetite  2.20 2.88 
 Bloating  3.15 2.79 
 Flatulence  2.74 2.43 
 Vomiting  .51 1.32 
General Signs Unhappy  2.36 2.29 
 Aggressive  2.68 2.61 
 Destructive  2.83 2.68 
 Spaced out/ Non Interactive  3.28 2.60 
 Agitated  3.30 2.39 
 Disagreeable 3.83 2.61 
    
Legend to Table 2-17:This table represents the means and standard deviation for parameters 
of the pre-treatment questionnaire 3 using a measure on a 10 point Likert scale where  0 = 
never shows this particular sign or behaviour; 1 = slight/unobtrusive; 2-3 = mild; 4-5 = 
moderate; 6-7 = severe; 8-9 = extreme/incapacitating. 
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Table 3-18 Descriptive Statistics Questionnaire 4 pre-treatment 
Subscales Parameters Mean SD 
Social behaviour and 
communication 
Lack of awareness and 
interaction with parent  
3.12 2.58 
 Abnormal greeting behaviour                       3.61 2.54 
 Abnormal comfort seeking  3.85 2.77 
 Can’t make friends Q4 5.07 3.02 
 Lack of awareness of social 
rules  
5.69 3.00 
 Lack of spontaneous speech  4.52 3.27 
 Abnormal word utilisation  4.29 3.04 
 Poor comprehension of 
verbal instructions  
4.44 2.60 
 Lack of eye contact  3.56 2.50 
Ritual and Repetitive 
Activities 
Abnormal repetitive gestures  
3.98 2.63 
 Need to maintain sameness  4.15 2.72 
 Need of fixed routine  3.73 2.95 
Digestive Signs Diarrhoea  2.23 2.67 
 Constipation  4.00 3.23 
 Poor Appetite  3.19 3.35 
 Bloating  2.95 2.85 
 Flatulence  2.84 2.68 
 Vomiting  .95 2.24 
General Signs Unhappy  2.20 2.25 
 Aggressive  2.39 2.49 
 Destructive  2.76 2.88 
 Spaced out/ Non Interactive  3.60 2.83 
 Agitated  3.85 2.36 
 Disagreeable  3.71 2.92 
    
Legend to Table 2-18: This table represents the means and standard deviation for parameters 
of the pre-treatment questionnaire 4 using a measure on a 10 point Likert scale where  0 = 
never shows this particular sign or behaviour; 1 = slight/unobtrusive; 2-3 = mild; 4-5 = 
moderate; 6-7 = severe; 8-9 = extreme/incapacitating. 
The pre-treatment means subscales of the 24 parameters S.O.S 
questionnaire collected from the 48 subjects were plotted on a box and 
whiskers plot (see Figure 3-6).  
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Figure 3-6 Box & Whisker plot for categories of the pre-treatment questionnaire using a 
measure on a 10 point scale 
 
Legend to Figure 3-6: 0 = never shows this particular sign or behaviour; 1 = 
slight/unobtrusive; 2-3 = mild; 4-5 = moderate; 6-7 = severe; 8-9 = extreme/incapacitating. 
Cronbach’s Alpha analysis was conducted to evaluate the reliability of the four 
pre- treatments S.O.S questionnaire and its subscales (S.O.S questionnaire 
subscales are listed in the methodology section). The results of the 
Cronbach’s test suggest that the overall internal consistency of the mean 
scores for the pre-treatment questionnaires was 0.8 which is a good overall 
reliability (Cronbach’s Alpha=0.8 or 80%). This suggests that the means 
scores for the pre-treatment questionnaire measures are reliable to be used 
as a baseline for this thesis. All of the 48 subjects subscales were assessed 
for means and standard deviation (see Table 3-19). 
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Table 3-19 Mean and Standard deviation for four categories of the pre-treatment 
questionnaire subscales 
Subscales  M SD N 
Social behaviour and 
communication 
4.3 2.1 48 
Ritual and Repetitive 
Activities 
4.3 2.4 48 
Digestive Signs 2.7 1.4 48 
General Signs 3.1 1.9 48 
3.3.5 Period I – Study I (Part-E) – Analysis of Correlations between 
calprotectin, M2-PK and lactoferrin  
Statistical analysis was used to determine whether there was a correlation 
between calprotectin, M2-PK and lactoferrin concentration in the samples 
collected during the control/baseline period.  
3.3.5.1 Pre-treatment Calprotectin Concentration Scores and Pre-
Treatment M2-PK Concentration Scores 
Five Pearson correlations were conducted to determine whether there was a 
significant linear relationship between pre-treatment calprotectin scores and 
M2PK scores in total and between each of the 4 pre-treatment measures. The 
Pearson r coefficient indicates to what extent the scores of two variables co-
vary (Field, 2012; Tabachnick & Fidel, 2012). See methodology (Table 2-9) for 
Pearson correlation values according to Cohen (1983).  
Results indicated that there was a significant, positive correlation that was 
moderate in size between the total calprotectin pre-treatment scores and the 
total M2PK scores, r = 0.40, n = 38, p = 0.01 (see Table 3-20 calprotectin 
total/ M2-PK total). There was no significant correlation between pre-
treatment 1 calprotectin and M2PK scores, r = 0.18, n = 38, p = 0.27, pre-
treatment 2 calprotectin and M2PK scores, r = 0.23, n = 37, p = 15, or pre-
treatment 4 calprotectin and M2PK scores, r = 0.06, n = 35, p = 0.73 (see 
Table 3-20). However, there was a significant correlation between pre-
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treatment 3 calprotectin and M2PK concentration scores that was moderately 
strong, r = 0.43, n = 36, p = 0.007 (see Table 3-20 and Figure 3-7).  
Table 3-20 Correlation Matrix of Calprotectin and M2PK pre-treatment Concentration 
Scores  
 Calpro 1 Calpro 2 Calpro 3 Calpro 4 Calpro Total 
M2PK 1 0.18     
M2PK 2  0.23    
M2PK 3   0.43*   
M2PK 4    0.06  
M2PK Total     0.40* 
*Significant correlation p<0.05  




3.3.5.2 Pre-treatment Calprotectin and Lactoferrin Concentration Scores 
Bivariate correlations were performed to determine if there was a significant 
linear relationship between total pre-treatment calprotectin and lactoferrin 
mean concentration scores, as well as for individual pre-treatment 
concentration scores. Results indicated that there was a significant, strong, 
positive relationship between the total calprotectin scores and the total 
lactoferrin scores, r = 0.65, n = 24, p < 0.001, (based on Cohen’s guidelines, 
Cohen 1983) (see methodology, 2.26.1) (see Table 3-21 calprotectin 
total/lactoferrin total). Results also indicated that there was a significant strong 
positive correlation between pre-treatment 1 of calprotectin and lactoferrin 
scores, r = 0.75, n = 37, p = < 0.001, and a significant, moderate, correlation 
between pre-treatment 3 of calprotectin and lactoferrin scores, r = 0.46, n = 
30, p <= 0.01 (see Table 3-21). There was no significant correlation between 
pre-treatment 2, (r = 0.26, n = 46, p = 0.08), or pre-treatment 4 (r = 0.14, n = 
42, p = 0.34) concentration scores (see Table 3-21). The total mean 
concentration scores of calprotectin and lactoferrin showed a strong linear 
relationship (see Figure 3-8). 
Table 3-21 Correlation Matrix of Calprotectin and lactoferrin pre-treatment 
concentration scores  
 Calpro 1 Calpro 2 Calpro 3 Calpro 4 Calpro Total 
Lactoferrin 1 0.75*     
Lactoferrin 2  0.25    
Lactoferrin 3   0.46   
Lactoferrin 4    0.14  
Lactoferrin Total     0.65* 
*Significant correlation p <0.05 
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Figure 3-8 Scatterplot of pre-treatment Calprotectin & Lactoferrin mean concentration 
scores. 
 
3.4 Statistical Analysis Period I, Period II and Period III  
This section correlates the data collected during the Control/Baseline Period 
(Period I) (see section 3.1) with the data collected during and post treatment 
periods (Periods II & III).  
Data collected during Period II consisted of four questionnaires completed 
during the six week treatment period of the clinical trial. At least three stool 
samples for calprotectin/M2-PK/lactoferrin analysis were also collected. Data 
collected from Period III was generated from one questionnaire and one 
faecal sample for calprotectin/M2-PK/lactoferrin analysis collected six weeks 
after completion of the treatment period (see section 2.9 in methods for 
detailed information of each period). 
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3.4.1  Period I, Period II and Period III results section 
In this section of the results chapter the data are presented as three studies 
which correspond to the analysis of data from the periods I, II and III. This is 
discussed in the discussion chapter of this thesis. The organisation of the 
studies – Period I, Period II and Period III is shown in Figure 3-2.  
Study II: Twenty-four parameter S.O.S questionnaires evaluation at Period I, 
Period II and Period III.  
Study III: Calprotectin, M2-PK and lactoferrin concentrations measured at 
Period I, II and III.  
Study IV: The relationship between calprotectin and twenty-four parameter 
S.O.S questionnaires. 
3.5 Results Study II - Twenty-four parameter S.O.S 
questionnaires evaluation at Period I, Period II and Period III 
All results from the control, treatment and post-treatment periods of the study 
were recorded and analysed. The data generated from the questionnaires 
collected from the control period were used as a baseline which was then 
compared to the data generated from the treatment and post-treatment 
periods. 
The S.O.S questionnaire was used to assess behavioural and GI symptoms 
and is structured as a 24 parameter grid, with four sub-scales for social 
behaviour, ritual and repetitive activities, digestive symptoms, and general 
symptoms (Rimland, 1998, Brudnak et al., 2002, Esch and Carr, 2004b, 
Erickson et al., 2005a, Sturmey, 2005, Williams et al., 2005) (see Appendix 
5). 
3.5.1  Repeated Measure ANOVA Period I, II and III – S.O.S Questionnaire 
A repeated measure ANOVA was conducted to determine whether there was 
a significant difference between the means for the control, treatment and post-
treatment scores accessed via the modified S.O.S questionnaire. The 
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independent variable was time (periods I, II, and III) and the dependent 
variable was the mean scores across the questionnaires administered during 
the control, treatment, and post-treatment periods. Wilk’s Lambda was the 
multivariate statistic used to determine whether there was a significant main 
effect. A significant main effect, indicated by a p value of less than 0.05, was 
followed up by post comparison tests between each of the three mean scores.  
Results of the repeated measures ANOVA indicated that there was a 
significant difference between the mean scores, Wilk’s Lamba (W) = 0.76, F 
(2, 35) = 5.27, p = 0.01.  
To determine which groups were significantly different from each other, post-
hoc tests employing the Bonferroni adjustment were conducted. Results of the 
post-hoc test revealed that the control mean score (M = 3.55, SD = 1.30) was 
significantly higher than both the treatment mean score (M = 3.14, SD = 1.31) 
and the post-treatment mean score (M = 3.2, SD = 1.23). However, there was 
no significant difference between the treatment mean score and the post- 
treatment mean score.  
3.5.2 Descriptive statistics performed in each Questionnaire Subscale 
Descriptive statistics were performed on each individual sub-scale (see Table 
3-22; Table 3-23; Table 3-24 and Table 3-25).  
Table 3-22 Descriptive statistics for social behaviour and communication subscale  
Study Period N Mean SD 
 
Min Max 
Control  48 4.34 2.14 0.20 8.11 
Treatment  45 4.09 2.00 0.72 8.00 
Post-treatment 29 3.76 2.18 0.44 8.71 
Legend to Table 3-22: This table represents the means and standard deviations for 
parameters social behaviour and communication of the pre-treatment, treatment and post-
treatment questionnaire using a measure on a 10 point Likert scale where 0 = never shows 
this particular sign or behaviour; 1 = slight/unobtrusive; 2-3 = mild; 4-5 = moderate; 6-7 = 
severe; 8-9 = extreme/incapacitating. 
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Table 3-23 Descriptive statistics for ritual and repetitive activities subscale  
Study Period N Mean SD 
 
Min Max 
Control  48 4.34 2.14 0.10 8.67 
Treatment  44 3.89 2.05 0.00 8.17 
Post-treatment 29 3.49 2.10 0.00 7.00 
Legend to Table 3-23: This table represents the means and standard deviations for 
parameters ritual and repetitive activities of the pre-treatment, treatment and post-treatment 
questionnaire using a measure on a 10 point Likert scale where 0 = never shows this 
particular sign or behaviour; 1 = slight/unobtrusive; 2-3 = mild; 4-5 = moderate; 6-7 = severe; 
8-9 = extreme/incapacitating. 
Table 3-24 Descriptive statistics for digestive signs subscale 
Study Period N Mean SD 
 
Min Max 
Control  48 2.75 1.49 0.21 6.00 
Treatment  45 2.21 1.34 0.08 5.40 
Post-treatment 29 2.10 1.70 0.00 6.20 
Legend to Table 3-24: This table represents the means and standard deviations for 
parameters digestive signs of the pre-treatment, treatment and post-treatment questionnaire 
using a measure on a 10 point Likert scale where 0 = never shows this particular sign or 
behaviour; 1 = slight/unobtrusive; 2-3 = mild; 4-5 = moderate; 6-7 = severe; 8-9 = 
extreme/incapacitating. 
Table 3-25 Descriptive statistics for general signs subscale 
Study Period N Mean SD Min Max 
Control  48 3.18 1.90 0.21 7.46 
Treatment  45 2.99 1.91 0.13 7.50 
Post-treatment 29 2.76 1.85 0.17 7.83 
Legend to Table 3-25: This table represents the means and standard deviations for 
parameters general signs of the pre-treatment, treatment and post-treatment questionnaire 
using a measure on a 10 point Likert scale where 0 = never shows this particular sign or 
behaviour; 1 = slight/unobtrusive; 2-3 = mild; 4-5 = moderate; 6-7 = severe; 8-9 = 
extreme/incapacitating. 
125 
3.5.3 Repeated Measure ANOVA performed in each questionnaire 
subscale 
A series of repeated measures ANOVAs were conducted to determine 
whether there were significant differences across pre-treatment, treatment, 
and post-treatment time frames (Period I,II and III) on subscale questionnaire 
scores. The subscales in question were social behaviour and communication, 
ritual and repetitive activities, digestive signs, and general signs. Pos hoc test 
(Bonferroni test) was used if the ANOVA idetifed any significance within the 
means of the periods. Bonferroni tested the three period means and explored 
the differences between them, providing specific information on each mean 
and therefore identifying any significant difference from each period tested. 
3.5.3.1 Repeated measure ANOVA for subscale – social behaviour and 
communication  
Repeated measure ANOVA analysis indicated that there was a significant 
difference within the three time periods for the subscale social behaviour and 
communication, W = 0.39, F(1, 27) = 104.55, p < 0.001. The Bonferroni 
adjustment was used to maintain the p value at 0.05. Post hoc tests indicated 
that social behaviour and communication pre-treatment scores (M = 4.41, SD 
= 2.12) were significantly higher than treatment (M = 3.93, SD = 2.13) and 
post-treatment scores (M = 3.76, SD = 2.18). There were no significant 
differences beween the treatment and post-treatment social scores. 
3.5.3.2 Repeated measure ANOVA for subscale – ritual and repetitive 
activities  
Results of the ritual and repetitive activities subscale repeated measures 
ANOVA revealed that there was a significant difference between test scores, 
W = 0.31, F(2, 26) = 6.04, p = 0.007. Post hoc tests indicated that the ritual 
and repetitive activities pre-treatment (M = 4.25, SD = 2.43) was significantly 
higher (p =0.05) than the post-treatment scores (M = 3.49, SD = 2.10), but not 
significantly different (p=0.05) from the treatment test (M = 3.79, SD = 2.21). 
There was no significant difference between ritual and repetitive activities 
treatment and post-treatment scores. 
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3.5.3.3 Repeated measure ANOVA for subscale – digestive signs 
The repeated measure ANOVA for the digestive signs produced a significant 
main effect, W = 0.75, F (2, 27) = 4.42, p = 0.02. Post hoc results revealed pre 
treatment scores (M = 2.72, SD = 1.48) that were significantly higher (p=0.05) 
than both treatment scores (M = 2.21, SD = 1.36) and post-treatment scores 
(M = 2.10, SD = 1.74). There was no significant difference between treatment 
and post-treatment scores. 
3.5.3.4 Repeated measure ANOVA for subscale – general signs 
The analysis of variance for the general signs subscale produced a non 
significant main effect, indicating that there was no difference between pre-
treatment (M = 3.2, SD = 1.79), treatment (M = 3.10, SD = 2.76), and post- 
treatment scores (M = 2.76, SD = 1.85), W = 0.88, F(2, 26) = 1.64, p = 0.21. 
The 24 parameter questionnaires were analysed individually using Wilcoxon 
signed-rank test. Data from the four questionnaires collected during the 
control period were analysed and compared with the four completed during 
the treatment period. Statistical analysis indicated an improvement in three of 
the 24 parameters tested. The GI parameters that demonstrated a significant 
improvement after treatment with VOTs were ‘vomiting’ (p = 0.00029) (see 
Figure 3-9) ‘poor appetite’ (p= 0.039) (see Figure 3-10), and ‘eye contact’ (p = 
0.035) (see Figure 3-11), the latter being one of the most characteristic social 
behavioural signs of autism.  
The data for the box and whisker plots was divided into four equal groups in 
order to generate three cut-off points or quartiles (Q1,Q2 and Q3). The 


































Figure 3-9: Box & Whisker plot for vomiting scores during the control and treatment 
periods  
 
Legend to Figure 3-9: Children with autism demonstrated a significant decrease in vomiting 
scores after six weeks of VOT treatment (p = 0.00029). The data indicate that 75% (Q3) of 
the subjects showed a decrease in their symptom score of 2 points on a 10 point scale from 
the control period to the treatment period.  
Figure 3-10: Box & Whisker plot for poor appetite scores during the control and 
treatment periods 
  
Legend to Figure 3-10: Children with autism demonstrated a significant decrease in poor 
appetite scores after six weeks of VOT treatment (p = 0.039). The data indicates that 50% 
(Q2) of the subjects showed a decrease in their symptom score of 2 points on a 10 point 
scale from the control period to the treatment period.  
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Figure 3-11: Box & Whisker plot for lack of eye contact scores during the control and 
treatment periods 
  
Legend to Figure 3-11: Children with autism demonstrated significant decrease in lack of eye 
contact scores after six weeks of VOT treatment (p =0.035). The data indicates that 75% (Q3) 
of the subjects showed a decrease in their symptom score of 1 point on a 10 point scale from 
the control period to the treatment period.  
3.6 Results Study III - Calprotectin, M2-PK and lactoferrin 
concentrations measured at Period I, II and III 
The statistical analysis of the study was performed using the SPSS software 
package, IBM® SPSS® Statistics 21, for each individual marker separately 
during the three distinct periods of the study (Period I, Period II and Period III).  
3.6.1 Calprotectin  
A repeated measure ANOVA was conducted to evaluate the differences in 
calprotectin levels in samples from Period I - control, Period II - treatment and 
Period III - post-treatment (one subject was excluded as this subject had only 
one sample for the pre-treatment period – see section 3.3.1 ). Three mean 
concentrations were calculated using the calprotectin levels corresponding to 
the three distinct periods (see Table 3-26). Only subjects with no missing 
calprotectin values across the three periods, were included in the analysis; 
therefore, the final number of subjects was 29 (n=29).  
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Table 3-26 Descriptive statistics for calprotectin concentrations 
Calprotectin M SD N 
Control Mean 22.9 13.2 29 
Treatment Mean 30.1 29.4 29 
Post-treatment Mean 39.3 57.2 29 
    
Figure 3-12 Mean concentrations of calprotectin during Period I, Period II and Period III  
Legend to Figure 3-12: This figure represents the mean scores (mg/mL) for calprotectin 
samples collected during the three distinct periods of the study. 
The results of the repeated measures ANOVA indicated that there was no 
significant difference between the three mean scores (Wilk’s Lambda = 0.89, 
F (2, 27) = 1.61, p = 0.21 (see Table 3-27). 
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Table 3-27: Repeated measures ANOVA – Wilk’s Lambda for calprotectin 
concentrations in Period I, Period II and Period III  
Wilks' Lambda F Hypothesis df Error df p 
0.893 1.61 2.00 27.00 0.21 
3.6.2 M2-PK  
A repeated measure ANOVA was conducted to evaluate the differences in the 
M2-PK concentrations in the samples from Period I - control, Period II - 
treatment and Period III - post-treatment. Only subjects with no missing M2-
PK values across the three periods, were included in the analysis therefore 
the final number of subjects was 29 (n=29). Three mean concentrations were 
calculated using the M2-PK levels corresponding to the three distinct periods 
(see Table 3-25). The Box & Whisker plot represents the estimated marginal 
means of M2-PK (U/mL) across the three periods (see Table 3-28). 
Table 3-28: Descriptive statistics for M2PK concentrations (U/mL) 
M2-PK M SD N 
Control Mean 2.37 3.55 29 
Treatment Mean 2.27 2.89 29 




Figure 3-13: Mean concentrations of M2-PK during Period I, Period II and Period III 
Legend to the figure 3-13: This figure represents the mean scores (U/mL) for M2-PK samples 
collected during the three distinct periods of the study. 
The results of the repeated measures ANOVA indicated that there was no 
significant difference between the three mean scores (Wilks’ Lambda = 0.947, 
F (2, 32) = 0.900, p = 0.417 (see Table 3-29). 
Table 3-29: Repeated measures ANOVA – Wilk’s Lambda for M2PK concentrations in 
Period I, Period II and Period III  
Wilks’ Lambda F Hypothesis df Error df p 
0.947 0.900 2.000 32.000 0.417 
3.6.3 Lactoferrin  
A repeated measure ANOVA was conducted to evaluate the differences in the 
lactoferrin concentrations in the samples from Period I - control, Period II - 
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treatment and Period III - post-treatment. Three mean concentrations were 
calculated using lactoferrin scores corresponding to the three distinct periods 
(see Table 3-30). Only subjects with no missing lactoferrin values were 
included in the analysis; therefore, the final number of subjects was 24 (N=24) 
(please see Appendix 10 for King’s College Hospital letter on the accidental 
discard of samples). The Boxplot represents the estimated marginal means of 
lactoferrin (ng/mL) across the three periods (see Figure 3-14). 
Table 3-30: Descriptive statistics for lactoferrin concentrations 
Lactoferrin M SD N 
Control Mean 1488 1621 24 
Treatment Mean 1278 1123 24 
Post-treatment Mean 1701 1912 24 
Figure 3-14: Lactoferrin mean scores over Period I, Period II and Period III  
Legend to the Figure 3-14 figure represents the mean scores (ng/mL) for lactoferrin samples 





































































The results of the repeated measures ANOVA indicated that there was no 
significant difference between the three mean scores (Wilks’ Lambda = 0.94, 
F (2, 20) = 0.64, p = 0.54 (see Table 3-31). 
Table 3-31: Repeated measures ANOVA – Wilk’s Lambda for lactoferrin concentrations 
in Period I, Period II and Period III  
Wilks’ Lambda F Hypothesis df Error df p 
0.94 0.61 2.000 20.000 0.54 
3.7 Results Study IV - The relationship between calprotectin 
and twenty-four parameter S.O.S questionnaires.  
3.7.1 Data Collection Procedure 
The data collected was analysed using the R Project for Statistical Computing 
version 2.15 (R Development Core Team, 2012). GI inflammation was 
assessed using faecal calprotectin levels while GI and behavioural symptoms 
were assessed using the completed questionnaires (See section 2.22 for 
S.O.S questionnaire parameters and methods of use).  
3.7.2 Association between questionnaire data and calprotectin adjusted 
by patient and sample 
The data generated from the set of eight questionnaires were correlated with 
the results of the eight sets of faecal calprotectin concentrations. The twenty-
four parameters from the questionnaires were matched with the faecal sample 
collecting times and calprotectin results. Each parameter from the 
questionnaire was analysed individually using a univariate model.  
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Table 3-32 shows the results of the univariate analysis, which is a method 
commonly used in prediction research as it includes all the univariate 
variables tested. The variable where p <0.15 were manually deleted and not 
included in the multivariate model (see raw data appendix 7). Each parameter 
was analysed repeatedly at several time points, corrected by patient and by 
sample, and correlated to the levels of calprotectin detected. Univariate 
analysis is an established strategy to measure longitudinal data for single 
outcome variables (Nakai, 2009). Aiming to keep variables within the 
regression model, a more liberal p = 0.15-0.25 was employed, which has 
been established as a common procedure within predictor research (Harrell et 
al., 1996, Kalkman et al., 2003). A p value of <0.15 was set as an initial filter 
for the univariate model of analysis (Bursac et al., 2008, Heinze, 2008). The 
parameters ‘lack of awareness’ and ‘interaction with parent’ (p = 0.02), 
‘abnormal repetitive gestures’ (p = 0.009), ‘need to maintain sameness’ (p = 
0.0093) and ‘need for a fixed routine’ (p = 0.003) were found to be significant. 
The parameters ‘constipation’ (p = 0.108) and ‘bloating’ (p = 0.086) were not 
significant at p <0.05, but both parameters fit the required filter criteria with p 
<0.15 and were incorporated in the multivariate analysis.  
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Table 3-32: Initial univariate model data 
Variable  Std Error p-value 
1. Lack of awareness and interaction with parent 0.90 0.02* 
2. Abnormal greeting behaviour 0.81 0.35 
3. Abnormal comfort seeking 0.81 0.32  
4. Can’t make friends 0.66 0.80  
5. Lack of awareness of social rules 0.70 0.79  
6. Lack of spontaneous speech 1.15 0.28 
7. Abnormal word utilisation 0.67 0.69  
8. Poor comprehension of verbal instructions 0.77 0.32  
9. Lack of eye contact 0.92 0.57  
10. Abnormal repetitive gestures 0.77 0.009  
11. Need to maintain sameness 0.78 0.009*  
12. Need of fixed routine 0.79 0.0003*  
13. Diarrhoea 0.78 0.86  
14. Constipation 0.69 0.10*  
15. Poor Appetite 0.74 0.65  
16. Bloating 0.76 0.08*  
17. Flatulence 0.85 0.41  
18. Vomiting 1.26 0.39  
19. Unhappy 1.07 0.35  
20. Aggressive 0.89 0.20  
21. Destructive 0.82 0.36  
22. Spaced out/ Non Interactive 0.79 0.14  
23. Agitated 0.91 0.22  
24. Disagreeable 0.82 0.01*  
Legend to the Table 3-32:This table includes all the univariate variables tested. As is common 
in prediction research those variables where p >0.15 were manually deleted and not included 
in the multivariate model. The asterisks indicate that the variable was kept in the multivariate 
model.  
The six variables in Table 3-32 were retested using the multivariate model, 
and the variables presenting with the least significant p values were 
successively eliminated from the mixed effect model. This resulted in a more 
concise model of variables as represented in Table 3-33. 
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Table 3-33: Final univariate model 
Variable p set at <0.15 used as 
an initial filter 
1. Lack of awareness and interaction with 
parent 
0.02* 
2. Abnormal repetitive gestures 0.0009* 
3. Need to maintain sameness 0.0093* 
4. Need of a fixed routine 0.0003* 
5. Constipation 0.10 
6. Bloating 0.08 
Legend to the Table 3-33: This includes all of the variables that satisfied the initial filter of p 
<0.15 in the univariate analysis of the mixed effect model. Parameters 1-4 demonstrated a 
significant correlation with the inflammatory marker calprotectin at p <0.05. The parameters 
‘constipation’ and ‘bloating’, although not significant in the univariate model were when p 
<0.15, which satisfies the filter value required to be included in a multivariate model. 
 The six parameters from the univariate model were then included on the 
multivariate model and retested. The data indicates a strong association 
between several parameters from the questionnaire and levels of faecal 
calprotectin. The parameter ‘need for a fixed routine’ was found to be highly 
significant (p<0.00009), and the multivariate coefficient of 3.227 suggests that 
autistic children who display an increase in a ‘need for a fixed routine’ also 
show elevated calprotectin levels which indicates GI inflammation. 
Paradoxically, the parameter ‘constipation’, although demonstrating a 
significant change (p <0.02) gave a negative multivariate coefficient of -1.584, 
corresponding to a decrease in calprotectin levels, possibly indicating 
decreased GI inflammation (see Table 3-34). This negative value for the 
parameter ‘constipation’ is directly associated with the positive value for ‘need 
for a fixed routine’, which may be considered as independent but reciprocal 
predictors of GI inflammation in these autistic children. 
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Table 3-34: Final Multivariate Model 
Variable Multivariate 
Coefficient  
SE p-value  
(Intercept)* 22.8 4.0 p set at < 0.05  
Need of a fixed 
routine 
3.2 0.8 0.00009  
Constipation -1.5 0.6 0.02269  
Legend to Table 3-34: This represents the final multivariate model results for the two 
significant parameters. ‘Need for a fixed routine’ (p = 0.00009) and ‘constipation’ (p = 0.02) 
were found to correlate with GI inflammation as assessed by levels of calprotectin. *Intercept 
is a baseline for the calprotectin concentration in this multivariate model. 
3.8  Case history anecdotal Observations  
The following information is anecdotal and is not intended to be correlated or 
compared with the outcome measures of this thesis. However, it was included 
in the results section as case history anecdotal observations as it 
demonstrated value in illustrating the behaviour and GI signs and symptoms 
of autistic children during treatment. 
Following acceptance of inclusion criteria, the osteopathic sessions were 
organised once a week for six weeks. All subjects were treated using the 
same set of VOTs described in the methodology section of this thesis. Due to 
the nature of autism, the approach to the subject was accommodated 
according to the subject’s behaviour.  
Generally, all of the subjects had to spend some time getting acquainted with 
the osteopath. This was done by giving them the time to explore the room and 
to become comfortable with the environment. Normally the osteopath used 
some toys and verbal communication to be able to approach the child. Once 
the verbal contact was made and a little interaction between the 
subject/osteopath occurred, the osteopath started the treatment.  
Usually an osteopathic session was undertaken on a plinth, however, that was 
seen as a big imposition on the subjects. Therefore, the subjects were shown 
to the plinth or to a floor mat (option from the plinth), allowing them to decide 
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where they felt most comfortable to lie down. The VOT sessions were patient 
centred and it was the osteopath who had to adapt the treatment position to 
be able to treat the subjects. This means that the treatment may have 
occurred with some variation, with the subject sitting on a chair or standing in 
the corner of the room facing the wall. All these places within the room were 
chosen by the subject. 
After the first or second session, some subjects displayed a clear 
understanding of the treatment. This was demonstrated by running to the 
treatment room and lying on the plinth or on the floor mat. They did not 
appear to be fazed or worried that they were about to be treated. More often 
than not, the subjects would place their hands on their abdominal area and 
would lift their top in an attempt to indicate that they were about to be treated 
or, apparently, that they wanted to be treated. More than one subject would 
place their hands on the osteopath’s hand in an attempt to help with the 
techniques or to indicate they were content to be treated.  
The subjects had some interesting responses that were quite remarkable. 
One specific subject who was non-verbal and very low on the ASD spectrum 
managed to verbalise ‘butterfly’ after the 4th session. This was by making eye 
contact with the osteopath and pointing to a butterfly mobile hanging in the 
corner of the treatment room. The parent, who witnessed the behaviour of the 
child, was clearly surprised and emotionally affected by the response. It was 
observed that this particular subject continued to improve over the next few 
sessions, demonstrating more calmness and the ability to make more eye 
contact with the practitioner. As anecdotally reported by the parents, eye 
contact and verbalisation was not a usual occurrence of their child.  
Another interesting case was of a boy that displayed signs of faecal impaction 
on the lower quadrant of the abdomen and was constipated for 2 weeks prior 
to the initiation of the VOTs. The response that the subject had was 
remarkable; during the session he stood up and ran to the toilet (next door to 
the treatment room) and was able to pass a motion. This occurred at every 
VOT session he had during the study period. These observations may 
possibly imply that the treatment perhaps influenced the peristaltic motion. 
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There were definitely some difficulties when treating the children due the 
nature of the behaviour that some were displaying. Some were screaming and 
pushing, punching, spitting and hair pulling. However, the remarkable 
observation was that not a single child of the 49 treated had to be excluded 
due to not being able to cope with the session. Usually, the very ‘bad’ 
behaviour faded in less than 10 minutes into the session, which in itself is a 
remarkable response.  
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Chapter 4 - Discussion 
Patients with an autistic disorder may present with GI symptoms, such as 
abdominal distension and pain, constipation, chronic diarrhoea, foul-smelling 
stools and/or flatulence (Shattock and Savery, 1996, Lewis, 1998, Jyonouchi 
et al., 2005a, Jyonouchi et al., 2011) and a link has been suggested between 
these GI symptoms and the cognitive deficit and abnormal behaviour of 
autistic children (D'Eufemia et al., 1996, Horvath et al., 1999, Horvath, 2000, 
Horvath and Perman, 2002, Koves et al., 2004, Valicenti-McDermott et al., 
2008, Ibrahim et al., 2009, Nikolov et al., 2009, Chaidez et al., 2013). 
Carr and Owen-Deschryver (2007) proposed that the intensity and frequency 
of pain in autistic individuals could lead to problem behaviour and low 
spectrum ASD individuals with impaired language skills, may express GI pain 
and discomfort through body mannerisms and self-harm (Carr and Owen-
Deschryver, 2007). According to Breau et al. (2003), the lower the spectrum 
of behavioural or mental impairment the greater their pain and discomfort. A 
comparative study of 960 children including children developing normally, 
children with developmental delays and autistic children, suggested that the 
frequency of GI symptoms in ASD children is three times higher than in 
children developing normally (Chaidez et al., 2013). Chaidez et al. (2013) also 
suggested that the co-morbidity between behaviour and GI symptoms in 
autistic subjects may suggest possible treatment approaches.  
A report analysing statements based on expert opinion has attempted to 
establish the importance of assessing the GI function of children diagnosed as 
autistic and suggests that these autistic children present with atypical GI 
symptoms in and may go undiagnosed. Such children should not only be 
investigated and treated for their behavioural problems but also for their GI 
problems (Buie et al., 2010). A gut-brain axis has been proposed, linking 
autistic behavioural dysfunction and GI symptoms, whereby the worsening of 
behavioural symptoms may possibly be due to inflammatory gut reactions 
meditated by immunological signals (Jyonouchi et al., 2005a, Reichelt and 
Knivsberg, 2009, Forsythe et al., 2010).  
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Kearney and Brown-Chang (2008)Kearney and Brown-Chang (2008)Kearney 
and Brown-Chang (2008)Kearney and Brown-Chang (2008)Kearney and 
Brown-Chang (2008)Kearney and Brown-Chang (2008)Complementary and 
alternative methods of treatment have a role in IBS in adults due to the 
psychological benefits of combined ‘body and mind’ methods, Kearney and 
Brown-Chang (2008). However, the use of complementary medicine in the 
management of autistic children suffering from GI symptoms is in its infancy. 
This thesis has attempted to investigate the use of visceral osteopathy in 
autistic children, suffering from the classical behavioural and GI problems, by 
using objective measures to assess potential changes.  
4.1 Overview of the Studies Conducted 
Study I (see results chapter section 3.3) analysed the data collected during 
Period I – control, and created a baseline for the statistical analysis during the 
latter studies. Studies II, III and IV reported on the analysis of the data 
collected during the distinct study periods: Period I - control, Period II - 
treatment and Period III - post-treatment, and compared the baseline data 
collected during Period I with that from Periods II and III.  
In this chapter the results of all four studies are integrated and there is also a 
discussion of the incidental findings resulting from the analysis of the research 
baseline (Period I) and a comment on the anecdotal observations from the 
case notes (see also Results 3.8, Case History Anecdotal Observations).  
4.2 Sequential Calprotectin, M2-PK and Lactoferrin Sampling 
The three markers used for sample analysis in this thesis have been selected 
due to their high specificity and sensitivity in diagnosing IBDs as well as their 
reported positive correlations (Bunn et al., 2001, Summerton et al., 2002, 
Fagerberg et al., 2003, Sherwood et al., 2005, Walker et al., 2007, Sidhu et 
al., 2010b, Yamamoto et al., 2013). Study I generated from the control period 
is presented in five parts (Period I – Part A, B, C, D and E). Period I - parts A, 
B, and C are the results of the baseline for the three faecal biochemical 
markers. Part D is the result of the analysis of the sequential S.O.S 
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questionnaires and Part E is the correlation of the three biochemical markers 
during Period I.  
Laboratory analysis of the three selected markers followed strict 
manufacturer’s guidelines stated in the methodology section of this thesis 
(see methods 2.19 – 2.21). Each of the samples were analysed by a 
laboratory technician who was blinded to the study to avoid bias of the results.  
4.3 Discussion of studies  
4.3.1 Period I – Study I (Part A) – Calprotectin in Sequential Faecal 
Samples  
Faecal calprotectin is a stable marker of GI inflammation that has been used 
as a pre-screening tool for UC  and CD  (Fagerberg et al., 2005). Faecal 
calprotectin also has very high levels of specificity (100%) and sensitivity 
(80%) for GI diseases in children with IBD (Bunn et al., 2001). This non-
invasive test is proven to be valuable both in distinguishing between IBD and 
IBS in children, and as a pre-test for more invasive examinations such as 
colonoscopy (Aadland and Fagerhol, 2002, Summerton et al., 2002, 
Szarszewski et al., 2003, Yui et al., 2003, Fagerberg et al., 2005, Manz et al., 
2012). Elevated faecal calprotectin is a more specific and precise identifier of 
GI inflammation than serum markers, such as, serum tumour necrosis factor 
(TNF), TNF-α receptor levels, and various interleukins (IL-1, IL-6, IL-8), due to 
its direct contact with the intestinal mucosa (Pardi and Sandborn, 2005). 
Calprotectin detection could therefore be used as a non-invasive screening 
tool for identifying organic diseases of the small intestine or large bowel (Striz 
and Trebichavsky, 2004, Fagerberg et al., 2005, Lundberg et al., 2005, 
Stroncek et al., 2005). The calprotectin diagnostic ELISA is a good tool, since 
high calprotectin levels correlate well with the severity of UC  and CD  in 
children (Bunn et al., 2001, Fagerberg et al., 2005).  
Calprotectin was selected as a faecal marker for the current study owing to its 
stability and high levels of specificity and sensitivity for IBDs. The use of a 
non-invasive marker minimised disruption to the child’s day to day 
environment. 
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The objective of this study (Period I - Part A) was to determine the baseline 
for calprotectin using the four faecal samples collected. The baseline data for 
these sequential calprotectin samples (1- 4) was analysed in 48 subjects 
using a series of statistical tests presented in the result section (Period I – 
Part A).  
Continuous variability of calprotectin was represented via a Box and Whisker 
plot (see Figure 3-3). The presence of outliers across the Box and Whisker 
plot influenced the SD and the mean across the four pre-treatment 
calprotectin samples (see Table 3-2) resulting in a wide spread of the data.  
As previously stated, it has been shown that calproctectin is a remarkably 
stable and reliable marker to assess IBDs using a faecal sample (Bunn et al., 
2001, Aadland and Fagerhol, 2002, Summerton et al., 2002, Fagerberg et al., 
2003, Szarszewski et al., 2003, Striz and Trebichavsky, 2004, Lundberg et al., 
2005, Langhorst et al., 2008, Manz et al., 2012). The marker has proven to be 
highly reliable (Ton et al., 2000, Fagerberg et al., 2003) regarding stability, 
sensitivity and specificity but these studies were based on single samples and 
therefore cannot be relied upon to shed light on the intra-individual biological 
variability  of the marker. These are two distinct and important features of bio-
analysis. The measurement of the marker itself is stable, sensitive, specific 
and reproducible but the production/secretion from the GI tract varies 
according to the patho-physiological state of the subject and thus there is 
intra-individual biological variability . Gilbert et al. (1996) and Husebye et al. 
(2001) analysed a series of faecal samples from “normal” subjects and found 
that they displayed biological variability. The authors suggest that day to day 
physiological change contributes to significant intra-individual biological 
variation. The published data on sequential calprotectin samples are sparse, 
however, giving little evidence to determine reliability of baseline intra-
individual biological variability . Therefore, it was necessary to attempt to 
create a biological/physiological baseline over time for comparison with a 
post-intervention calprotectin assessment. The initial analysis performed on 
the results was a Cronbach’s Alpha test (see methodology 2.26.3 for 
information on the test). According to Cronbach’s Alpha test the baseline 
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results indicated that the four calprotectin samples showed internal reliability 
of 0.70 or 70%. According to the literature (Bland and Altman, 1997) a 
Cronbach’s Alpha result of 0.70 indicates a satisfactory reliable measure 
(Bland and Altman, 1997, Tavakol and Dennick, 2011).  
A test-retest reliability analysis was performed on matching samples during 
the six weeks of the pre-treatment period to determine how calprotectin was 
excreted in stool samples over time. The individual results of the test-retest 
reliability (see table 3-2) suggested that the three correlations, from the four 
collected pre-treatment calprotectin samples, ranged from unacceptable to 
poor reliability with only one correlation suggesting an excellent reliability. The 
results from the test-retest reliability suggest that the results of the sequential 
calprotectin pre-treatment samples were influenced by biological variation 
over time.  
It is important to highlight the results from the Cronbach’s Alpha (Cronbach’s 
Alpha = 0.7) analysis that suggest a satisfactory overall reliability for the mean 
values baseline data.  This interestingly contrasts with the individual subject 
sequential results (Table 3-6). The reliability (Cronbach’s Alpha = 0.7) of the 
mean baseline results, however, suggests that the mean results collected 
from the pre-treatment calprotectin samples may be compared with the 
treatment period and post treatment periods with confidence.  
According to Rosner (2011) the normal procedure in analyses of variance 
ANOVA is to eliminate outliers, three box lengths from the edge of the box, as 
they usually skew the results. Outliers were, therefore, withdrawn from the 
data set before the ANOVA was performed. It was observed that withdrawing 
the outliers from the data set decreased the SD spread. (see Table 3-3). The 
ANOVA analysis was performed on a total of 172 matching samples from the 
43 subjects. The results from the ANOVA show no significant difference in the 
means across the four pre-treatment scores, suggesting that the data is stable 
with minimal variance. These mean data were then used as a baseline 
throughout the thesis. 
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As previously stated, outliers may reflect and potentially reveal an important 
occurrence. A decision was made, therefore, to reintroduce the outliers on the 
final descriptive table of this study (see Table 3-5). The analysis of the four 
sequential calprotectin samples, including the outliers (n=46) (See Table 3-5) 
suggests that 65% (30/46) of this autistic population displayed relatively stable 
calprotectin levels over time, and these were mostly within the normal range. 
However, further, individual, analysis suggests that 35% (16/46) of this 
population showed a wider calprotectin reference range over the six week 
period.  
Levels of calprotectin determined across the four sequential samples showed 
that 15% (7/46) of the total population included at least one of the scores 
entering the IBS clinical range of 51-121 mg/mL, and each of these individuals 
exhibited a 25% chance of inflammation. Five subjects (11%) presented with 
two of the four scores between 56-640 mg/mL, and therefore displayed a 50% 
chance of active/non-active IBD. One subject (2%) had three scores above 50 
mg/mL, between 121-195 mg/mL, and consequently this subject had a 75% 
chance of IBS. Finally, there were three subjects where all four of their 
calprotectin scores were above 50 mg/mL, and these were between 66–1593 
mg/mL. These subjects had a 100% chance of their calprotectin results 
indicating non-active/active IBD. 
It is possible that individual physiological changes may have affected the 
results of test-retest reliability. The observation that changes occurred 
between individual calprotectin samples over a relatively short period of time 
does not explain why results varied, only that they did vary. These changes 
may be influenced by the day to day physiological changes that occur in the 
human living organism, potentially being the result of biological variation. 
Biological variation is the result of a continuous fluctuation of internal 
biological components. These variations may occur as a cyclical variation 
hourly, daily, monthly or randomly over any timeframe (Ricós et al., 2009, 
Perich et al., 2014). Despite there being a large amount of literature on the 
reliability of calprotectin as a marker of GI inflammation there is very little 
literature on the intra-individual biological variability  or biological variation of 
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the marker over time (Husebye et al., 2001). These authors have, however, 
raised the question of the day to day variability of the marker. Their study 
tested eight consecutive calprotectin samples in fourteen subjects (Husebye 
et al., 2001). Results revealed that in healthy controls 63% of subjects 
displayed all eight calprotectin values <30 mg/mL which is normal range for 
calprotectin levels. Seven of the fourteen subjects (37%) had high or 
abnormal levels of calprotectin in at least one measurement. The results 
suggested by Husebye et al. (2001) are confirmed by this current study. 
Currently, This variation of calprotectin over time cannot be explained.  
The data from this study suggest that one random stool sample is not 
sufficient to reliably indicate inflammation or to reliably assess, either 
positively or negatively, autistic children for organic diseases such as IBDs or 
IBS. Thus, a single measurement of calprotectin levels may be insufficient, 
either to corroborate the reported clinical symptoms or to establish a 
diagnosis. In fact, biological variation could create an artefactually higher 
chance of the calprotectin result not correlating with, or reflecting, the reported 
clinical symptoms. Autistic children with clear clinical symptoms of IBS or IBD 
should therefore have more than one, preferably three, sequential faecal 
samples taken and analysed to determine calprotectin concentration more 
confidently.  
There are to date two studies that have analysed sequential faecal 
calprotectin samples, both with smaller population samples than this study 
and with normal, symptom free subjects (Gilbert et al., 1996, Husebye et al., 
2001). This current study has analysed sequential samples from autistic 
children who also display GI symptoms. The results of this study suggest that 
intra-individual biological variability  of calprotectin in sequential samples 
needs more research for complete understanding.  
4.3.2 Period I – Study I (Part B) – Discussion of M2-PK in Sequential 
Faecal Samples  
Recently, the dimeric isoform of pyruvate kinase, M2-PK, has been identified 
as a novel metabolic marker for various tumours, including colorectal 
(Sherwood et al., 2005, Ewald et al., 2007), pancreatic, lung, ovarian (Ahmed 
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et al., 2007), and breast (Sherwood et al., 2005, Ahmed et al., 2007, Lazarev 
et al., 2010). M2-PK reflects tumour metabolic activity and provides useful 
information on follow-up screening after surgery or during chemotherapy 
(Eigenbrodt, 2001). It is also considered to be a stable marker for the 
detection of IBD (Chung-Faye et al., 2007, Day et al., 2012).  
A recent study reported that the faecal M2-PK marker has a sensitivity of 92% 
for the detection of colorectal cancer, 60% for the detection of large polyps 
and 25% for the detection of small polyps, and specificity was also 92% (Koss 
et al., 2005).  
Chung-Faye et al. (2007) demonstrated a possible linear correlation between 
levels of calprotectin and the levels of M2-PK and suggested M2-PK to be a 
novel marker to differentiate IBD from functional bowel disorders. Another 
study demonstrated that M2-PK is an effective marker for detecting GI 
mucosal inflammation in children suffering from CD  when compared to 
healthy controls. This suggests that M2-PK is a possible non-invasive marker 
for detecting active IBD in a paediatric population (Day et al., 2012).  
M2-PK was selected as a faecal marker for assessing GI inflammation in 
autistic subjects because of its linear correlation with calprotectin levels 
(Fengming and Jianbing, 2014) and its non-invasive quality. Moreover, both 
markers could be assessed from the same stool sample, facilitating sample 
control. In addition, M2-PK is suggested to be a useful non-invasive marker of 
cell turnover, helpful in assessment and differentiation of IBD and IBS in 
children (Czub et al., 2007). 
The sequential analysis of M2-PK (Period I – Part B) matches with the 
analysis of calprotectin sequential samples. The marker is stable and displays 
high levels of specificity and sensitivity in detecting IBDs. To date no literature 
has been found on sequential sampling for M2-PK in either adults or children. 
Therefore, it was necessary to create a baseline for M2-PK samples to be 
used to correlate with the periods II and III of the current thesis. 
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The same stool specimen collected from 48 subjects (n=48) used for 
calprotectin    (Period I –Part A) assessment was utilised for the analysis of 
M2-PK. The statistical analysis of the initial 48 subjects presented a wide 
standard deviation for the collected sequential faecal M2-PK samples (Period 
I – Part B). The SD ranged from 2.7 to 5.1 for a mean range of 1 - 19 (see 
Table 3-6). The results from the sequential M2-PK samples show a similar 
trend and tend to corroborate the results from the analysis of calprotectin pre-
treatment therefore also raising questions on the intra-individual biological 
variability of the marker.  
Intra-individual biological variability of M2-PK may be suggested by the results 
from the test re-test reliability analysis that showed unacceptable to 
questionable reliability when comparing individual samples over time (see 
Table 3-7). However, the analysis performed for the Cronbach’s Alpha 
suggests a very strong overall internal consistency (Cronbach’s Alpha = 0.8 or 
80%) of the pre-treatment mean result s. Therefore, the mean levels from pre-
treatment M2-PK samples s can be used as a baseline to compare the 
treatment period and post treatment period means. 
Outliers were also present in the analysis of M2-PK weekly samples. These 
were excluded before the ANOVA analysis was performed bringing the 
sample numbers to 45 (outliers - subjects 39, 40 and 45). Two of the outliers 
that were detected on the M2-PK analysis were also detected in the 
calprotectin outlier analysis (subjects 39 and 40) (Figure 3-3 and 3-4).  
The repeated ANOVA (see Table 3-9) demonstrated a significant lack of 
variation between the four M2-PK sequential scores. These results together 
with the results of the Cronbach’s Alpha confirm that the mean data can be 
used as a baseline to correlate with the means of the periods II and III.  
However, the analysis in table 3-10 demonstrates differences in the weekly 
M2-PK value levels ranging from 1U/mL to 20 U/mL (normal to abnormal). 
This variation in the sequential values for M2-PK for individual subjects may 
indicate that, as with calprotectin analysis (Period I – Part A), the weekly 
samples for M2-PK may be influenced by physiological intra-individual 
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biological variability. According to the data obtained, a single sample analysis 
gives a 70% of chance of showing a consistent level of M2-PK. However, 
there is a 30% chance that any of the four samples could display an 
inconsistent result. Therefore, subjects relying on diagnosis via collection of a 
single sample have a 30% chance of being incorrectly diagnosed.  
Results from M2-PK statistical analysis of sequential samples are similar to 
the analysis of calprotectin. To assess M2-PK levels reliably, either for a 
normal or for an abnormal range in autistic children, a single sample faecal 
M2-PK analysis is insufficient to confidently corroborate the clinical 
signs/symptoms or to establish a biochemical diagnosis. In the absence of 
publications regarding sequential M2-PK faecal markers, corroborative 
evidence from the literature was not possible.  
The novelty of this study lies in the analysis of four sequential M2-PK faecal 
samples from autistic children suffering from GI symptoms. The result of this 
study is similar to the calprotectin sequential analysis, both markers may 
potentially be influenced by intra-individual biological variability and therefore 
more research on sequential samples is advised for both markers. 
4.3.3 Period I – Study I (Part C) – Discussion of Lactoferrin in Sequential 
Faecal Samples  
Lactoferrin is a 703 amino acid iron binding glycoprotein present in mucosal 
secretions and in the secondary granules of neutrophils (Levay and Viljoen, 
1995, Walker et al., 2007). Is has been suggested that lactoferrin is a possible 
marker for assessing IBD activity and, therefore, a potential non-invasive 
marker of inflammatory bowel diseases such as CD  , UC  and a 
discriminative marker of IBD and IBS (Sidhu et al., 2010a, Sidhu et al., 
2010b). Lactoferrin has the ability to respond to several changes in 
homeostatic balance, as its’ biological functions range from anti-bacterial, 
anti-viral, anti-parasitic, anti-fungal to anti-inflammatory (Gonzalez-Chavez et 
al., 2009, Jenssen and Hancock, 2009). A recent study evaluated lactoferrin 
levels in faecal samples from 170 children with a mean age of 13.4 years, to 
assess IBD disease activity. The study suggested that faecal lactoferrin levels 
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are a reliable non-invasive marker within the paediatric population (Walker et 
al., 2007). 
In the last decade studies have shown that lactoferrin has very high specificity 
and sensitivity levels for identifying IBDs and IBS (Kane et al., 2003, Lundberg 
et al., 2005, Sidhu et al., 2010b). A study by Kane et al. (2003) suggested that 
faecal lactoferrin was 90% specific for diagnosing active IBD and 100% 
specific in discarding IBS as a potential diagnosis, whilst Langhorst et al. 
(2008) suggested that lactoferrin levels were 85% sensitive and 77% specific 
diagnosis of IBS.  
Sidhu et al. (2010a) analysed the specificity and sensitivity of lactoferrin in 
CD, compared with the use of capsule endoscopy; a novel wireless imaging 
device, as a means for diagnosing IBD. The study suggested a correlation 
between faecal lactoferrin levels and capsule endoscopy (p = 0.03). 
Lactoferrin sensitivity and specificity was reported to be 71% and 100%, 
respectively; however, only seventeen patients were recruited to this study 
(Sidhu et al., 2010a). Another study by Sidhu et al. (2010b) analysed single 
samples from subjects to determine the sensitivity and specificity of faecal 
lactoferrin in differentiating between IBD and IBS. This study recruited a total 
of 465 subjects, 137 with IBS, 126 with UC, 104 with CD and 98 healthy 
volunteers and suggested that lactoferrin has a higher discrimination for IBD 
compared with IBS; with a sensitivity of 67% and a specificity of 96%.  
The rationale for the use of lactoferrin as a marker of inflammation was due to 
its non-invasive nature as well as a high correlation with faecal calprotectin 
(Period I -Part I) in diagnosing IBDs. Therefore, both markers act well as 
surrogate markers for disease activity.  
The sample size for this analysis differed from the analysis of calprotectin and 
M2-PK due to an accidental discard of samples by the laboratory, and was, 
therefore, outside of the author’s control (see Appendix 10). The total sample 
size for this study was 24 (n=24). 
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A test-retest reliability analysis revealed that individual lactoferrin samples had 
unacceptable reliability (see table 3-11). However, further analysis was 
performed to assess the variation between each sample mean. A repeated 
measure ANOVA (n=24) was conducted which revealed no significant 
variation between the four lactoferrin sample mean values, W = 0.82, F (3, 21) 
= 1.45, p = 0.25 (see Table 3-13). These results confirm that the mean data 
can be used as a baseline to correlate with the periods II and III of the current 
thesis.  
According to Lundberg et al. (2005) and TechLab® (2008) (see methodology 
table 2.21.4) lactoferrin faecal sample results below 7.25 µg/mL are 
considered negative for IBD and IBS. In this study, 18 subjects (75%) (see 
Table 3-14) presented with all four scores below the cut-off level (7.25 µg/mL), 
thereby indicating a negative test result for either IBD or IBS. The remaining 
six subjects, (25%) (see Table 3-14), presented with one or two scores above 
the cut-off level (7.25 µg/mL), and were therefore consistent with a positive 
result for either IBD or IBS. The data suggest that 75% showed consistent 
results across the sequential samples. However, the remaining 25% of the 
weekly sample results were not consistent. Therefore, in common with 
calprotectin and M2-PK sample analysis, it is possible that the variation of the 
samples was due to individual intra-individual biological variability.  
The novelty of this study was the analysis of four sequential lactoferrin faecal 
samples from autistic children suffering from GI symptoms. All previous 
studies found have been based on single faecal lactoferrin samples and, it 
has not been possible to produce corroborative evidence from the literature.  
Although the data suggest that a single sample analysis gives a 75% chance 
of being consistent for levels of lactoferrin, further analysis revealed a wide 
variation of the marker across the weekly individual results. To reliably 
assess, either for normal or for abnormal lactoferrin ranges in autistic children, 
and for organic diseases such as IBD or IBS, a single lactoferrin faecal 
analysis may not be sufficient to either corroborate the clinical symptoms or to 
establish a biochemical diagnosis.  
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A limitation of this study was the small number of subjects tested (n=24). Even 
though the sample size was smaller compared with the other two markers 
tested in this thesis, lactoferrin results were similar in trend to the other 
markers tested. It is concluded that potentially all three markers may be 
influenced by individual day to day intra-individual biological variability  and 
therefore more research on sequential faecal samples markers is necessary.  
4.3.4 Period I – Study I (Part-D) – Discussion of sequential S.0.S 
Questionnaire  
As stated previously in the methodology section of this thesis, an outcome 
measure used to assess behaviour and GI signs was a ten point scale 
questionnaire based on the Autism Research Institute Secretin Outcomes 
Survey Form (the ‘S.O.S Form’), which is a validated and standardised 
questionnaire (Rimland, 1998, Brudnak et al., 2002, Unis et al., 2002, Esch 
and Carr, 2004, Erickson et al., 2005, Sturmey, 2005, Williams et al., 2005). 
To create a baseline, parents completed the questionnaire four times during 
the pre-treatment period (Period I/baseline control period) according to their 
assessment of their child’s GI and behavioural signs and symptoms (see 
questionnaire appendix 5)  
Statistical analyses of the four S.O.S pre-treatment questionnaires of the 48 
subjects (n=48) are presented in the results section (see results chapter 
section 3.3.4). Descriptive analysis of the 24 parameter questionnaires were 
divided into four tables (see Table 3-15, Table 3-16, Table 3-17 and Table 3-
18). Each of the parameters was individually assessed for the means and 
standard deviation which varied according to each parameter.  
The results from the Cronbach’s Alpha (Cronbach’s Alpha = 0.8 or 80% of 
reliability) analysis revealed that the S.O.S questionnaire displayed good 
overall reliability as a tool for measuring behaviour and digestive signs in 
children suffering from ASD. This suggests that the tool can be used reliably 
to compare data across the different periods of this thesis.  
The S.O.S questionnaire parameters were subdivided into four sections called 
the subscales. Each subscale recorded one specific group of signs. The 
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results of the statistical analysis of the questionnaire per subscale can be 
seen in the Box & Whisker Plot, Figure 3-6. The subscale, ‘Social Behaviour 
and Communication’, (see questionnaire appendix 5) demonstrated a similar 
mean and standard deviation to the subscale ‘Ritual and Repetitive Activities’. 
In comparison the subscale ‘Digestive Signs’ and ‘General Signs’ showed 
much lower means and SDs indicating that the subjects were more affected 
using these parameters as assessment criteria.  
According to Jerckings (1998), the advantages of using questionnaires in 
quantitative research include that a large amount of information can be 
collected in a relative short period of time, information can be collected by a 
number of people with limited effect on the validity, the data generated from 
the questionnaires can be quantified easily and therefore used scientifically,; 
data can be compared and correlated with other researches, and data can be 
used to measure changes before and after intervention.  
However, no scientific measuring tool is perfect and there are some known 
disadvantages of using a questionnaire to collect data for scientific research. 
These are: reliability and accuracy of recall, the level of subjectivity of 
people’s perception when answering a question, and the possibility that 
important questions for the study may not have been answered (Rosner, 
2011).  
All of the questionnaires used for the baseline and for later stages of this 
research were based on parental perception of their child’s behaviour and 
digestive signs. Using parent’s perceptions may be seen as a limitation to the 
study potentially skewing the data because parents might underestimate or 
overestimate the scoring system of the questionnaire erroneously. This may 
be dependent on several factors; including; proper understanding of what was 
asked, lack of commitment when answering the questionnaire or, for example, 
a subconscious desire to please the researcher. This may generate a bias 
that could potentially skew the data. In an attempt to decrease the possibility 
of the data being influenced by bias, parents were asked to answer the same 
questionnaire at four different instances during a six weeks period. Splitting 
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the questionnaires into different times may potentially create a random 
answering effect and potentially decrease the possibility of the bias.  
Parents and guardians of autistic children are constantly affected by the 
stresses of dealing with the day to day aspects of raising a child with ASD. In 
a report by Nock and Kazdin (2001), the authors suggested that parents of 
autistic children have low expectations of any type of treatment for their child. 
This could result in the possibility that parents over-grade the symptoms and 
under-grade any positive effect of the treatment when responding to a 
questionnaire (see discussion in Period II of this thesis). This effect, if it 
occurred, would result in underestimation of any positive post-treatment 
response.  
Even though each parent’s perception was important for this study, parents 
themselves were not assessed as it was beyond the scope of this thesis. 
Hence, no assumptions can be made in terms of their wellbeing and how that 
may have affected the questionnaire scores. Acknowledging this, it cannot be 
denied that their own wellbeing may have affected their answers to the 
questionnaires.  
At this stage there is no conclusion to be drawn from the baseline results of 
the four sequential S.O.S questionnaires. The questionnaire parameters were 
re-tested during the treatment period and collated with the contemporaneous 
faecal marker results for calprotectin, M2-PK and lactoferrin in a later stage of 
the research. 
4.3.5 Period I – Study I (Part-E) – Discussion of Correlations between 
calprotectin, M2-PK and lactoferrin  
The final statistical analysis performed on the baseline data was a correlation 
analysis between calprotectin/M2-PK and calprotectin/lactoferrin. The 
correlation utilised the results from calprotectin baseline on matched samples 
for M2-PK and lactoferrin. The rationale for utilising calprotectin as the main 
marker for this thesis was its remarkable stability and its high specificity 
(100%) and sensitivity (80%) for diagnosing IBDs and IBS. M2-PK and 
lactoferrin were used as secondary markers. Therefore, this study attempted 
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to assess whether a correlation existed between biochemical markers in 
sequential faecal stool samples taken from autistic children suffering from GI 
symptoms. 
A Pearson correlation (see methodology 2.27.4 for statistical test explanation) 
was conducted to determine whether there was a significant linear 
relationship between the means of the calprotectin and M2-PK sample 
concentrations. The results indicated that there was a significant moderate 
positive correlation (r = 0.40) between the calprotectin and M2-PK means (r = 
0.40 n = 38 2-tailed p = 0.01), significant at p <0.05, (see table 3-20) (see 
section 3.3.5.1). Increases in calprotectin faecal concentrations were weakly 
associated with increases in M2-PK faecal concentrations (see   
Figure 3-7). A correlation between calproctectin and M2-PK was previously 
suggested by Chung-Faye et al. (2007), however these authors utilised single 
faecal samples. The current study utilised sequential calprotectin and M2-PK 
matched samples and attempted to correlate the means.  
A Pearson correlation was performed to determine whether there was a 
significant relationship between the total mean concentrations of calprotectin 
and lactoferrin. The analysis indicated that there was a significant moderate 
positive relationship between the two variables (r = 0.66, n = 24, p <0.001), 
(see Table 3-21 and Figure 3-6) These results should, however, be viewed 
with caution as the lactoferrin sample size was small following the accidental 
discard of some samples which was outside the control of the author (see 
appendix 10).  
No known study to date has used sequential faecal biochemical markers to 
assess GI inflammation. Previous studies have used a single sample to 
attempt a correlation between calprotectin and M2-PK, suggesting a strong 
linear relationship between the two markers (Chung-Faye et al., 2007). 
Another study supports the idea that lactoferrin is a useful marker in predicting 
IBDs and it correlates well with capsule endoscopic assessment (Sidhu et al., 
2010a). Previous studies also suggested that calprotectin and lactoferrin 
correlate well with endoscopic examination. (Yamamoto et al., 2013).  
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After matching the appropriate samples, the data was analysed using a 
Pearson’s correlation test. The results of the current study suggest that there 
is a weak linear correlation between calprotectin and M2-PK mean values 
suggesting that these markers may potentially be used together as markers of 
inflammation or disease activity in autistic children suffering from GI problems. 
However, due to the weak linear correlation the results should be viewed with 
caution.  
There was moderate correlation between calprotectin and lactoferrin 
concentrations. This indicates that these two markers may also potentially be 
used together as markers of inflammation in autistic children. 
Even though the results from the correlations between markes were positive, 
these results should be treated with caution. The sample sizes were small, a 
limitation of the study, particularly regarding the correlations between 
calprotectin and lactoferrin. 
No known study to date has published data on the analysis of sequential 
calprotectin, M2-PK and lactoferrin faecal samples in children displaying the 
autistic spectrum disorder (ASD) who also show GI symptoms. Despite the 
limitations of the study the results are encouraging and may stimulate more 
research in this field.  
4.3.6 Discussion Study II - Twenty-four parameter S.O.S questionnaires 
evaluation at Period I, Period II and Period III 
In the past fifteen years, research into ASD has suggested that there is a 
possible gut-brain axis, where the worsening of behavioural symptoms may 
possibly be due to inflammatory gut reactions meditated by immunological 
signals (Jyonouchi et al., 2005a, Reichelt and Knivsberg, 2009, Forsythe et 
al., 2010). 
This suggests that the positive comparative results between the periods I, II 
and III, suggested and presented in the results section of this thesis, may be 
of high importance. Nock and Kazdin (2001), suggest that these results may 
reflect a much greater significance of real positive changes.  
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The significant overall results, demonstrated by the repeated measure 
ANOVA analysis of the mean values, between the periods and the post hoc 
test (see results section 3.5.1), revealed that VOT may be effective in 
decreasing overall signs and symptoms of autistic children as perceived by 
their parents. This is reflected in a significant decrease in signs and symptoms 
when comparing the control/baseline period, the treatment period and the 
post treatment period. 
Significant changes were also perceived in the individual questionnaire 
subscales reported on section 3.5.3 of this thesis. The subscales, ‘social 
behaviour and communication’ and ‘digestive signs’, produced a significant 
main effect on the repeated measures ANOVA and also demonstrated 
significant changes between the pre-treatment and the treatment post hoc 
test. This suggests that there was an overall positive significant improvement 
(p <0.05) between before and after VOT treatment in autistic children suffering 
from GI symptoms.  
Individual analysis of three of the twenty four parameters tested also showed 
significant changes (see Figure 3-9, Figure 3-10 and Figure 3-11). Seventy 
five percent of the study population showed an improvement in the parameter 
‘vomiting’ (p = 0.00029) by 2 points on a 10 point scale, fifty percent showed 
improvement in ‘poor Appetite’ by 2 points on a 10 point scale (p = 0.039) and 
fifty percent showed improvement in the parameter ‘lack of eye contact’ by 1 
point on a 10 point scale (p = 0.035). The data analysis of the ‘vomiting’, ‘poor 
appetite’ and ‘lack of eye contact’ parameters demonstrated statistically 
significant improvements, suggesting that the use of VOTs may be of benefit 
to children with autism.  
VOTs are a low-invasive form of treatment that uses manipulation of the 
abdominal tissues and organs, possibly improving blood and lymphatic 
circulation within the abdomen. However, the purpose of this study was to 
determine whether there were any changes resulting from a VOT treatment 
intervention; not to investigate any mechanism behind such GI and/or 
behavioural symptomatic changes. 
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It is possible to speculate that the changes which occurred after application of 
VOT on autistic children may be the result of improvements in the lymphatic 
system. Data from an animal model (dogs) support the idea that rhythmic 
compressions of the abdominal area may facilitate the flow of inflammatory 
mediators into the lymphatic circulation (Huff et al., 2008). Huff et al. (2008) 
also found that the rhythmic pumping of the abdominal area increases the 
number of T and B cells within the lymphatic circulation and an abdominal 
pumping action helps the transport of leukocytes from the mesenteric lymph 
nodes to the thoracic duct. Similarly, Hodge et al. (2010) found that a pumping 
action of the lymphatic system of dogs might also result in the mobilisation of 
inflammatory mediators into the lymphatic circulation. The authors postulated 
that this could support a potential therapeutic rationale for the enhancement of 
lymphatic system efficiency in the treatment of infections (Hodge et al., 2010). 
It has also been proposed that visceral homeostasis may be supported by the 
relief of congestion, which may possibly be achieved via mobilisation of GI 
structures (Huff et al., 2008). Therefore, it may be possible that the significant 
changes reported on the GI and behavioural patterns of autistic children 
(result section 3.5), may be the response of positive changes in the lymphatic 
system, although this is currently speculative.  
As discussed in the introduction of this thesis (section 1.10), the brain-gut axis 
may play a role in the severity of the GI and behavioural signs and symptoms 
of autistic children. The significant improvement after application of VOT in 
some of the parameters tested using the S.O.S questionnaire may have been 
influenced by changes in this bi-directional system. Since D'Eufemia et al. 
(1996) published a paper suggesting the occurrence of GI abnormalities in 
autistic children, researchers have been investigating the influence of GI 
imbalances on the behaviour of autistic children (D'Eufemia et al., 1996, 
Horvath et al., 1999, Ibrahim et al., 2009, Nikolov et al., 2009). It may be 
possible that the enteric nervous system, via the IPANS with its stretch 
receptors (Furness, 2000), may be influenced by the application of VOT. 
Consequently, this may influence the neuro-regulatory pathway in the autistic 
children resulting in positive GI and behaviour changes after application of 
VOT, although again this is speculative.  
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Gershon (1999) and Goehler et al. (2007) reported that changes in the mood 
and cognition of autistic children may be the result of ENS imbalances. 
Therefore, it is possible that treating the GI problems in these children may 
also potentially improve behavioural changes. In this current study, lack of eye 
contact, one of the most noticeable behavioural patterns in autism, 
demonstrated a significant improvement. Even though the mechanism of this 
change cannot be explained it might be hypothesised that positive changes in 
the ENS could be effected by manual treatment.  
One of the limitations of the present study is that autistic children in the low 
spectrum usually lack the ability to describe their symptoms. Therefore, the 
present research relied on the parents’ perceptions of their child’s 
symptomatic changes. Due to ethical constraints relating to the awareness of 
autistic children, the study was designed as a before and after intervention 
(internally controlled study). All designs have intrinsic limitations, but the most 
appropriate design is that which affords the research an ability to achieve 
adequate results and conclusions, but with minimal, if any, negative impact on 
the participants. Using the same subjects as their own control provides a 
secure and well established method of achieving a baseline which may then 
be used as the control.  
The novel approach of using VOTs for this project to treat children with 
autism, has indicated that this low-invasive form of treatment could have a 
significant and important impact on the quality of life and wellbeing of children 
with autism who also suffer GI symptoms. This research reports some 
promising positive results, specifically behavioural and GI symptoms of 
autistic children following VOT treatment. The results may be considered to 
add weight to the gut-brain axis hypothesis postulated in recent papers 
(Mayer et al., 2006, Reichelt and Knivsberg, 2009, Forsythe et al., 2010, 
Mayer and Tillisch, 2011). 
4.3.7 Discussion Study III Calprotectin, M2-PK and lactoferrin 
concentrations measured at Period I, II and III 
This study assessed levels of nine sequential samples of faecal biochemical 
inflammatory markers, calprotectin, M2-PK and lactoferrin, before VOT 
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(Period I – control Period), during VOT (Period II – treatment period) and after 
VOT (Period III – post-treatment period) in autistic children. 
Studies have suggested that the cognitive deficit in autistic children may be 
linked to GI symptoms (Horvath, 2000, Horvath and Perman, 2002, Koves et 
al., 2004, Valicenti-McDermott et al., 2008). Autistic individuals at the lower 
end of the spectrum and with impaired language skills, may potentially 
express GI pain and discomfort through body mannerism and self-harm (Carr 
and Owen-Deschryver, 2007). According to Breau et al. (2003), the greater 
the behavioural or mental impairment the higher the pain and discomfort. The 
action of pushing the abdominal area against objects, running around in 
circles or jumping several times, may possibly be a way to alleviate GI 
discomfort.  
The bowel symptoms of autistic children resemble elements of IBS; however, 
a specific link has not been found. Carr and Owen-Deschryver (2007), 
postulate that the intensity and frequency of pain in autistic individuals could 
lead to problem behaviour. A consensus report analysed anecdotal reports 
from parents in an attempt to establish the importance of assessing the GI 
function of autistic children. This report suggested that autistic children should 
not only be investigated and treated for their behavioural problems, but should 
also be investigated and possibly treated for GI problems as these may be 
atypical and therefore may go undiagnosed (Buie et al., 2010). Kearney and 
Brown-Chang (2008) support the idea of complementary and alternative 
methods for the treatment of IBS patients due to the psychological benefits of 
combined ‘body and mind’ methods. 
The faecal markers used for this analysis have already been presented in the 
discussion of the baseline results of Study I – Parts A, B and C (see sections 
4.3.1; 4.3.2 and 4.3.3). All three markers displayed high levels of sensitivity 
and specificity for diagnosing IBDs and differentiating IBS. The three markers’ 
baseline presented in Study I – Parts A, B and C have created a satisfactory 
overall reliability for the mean values data for all three markers. This baseline 
has been used to compare the results of calprotectin, M2-PK and lactoferrin 
during period II and III of this thesis.  
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The analysis of the repeated measure ANOVAs suggests that there are no 
significant changes in the inflammatory biochemical markers calprotectin, M2-
PK and lactoferrin between Period I - control, Period II - treatment and Period 
III - post-treatment. However, there is a progressive increase in calprotectin 
mean concentrations between Periods I, II and III of the study (see Table 3-27 
and Figure 3-12). Although, this increase is not significant, it may suggest that 
the use of VOTs between Period I - control period and Period II - treatment 
period has possibly influenced the changes in the inflammatory marker levels. 
There is also a progressive increase in calprotectin mean levels between 
Period II - treatment period and Period III - post-treatment period, which was 
measured six weeks after the last VOT session.  
Analysis of the M2-PK and lactoferrin levels also demonstrates changes in the 
mean scores between Period I - control, Period II - treatment and Period III - 
post-treatment (see Table 3-29 and Table 3-31) (see Figure 3-13 and Figure 
3-14 ). These changes occurred during the application of VOTs, between 
Period I - control period and Period II - treatment period, where a drop in the 
mean levels of both biochemical markers was observed. During Period III – 
post-treatment period, six weeks after the last VOT session, the mean 
concentrations of M2-PK and lactoferrin increased.  
Although there were no significant changes in the mean concentrations of the 
faecal biochemical markers, further analysis demonstrated notable changes 
when comparing the three distinct study periods, which although not 
statistically significant should not be ignored.  
This is the first study to employ the use of biochemical markers to measure 
symptomatic changes before, during and after VOTs and to date, no 
comparative study has been published. Further studies on the effect of VOTs 
on autistic children suffering from GI may provide more robust answers. 
4.3.8 The relationship between calprotectin and twenty-four parameter 
S.O.S questionnaires  
Another aim of this study was to determine whether a correlation exists 
between the very stable faecal GI inflammatory marker calprotectin, the main 
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marker for this thesis, and the perception of the parents of autistic children to 
their child’s GI symptoms. A twenty-four parameter questionnaire was used, 
the S.O.S questionnaire, to assess parents’ perceptions and a standard 
ELISA test used to assess calprotectin levels present in the stools (see 
methodology chapter for information on the marker and the S.O.S 
questionnaire 2.19 and 2.22).  
There are a number of methods for determining bowel inflammation, including 
biopsy, endoscopy, colonoscopy and stool analysis for biochemical markers 
(Sherwood, 2012, Berthold et al., 2013). The least invasive, particularly 
important in children, utilises biochemical markers, including the S100 group 
of proteins (Aomatsu et al., 2011). Calprotectin is a member of the S100 
protein family, also known as MRP8/14, and is a heterodimer of two calcium 
binding-proteins (Striz and Trebichavsky, 2004, Stroncek et al., 2005) and 
accounts for 30% to 60% of total cytosolic protein found within neutrophils 
(Olafsdottir et al., 2002, Yui et al., 2003, Stroncek et al., 2005).  
Currently, the main application for the calprotectin ELISA test is to 
differentiate between IBD and IBS (Tibble et al., 2002). The concentration of 
calprotectin decreases during successful IBD therapy and higher levels may 
be indicative of an IBD relapse (D'Inca et al., 2008). Assessing faecal 
calprotectin has been found to be a reliable diagnostic tool for patients who 
present with IBD symptoms (Xiang et al., 2008). Furthermore, a meta-analysis 
by (Van Rheenen et al., 2010) determined that calprotectin as a predictor of 
inflammation in adults had a sensitivity of 93% and a specificity of 96%, whilst 
the corresponding values for children and teenagers were 92% and 76%, 
respectively. Calprotectin has been used as a non-invasive marker for 
identifying organic disease of the GI tract and it has been suggested that it 
can be used before more invasive procedures (Bunn et al., 2001, Van 
Rheenen et al., 2010, Zippi et al., 2010). 
This study sought to investigate a twenty-four parameter questionnaire and 
determine whether an association existed with the biochemical marker 
calprotectin. The study found a significant correlation between the parameters 
‘need for a fixed routine’ and ‘constipation’, and the inflammatory biochemical 
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faecal marker calprotectin. These results suggest that these two parameters 
could be used together as an initial screen in a standardised questionnaire, 
which would be a simple to use, non-invasive and inexpensive predictor of 
inflammatory bowel processes in autistic children between the ages of 3 ½ 
and 8 years old.  
The results from the univariate study indicate a further four parameters as 
having a possible association with levels of calprotectin (see Table 3-32 and 
Table 3-33). Although they are not independent predictors of GI inflammation, 
they could be appropriately used in combination with the two multivariable 
parameters ‘need for a fixed routine’ and ‘constipation’.  
This final set of six parameters could be used as a standard questionnaire 
within clinical settings in order to simplify the diagnostic process, thereby 
enabling greater cost efficiency and more effectively directing subjects to 
further diagnostic examination (see Table 3-33). Combining these six 
parameters into one single questionnaire could enable a reduction in the 
number of parameters to be tested from twenty-four to six, without any loss of 
power or sensitivity. Such a standardised six parameter questionnaire would 
not replace any other form of diagnostic testing for GI inflammation, but could 
be a cost effective, non-invasive initial screen for clinical diagnosis. 
The correlation between the behavioural characteristics of ‘lack of awareness 
and interaction with parent’, ‘abnormal repetitive gestures’, ‘need to maintain 
sameness’, ‘need of a fixed routine’, ‘constipation’ and ‘bloating’, and the 
inflammatory biochemical marker calprotectin, may be indicative of a 
connection between gut responses and the classic emotional behaviour 
exhibited by autistic children. 
From the study results it may be possible to create a useful, short 
questionnaire that is simple to use, reliable, non-invasive and inexpensive to 
be used as a screening tool which is capable of evaluating GI inflammation in 
autistic children. Such a questionnaire could be easily completed by parents 
or guardians and could potentially facilitate initial screening of GI inflammation 
in autistic children. 
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Chapter 5 - Conclusions and Summary of Future Work 
The conclusion of the outcome measures used before, during and after 
visceral osteopathic sessions in autistic children is presented in this chapter. 
The chapter is subdivided into conclusion of study I, II, III and IV, as well as a 
summary of future work, limitations and contribution to knowledge.  
No known study to date has used sequential faecal biochemical markers and 
questionnaires to assess autistic children also suffering from GI symptoms 
before and during the application of VOTs. The results showed large 
biochemical marker concentration variations within faecal samples over time 
which is strongly suggestive of wide intra-individual biological variation.  Since 
this study used multiple sampling, also described by Gilbert et al. (1996) and 
by Husebye et al. (2001), rather than the single sampling techniques of other 
studies (Fagerberg et al., 2003, Lundberg et al., 2005, Sherwood et al., 2005, 
Langhorst et al., 2008, Aomatsu et al., 2011, Sherwood, 2012) this finding of 
biological variation of the markers over time is a potentially important finding 
for future diagnostic protocols.  
The novel approach of this project in using VOTs to treat GI symptoms of 
ASD children has indicated that this low-invasive form of treatment could have 
a significant and important impact on their quality of life and wellbeing. This 
research may be considered, also, to add weight to the gut-brain axis 
hypothesis postulated in recent papers (Mayer et al., 2006, Reichelt and 
Knivsberg, 2009, Forsythe et al., 2010, Mayer and Tillisch, 2011). 
An important contribution of this research is that it shows sufficiently positive 
outcomes to support and stimulate further investigation into the use of VOTs 
in these children. 
This innovative study has involved treatment of behaviourally challenging 
autistic subjects (McClintock et al., 2003, Murphy et al., 2005, Chiang and Lin, 
2008) over an extended period of time (18 weeks) and taken serial 
measurements using questionnaires and biochemical markers. Moreover, 
involving the same subjects throughout the study has avoided the introduction 
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of variation that could occur between subject groups displaying a complex 
behavioural disorder, for example when using a different control population 
that could potentially create unmatched data for analysis (Mallinckrodt et al., 
2003, Nakai, 2009, Rosner, 2011).  
5.1 Conclusion Study I – Period I – Parts A, B and C 
An important feature of this study is the inclusion of multiple sampling of 
individual subjects. Multiple sampling creates an individual trend of 
inflammatory levels that reflects a more accurate appraisal of disease activity. 
The result is a more robust reflection of the real inflammatory state than given 
by an analysis using single sample testing. Other studies (Bunn et al., 2001, 
Aadland and Fagerhol, 2002, Summerton et al., 2002, Szarszewski et al., 
2003, Yui et al., 2003, Fagerberg et al., 2005, Chung-Faye et al., 2007, Sidhu 
et al., 2010a, Sidhu et al., 2010b, Day et al., 2012, Manz et al., 2012) have 
used single samples and taken the mean of the population. The design study 
of this work has enabled an innovative approach to the assessment of faecal 
biochemical marker levels. This study determined a mean concentration level 
for each biochemical marker from four sequential faecal samples, thus 
providing a more reliable baseline for Periods II and III of the study.  
5.1.1 Intra-Individual Biological Variability  
The biomarkers are not unstable as has been clearly stated (see sections 
2.19; 2.20 and 2.21), but there has been shown to be considerable intra-
individual biological variability in some subjects when multiple samples are 
assessed over time (see section 4.3.1). The method of taking multiple 
samples is considerably more robust than taking a single sample and then 
basing a diagnosis on that one result. Currently, the recommendation for 
diagnosticians to help distinguish between IBD from IBS is the use of a single 
faecal calprotectin analysis (NICE, 2013). NICE recommends further 
investigation such as blood tests, i.e. C-reactive protein and full blood count if 
the result of the faecal calprotectin analysis is raised (NICE, 2013). However, 
in this current project up to 4 samples were taken to obtain a background, or 
control level, during the pre-treatment period of each biochemical marker.  
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From this approach it can be seen that for some patients there is large 
biological variability even when there has been no overt intervention or 
treatment given. This background has shown some subjects with considerable 
outlier results, whereas other subjects have relatively constant levels.  The 
implication of this intra-individual biological variability has been discussed 
further in results sections 3.3 and discussion sections 4.2; 4.3.1; 4.3.2; 4.3.3 
and 4.3.7. 
Table 1-3 in section 1.11.1 clearly shows the levels of sensitivity and 
specificity of calprotectin, M2-PK and lactoferrin (Bunn et al., 2001, Fagerberg 
et al., 2003, Kane et al., 2003, Fagerberg et al., 2005, Chung-Faye et al., 
2007, Langhorst et al., 2008). Ton et al. (2000) have shown that calprotectin, 
the main faecal biochemical marker of the current study, has high levels of 
stability and reproducibility. Gilbert et al. (1996), Husebye et al. (2001) and 
Ricós et al. (2009) suggest that faecal markers may be influenced by the day 
to day physiological intra-individual biological variability of each particular 
individual. More recently, Calafat et al. (2015) have suggested significant 
intra-individual variation occurring within a day. However, the suggested intra-
individual biological variability does not impact on the high reproducibility, 
sensitivity and specificity of the markers.  
Calprotectin, M2-PK and lactoferrin were assessed weekly for individual 
scores (Table 3-5, 3-10 and 3-12). The data from Period I suggest that using 
one random stool sample to assess calprotectin, M2-PK and lactoferrin levels, 
is not a reliable measure of the presence or absence of inflammation and that 
it is probably necessary to perform multiple sample tests; either to corroborate 
the clinical symptoms or to establish a biochemical diagnosis. Utilising only 
one faecal sample could create an artificially higher chance, in either 
direction, of the calprotectin, M2-PK or lactoferrin results, not reflecting the 
true clinical picture/pathological changes. Autistic children who display clear 
clinical symptoms of IBS or an IBD should be screened via the analysis of 
more than one faecal calprotectin and/or M2-PK and/or lactoferrin sample, in 
order to ascertain that the assessment of these markers accurately reflects 
the real situation within their GI system.  
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There is to date, no known study of the analysis of sequential faecal samples 
in autistic children who also display GI symptoms. It is suggested that a larger 
sample population should be investigated using multiple sample testing to 
determine the validity of these markers as a tool in the identification of IBD or 
IBS in autistic who suffer from GI signs and symptoms. Also, future studies 
may consider attempting to correlate a standard examination tool, such as an 
endoscopic GI assessment, with sequential faecal markers, to further 
examine this non-invasive investigative procedure in autistic children.  
The statistical analysis of Study-I Parts A, B and C, concluded that changes in 
calprotectin, M2-PK and lactoferrin weekly scores may potentially be due to 
the results of individual physiological intra-individual biological variability , 
suggested by Husebye et al. (2001) and Ricós et al. (2009). Even though 
there is a possibility that individual intra-individual biological variability  is a 
feature of the markers, analysis suggested that the mean baseline data for the 
pre-treatment sequential samples for calprotectin, M2-PK and lactoferrin, 
were reliable.  
5.1.2 Conclusion Period I – Study I (Part-D): Sequential S.0.S 
Questionnaire  
The S.O.S questionnaire was used to measure 24 parameters subdivided into 
four sub scales. The data from four sequential questionnaires were used as 
baseline for later comparison with Periods II and III of the research. Hence, no 
conclusion was drawn from this study as it was used as comparative data 
only.  
5.1.3 Conclusion Period I – Study I (Part-E): Correlations between 
calprotectin, M2-PK and lactoferrin  
Analysis was performed to assess whether a correlation existed for the 
markers calprotectin and M2-PK during control/baseline – Period I. After 
matching the corresponding sequential sample results, the data were 
analysed using a Pearson’s linear correlation test. The results obtained 
suggest that there is a significant moderate linear correlation between the 
total calprotectin and total M2-PK mean values ( r = 0.40, n = 38, p = 0.01), 
thereby suggesting that these markers may be interpreted together as 
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markers of inflammation or disease activity in autistic children suffering from 
GI disturbances.  
A strong correlation was found between the calprotectin and lactoferrin 
sample results (r = 0.65, n = 24, p < 0.001), indicating that these two markers 
may potentially be interpreted together as linked markers of inflammation in 
autistic children. However, caution should be applied owing to small sample 
size (lactoferrin n = 24), as a result of the loss of a number of lactoferrin 
samples outside the author’s control (Appendix 10). Consequently, this 
correlation between mean scores for calprotectin and lactoferrin should be 
considered as being of potential interest until further research to confirm or 
refutes this. 
This is the first study to assess a possible correlation between biochemical 
markers and GI problems and the positive correlation presented here should 
enhance the published literature.  
5.1.4 Conclusion – Study II: Twenty-four parameter S.O.S questionnaires 
evaluation at Period I, Period II and Period III 
The analysis of the nine questionnaires completed by the parents during the 
different periods of the study, suggests that the use of VOTs in autistic 
children suffering from GI symptoms may be beneficial. The employment of a 
parental questionnaire was necessary in order to measure a child’s 
symptomatic status, since young children in the low autistic spectrum are not 
usually able to provide this information independently. Results of the repeated 
measures ANOVA for questionnaires 5-8, collected during Period II – 
treatment, and questionnaire 9 from Period III - post-treatment, demonstrated 
a significant difference (p<0.05) compared with the control questionnaires (1 – 
4), collected during Period I. This indicates that there was an observational 
appreciation of symptomatic improvement after application of VOTs within this 
study population. There was also significant positive change (p <0.05) 
between the control period scores and the post-treatment period scores 
indicating that the behavioural and gastrointestinal symptoms remained at an 
improved level compared with the control period, six weeks after treatment. 
This indicates, according to parental perception, a positive and lasting 
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statistically significant effect of VOT intervention on the symptoms 
experienced by autistic children at six weeks post treatment (Period III - post-
treatment).  
Analysis of individual parameters showed significant changes in three of the 
twenty four parameters tested: ‘vomiting’ ‘poor appetite’ and ‘lack of eye 
contact’.  
Statistical improvement is mirrored in the clinical findings reported by the 
parents and recorded in the case history. Although, this material is anecdotal 
and was not used as an outcome measure for this thesis, it follows the 
statistical trend, supporting the beneficial effect of VOT in the study group 
(result section 3.8, case history anecdotal observation). More often than not, 
the child would make eye contact with the practitioner and/or the parent 
during the treatment session, a remarkable event within the ASD experience, 
even for immediate family (see section 3.8 case history anecdotal 
observation). Interestingly, eye contact demonstrated statistically significant 
differences comparing the pre-treatment with the treatment outcome 
measures in the S.O.S questionnaire.  
The mechanism underlying the changes perceived and reported by the 
parents cannot be known. However, the gut-brain connection may play a role 
in giving possible clues to answers. Study II of this thesis, suggested positive 
changes, not only in the gastrointestinal symptoms but in behaviour patterns 
of autistic children after VOT application. The use of VOT potentially might 
have activated this complex bidirectional connection between the brain and 
the gut. However, this is speculation and specific research in this field is 
required. 
Several aspects of the data indicated that VOT is of benefit to autistic children 
suffering from GI symptoms. However, a limitation was apparent since the low 
spectrum autistic child is unable to interact with direct, reasoned discussion. 
Direct clinical benefit from the subjects’ perspective was therefore not 
possible. Further studies are advised in this field to determine if the same 
results are extended to a larger ASD cohort. 
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5.1.5 Conclusion – Study III: Calprotectin, M2-PK and lactoferrin 
concentrations measured at Period I, II and III 
The use of VOTs and their effect on faecal biochemical markers was analysed 
by comparing the concentrations of calprotectin, M2-PK and lactoferrin in 
samples collected during Period I – control, Period II – treatment, and Period 
III - post-treatment.  
A repeated measure ANOVA suggests that there were no significant changes 
for the inflammatory biochemical markers during any period of the study. 
However, a progressive increase in mean levels of calprotectin was observed 
between the three distinct periods of the study. Although this increase was not 
significant, it may suggest that the use of VOTs, between Periods I and II, 
influenced the change in calprotectin levels. A further increase in mean 
calprotectin levels was observed between Periods II and III, six weeks after 
the last VOT session.  
The increase in mean levels of calprotectin between the Periods II and III may 
have been the result of VOT treatment. Possibly, the increase of calprotectin 
may be supported by Schander et al. (2008). This author suggests that 
inflammatory mediators are pumped into the lymphatic circulation after 
manual mobilisation of the abdominal area. The progressive rise of 
calprotectin may possibly be explained by the increase in number of T and B 
cells within the lymphatic circulation, resulting in an inflammatory response, 
also supported byHodge et al. (2010). This study is not attempting to 
postulate a mechanism for biochemical changes between the treatment and 
post-treatment periods but it might be the effect of tissue repair within the gut 
lining. 
Analysis of the M2-PK and lactoferrin levels also demonstrated a change in 
these mean values between the three study periods, and following the 
application of VOTs there was a decrease in the mean scores for both 
biochemical markers between Periods I and II. The mean values for M2-PK 
and lactoferrin during Period III, indicated an increase in these faecal markers 
compared to Period II. The rationale for these results may possibly be that the 
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VOTs positively influenced inflammatory responses, resulting in a reduction in 
the levels of these inflammatory markers whilst treatment was applied.  
In Study III, the effect of VOT on the levels of objective markers was 
attempted. M2-PK and lactoferrin demonstrated a clear decrease in the mean 
scores during Period II – treatment and a clear increase in the mean score 
levels during Period III - post-treatment, whilst calprotectin values showed 
increasing levels from Period I - control through to Period III - post-treatment. 
The increasing levels of calprotectin during the treatment and post treatment 
period is, therefore, in direct contrast to the lactoferrin and M2-PK results, 
where the levels decreased during treatment but rose again post treatment. 
The reasons for these conflicting results are unknown, and larger studies will 
be required to investigate this phenomenon further. Whether the markers are 
reflecting more subtle changes in the inflammatory process, or whether they 
are measuring different stages of the process remains unclear. However, the 
aim of this research was not to analyse the mechanism of any changes.  
5.1.6 Conclusion Study IV – The relationship between calprotectin and 
twenty-four parameter S.O.S questionnaires  
In study IV, an attempt was made to test parental perception of symptomatic 
changes objectively and to correlate the faecal biochemical marker 
calprotectin results with the questionnaire results (parental perception to 
treatment).  
The potential correlation between the 24 parameters of the questionnaire and 
the biochemical markers was investigated. A significant correlation was found 
between the parameters, ‘need for a fixed routine’ and ‘constipation’ and the 
inflammatory biochemical faecal marker calprotectin. These results suggest 
that these two parameters could be used together as an initial screen in a 
standardised questionnaires a simple to use, non-invasive and inexpensive 
predictor of inflammatory bowel processes in autistic children between the 
ages of 3 ½ and 8 years.  
The results from the univariate analysis indicated four further parameters 
could have an association with levels of calprotectin. Although they are not 
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independent predictors of GI inflammation, they could be appropriately used 
in combination with the two multivariable parameters previously identified. 
Together, this set of six parameters could be used as a standard 
questionnaire within clinical settings in order to simplify the diagnostic 
process, thereby enabling greater cost efficiency and more effectively 
directing subjects to further appropriate diagnostic examination (Table 3-33). 
Combining these six parameters into one single questionnaire could enable a 
reduction in the number of questions from twenty-four to six, without any loss 
of power or sensitivity. Such a standardised six parameter questionnaire 
would not replace any other form of diagnostic testing for GI inflammation, but 
could be a cost effective, non-invasive initial screen for clinical diagnosis. 
Such a questionnaire could be completed by parents or guardians easily and 
could potentially facilitate initial screening of GI inflammation in autistic 
children. 
The study demonstrated a positive correlation between the marker and 
specific components of the questionnaires. This information may potentially 
be used as a standard questionnaire within clinical settings in order to aid the 
GI diagnostic process. 
5.2 Limitations of the Study  
One of the limitations of the study is that low spectrum autistic children usually 
lack the ability to describe or grade their symptoms. Therefore, the results 
from the questionnaires relied on the parents’ perception of their child’s 
symptomatic changes and it was not possible to determine how the subject 
personally felt in response to the VOT intervention. This limitation may 
possibly result in parents over or under estimating the rate value in the Likert 
scale, potentially creating biasing the results. An independent assessor rating 
the parameters blind could possibly prevent the introduction of bias. However, 
the professional would have to get acquainted with the child to be able to rate 
the questionnaire accurately and might still not perceive changes that parents 
are more aware of. Moreover, this solution would not be as cost effective as 
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introduction of independent professionals would substantially increase the 
cost of the research.  
Another limitation to this study was that the patients were self-referred. 
However, all possible measures were taken to safeguard the inclusion criteria 
of the research. One of them, presented in the methodology section 2.6, was 
that the subjects were required to present a formal diagnosis of autism and be 
assigned at a special school for autistic children registered by the National 
Autistic Society. All subjects were formally diagnosed following the same 
diagnostic criteria required by the DSM-IV and the ICD-10. However, children 
were not diagnosed by the same diagnostic centre or by the same 
professional and, therefore, it is not possible to know the impact of that on the 
results of the study. It is not known if there were any initial discrepancies in 
interpretation of the autism diagnosis. Future studies may benefit by using a 
single centre that would refer subjects to the initial screening research 
procedure. Participating patients could then be selected to be on the same 
level of the autistic spectrum. The same idea applies to the GI signs and 
symptoms of the subjects included in this research. Parents were self-
referring their children to the study and there was no formal diagnosis from a 
gastroenterologist. According to Chandler et al. (2013) and Gorrindo et al. 
(2012) there is a high concordance between parental reporting and the 
gastroenterologist’s evaluation of GI symptoms in autistic children. This 
research relied on parents’ perceptions of GI signs and symptoms. Even 
though studies claimed high concordance between the perception of the 
parents and the evaluation from the medical doctor, this research might have 
missed subtypes of gastrointestinal conditions that could have affected the 
results. Possibly, this could have been prevented if a gastroenterologist were 
part of the project and had been given responsibility for the screening 
process. However, that would have imposed financial constraints beyond the 
scope of this research.   
Another limitation to this trial is that it was not designed as a randomised 
control trial owing to constraints imposed by the Ethics Committee. The 
research was designed as a before and after intervention and does not 
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compare two intervention or placebo group measures that could potentially 
minimise bias. However, all designs have intrinsic limitations, and the most 
appropriate design is that which affords the research an ability to achieve 
adequate results and conclusions, with minimal, negative impacts upon the 
participants. Using the same subjects as their own control provides a secure 
and well established method of achieving a baseline that may then be used as 
the control.  
It was not the aim of this research to analyse the interaction between 
researcher and the subjects during application of VOT. However, the 
interaction between practitioner and child cannot be disregarded due to the 
nature of the VOT. Several studies have shown that ASD children may 
present with hypo or hyper sensitivity to touch, leading to challenging 
behaviour such as tactile defensiveness, withdrawal or avoidance of touch 
(Grandin, 1992, Cascio et al., 2013, Puts et al., 2014). Cullen et al. (2005), 
explored the effects of positive touch between parents and autistic children. 
The study suggests that the use of positive touch resulted in improvement of 
sleep patterns, relaxation and an overall positive effect on child-parent 
interaction. The general symptomatic changes of the current study support the 
findings of Cullen et al (2005). However, it was not possible to know if the 
patient/practitioner interaction influenced this positive result. This is because 
the application of the techniques was done by a sole osteopathic practitioner. 
Future studies may include a group of practitioners applying the VOT 
techniques so that a concordance among raters could be investigated to 
analyse the effectiveness of VOT on autistic children.  
This study followed clear guidelines for clinical safety and practice standards. 
According to the Osteopathic Practice Standards (General Osteopathic 
Council, 2012) it is the professional duty of an osteopath to take an 
appropriate case history for each patient who may potentially be treated by an 
osteopath (General Osteopathic Council, 2012). The data generated from the 
case histories were not part of the original hypothesis of the study but were 
recorded for professional clinical best practice and patient safety. Similarly, 
issues about utilising data from these case histories were not raised during 
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the MPhil/PhD registration document and the PhD transfer report. The main 
focus of this research was to help to fill the knowledge gap in understanding 
the impact of VOT on the behaviour and GI signs and symptoms of the study 
ASD subjects.  Any collected information was designed to build on the pilot 
study (Bramati-Castellarin and Janossa, 2002), by using both questionnaires 
and GI markers which were included to generate objective quantitative data. 
The case histories have generated interesting qualitative/anecdotal 
information which has been described in section 3.8. The analysis of the case 
histories, however, was not part of the study design and was neither 
submitted to nor, therefore, approved by the Ethics Committee.  However, the 
interesting data collected may potentially be used in subsequent qualitative 
research if Ethics is granted.   
The same applies to the information generated from the screening 
questionnaire (Appendix 5). This information was used to assess the inclusion 
and/or exclusion criteria of the study and the data it generated was not 
designed to be included as quantitative data and it was not, therefore, 
approved by the Ethics committee to be used as part of this research. 
The number of subjects in the study could be considered as a further 
limitation and this was exacerbated by the loss of the lactoferrin samples by 
the analysing laboratory thus reducing the power of the statistics through a 
substantial decrease in sample numbers for comparison. This resulted in a 
loss of power for this specific analysis and therefore further study is necessary 
to determine the validity of the results found. 
The implication of being a practitioner and researcher is a recognised 
limitation of this study. In mitigation measures were put in place when 
designing the methodology. The observed behavioural changes were 
assessed by parents and not the practitioner, and the biochemical markers 
were assessed independently to exclude researcher bias during 
measurement.  
It could be argued that the inclusion of more than one practitioner within the 
study would decrease any potential bias. Also any ‘bed side manner’ effect 
176 
potentially generated by a single practitioner applying the treatment protocol 
could decrease the nonspecific effects of treatment (Caspi et al., 2000, 
Licciardone and Russo, 2006). However, inclusion of a second practitioner or 
researcher would have incurred financial constrains that would have been 
prohibitive for this study and could have introduced other errors such as 
standardisation of treatment and heterogeneity of osteopathic manipulation 
(Licciardone and Russo (2006). Also, it could not be certain that the inclusion 
of more practitioners for the study would have been ethically acceptable as 
autistic children do not respond well to change (Wing, 1998). 
It cannot be argued that the role of practitioner/researcher does carry a 
potential for bias and forms a limitation of this study. However, the nature of 
the osteopathic profession cannot be separated from the interaction between 
practitioner and patient when establishing the effectiveness of a treatment 
application, particularly when the researcher meets the subject at each 
treatment session. According to Licciardone and Russo (2006), in this 
situation the non-specific effects of the treatment may be stronger. However, it 
is the professional duty of an osteopath or manual therapist to ensure the 
wellbeing of a patient and therefore the inclusion of a bias may possibly be in 
the nature of the profession (Herbert et al., 2001, Rogers, 2005). It is possible 
that only in a double blind control trial, where the researcher is often not 
present during the active research, that the subjectivity of the research is 
mostly removed (Caspi et al., 2000, Licciardone and Russo, 2006).  
In the current study, questionnaires were used as one of the outcome 
measures and assessed the perception of the parents regarding the signs and 
symptoms of the child. The questionnaire completion could have been 
influenced by the belief of parents that either a positive or negative outcome 
would occur (Rattray and Jones, 2007), and thus represent perception 
credibility of the practitioner/researcher or of the treatment itself (Caspi et al., 
2000, Stewart, 2010). Further studies may address this limitation and shed 
light on this complex area.   
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5.3 Contribution to Knowledge and Final Conclusions  
No known study to date has used sequential faecal biochemical markers and 
questionnaires to assess GI inflammation in autistic children suffering from GI 
symptoms. This thesis assessed levels of biochemical markers in sequential 
samples taken before and during the application of VOTs, and discovered 
unexpected score variations within faecal samples only previously described 
by Gilbert et al. (1996) and Husebye et al. (2001) as possibly due to biological 
variation of the markers over time. This is a potentially important finding 
suggesting the need for more studies in this area. 
The novel approach of this project in using VOTs to treat autistic children 
suffering from GI symptoms has indicated that this low-invasive form of 
treatment could have a significant and important impact on their quality of life 
and wellbeing. This research reports some promising positive results for 
specific behavioural and GI symptoms of autistic children following VOT 
treatment and can be considered to add weight to the gut-brain axis 
hypothesis postulated in recent papers (Mayer et al., 2006, Reichelt and 
Knivsberg, 2009, Forsythe et al., 2010, Mayer and Tillisch, 2011). 
An important contribution of this research is that it shows sufficiently positive 
outcomes to support and stimulate further investigation into the use of VOTs 
in autistic children suffering from GI symptoms. Correlation of the three 
markers with questionnaires on nine separate occasions resulted in the 
generation of a large volume of data and robust statistical analysis.  
This study is the first to use VOT on autistic children displaying GI signs and 
symptoms whilst assessing therapeutic outcome. Even though challenging, 
due to the nature of the ASD, the study is unique as it observes autistic 
subjects over an extended period of time (18 weeks). Moreover, the use of the 
same subjects displaying a range of complex behavioural disorder avoids the 
introduction of variations within subjects that could potentially create data 
inconsistency.  
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In the current study, clinical changes were perceived and reported by the 
parents. Initially, parents were apprehensive about the prospect of the child 
displaying touch avoidance during the treatment sessions, and were surprised 
to see the child accepting the treatment and relaxing. On more than one 
occasion, during the second or third sessions onwards, the child would run 
into the treatment room and lie down on the couch, taking the practitioner’s 
hand and placing it on his/her abdomen. This action seems to indicate that the 
child was accepting and perhaps desiring the intervention rather than being 
frightened of treatment. 
Additionally, parents often reported a general improvement in symptoms after 
treatment. The children appeared to be calmer and more socially interactive, 
while also showing signs of general GI symptom improvement and eye 
contact after treatment sessions. Children were also reported to have 
improved appetite, with two parents reporting that, during the weeks of 
treatment, their children started to eat a wider variety of food, including fish 
and meat, an otherwise very rare occurrence. Information regarding parents’ 
comments was recorded on the case history during each consultation, as part 
of the standard of care required of osteopathic treatment.  
Techniques used in this study may have had a positive influence on the 
immune system through the mobilisation of the greater momentum owing to 
its immunological function (Carlow et al., 2009). In addition, mobilisation of the 
internal organs following VOT treatment and the resulting increase in 
circulation and peristalsis, may have a positive effect on the pumping action of 
the lymphatic system, thereby enhancing its function (Huff et al., 2008, 
Schander et al., 2008, Hodge et al., 2010). 
5.3.1 Future Work 
The positive findings generated from the use of VOT in autistic children might 
possibly be implemented in clinical osteopathic settings. Moreover, visceral 
osteopathic treatment could become part of the treatment procedures within 
special schools for autistic children alongside other therapies such as speech 
therapy, behavioural therapy and occupational therapy. Future studies are 
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necessary to determine whether the outcome measures used for this thesis 
may be replicated.  
An interest in low-invasive gastrointestinal treatment for autistic children who 
also experience GI symptoms led to this thesis. The application of 
standardized VOT to the abdominal area of autistic children suffering from GI 
symptoms was a novel idea that may lead to a new application of a 
standardized low-invasive form of therapy previously unexplored in autistic 
patients. The results of this thesis may potentially be applied both in clinical 
settings and by parents as a form of home therapy to help to create a closer 
parent/child relationship. However, more studies are needed in this field to 
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Appendix 2 – Study information and recruitment letters 
Research Proposal 
Information FOR parents 
Background of investigation 
Although autism has been closely investigated over the last decade it still 
remains a disorder with no clear cause and no current effective treatment. There 
have been many hypotheses regarding the causes of autism, but recent theories 
focus on the possibility of autism being due to imbalances in gut function. A 
recent study suggests an association between the onset of gut symptoms, such 
as abdominal pain, diarrhoea, and bloating and in some cases food intolerance, 
with developmental regression. 
Our research group has decided to use visceral osteopathic techniques1 
(abdominal massage) to help the gut function of children who have been 
diagnosed as autistic. It is believed that manual stimulation of the gut may help 
to decrease inflammatory processes as well as aid in a decrease in constipation, 
diarrhoea and bloating suffered by autistic children. It may also help with 
amelioration of abnormal behavioural symptoms characteristic of autism. 
Aims of investigation: 
The aim of this investigation is to apply a soft tissue technique (massage) to the 
abdominal area to attempt to decrease bowel irritation.  
Methods/design of investigation: 
The proposal is to analyse bowel function and behaviour of the autistic children 
before and after the application of soft tissue techniques on the abdominal area 
                                            
1
 The abdominal visceral soft tissue technique may change bowel movements, but apart from this there 
are not known risks. 
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(tummy area). The subjects’ ages will range from 3 to 8 years old. The evaluation 
of the study will be performed via four questionnaires given to the parents; who 
will be able to observe the child’s response to the massage techniques, e.g. 
differences in frequency of bowel movements. These questionnaires will be 
given to the parents before treatment, twice during the treatment phase and after 
the last treatment. Also, the children will be assessed by analysing stool 
samples. Parents will be asked to collect stool samples before the initiation of the 
treatment, during treatment and after the last treatment session. Parents will be 
provided with a ‘Stool Collection Kit’ in which samples may be sent to King’s 
College Hospital in a stamped addressed Safebox™.. More details on how to 
collect the material will be provided in the ‘Stool Collection Kit’. The purpose of 
stool analysis is to measure bowel inflammation. 
There will be six treatment sessions, each lasting for 30 minutes, depending on 
the child’s co-operation. In the event of a child being distressed or 
oncooperative, the parent/guardian together with the researcher will decide on 
the merits of continuing treatment. 
The children will be assessed at their own school, although a parent or a 
guardian must be present during application of the technique. 
Duration of investigation: 
Study Period Weeks 
Period I. The control period  1-6 
Period II. The treatment period 7-12 
Phase III. The post-treatment period 18 
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Letter to Parents 
IPD/IB-C 
March 2007 
Dear Parents  
I am a Registered Osteopath practising in London with a special interest in 
children suffering from autism. I have been developing a research project as part 
of my MPhil/PhD studies at BCOM/University of Westminster. The aim of the 
study is to attempt to positively influence behaviour and bowel function in the 
children suffering from autism. 
The study involves the treatment of the child’s abdomen using osteopathic 
visceral treatment – tummy massage. Behaviour patterns and biochemical 
analysis of stool samples before and after treatment would be scrutinised to 
determine the effects on the child’s gut function and behaviour. For the study to 
be effective volunteers are necessary and I would like to invite your child to 
participate. The treatment is planned to take place at your child’s school 
premises to minimise disruption and to cause as little inconvenience to you and 
the children. 
I am enclosing a brief information pack which will help you to understand a little 
more about how the treatment would work. Also, it may indicate how you and 
your child can help the study determine whether osteopathic treatment is an 
effective treatment to improve the gut function of children suffering from autism. 
If you would like to be involved then perhaps you could please inform 
Ms/Mrs......at the school.  
The treatments are due to start next year (2007) and you would be informed in 
plenty of time of the start date, probably in March. If you need any further 








Iona Bramati Castellarin BSc(Hons) Ost Med DO,ND 





Dr Ian Drysdale BSc, ND, DO, PhD 
Director of Studies 
 
THIS PROJECT IS UNDERTAKEN WITH THE SUPPORT OF KING’S 




Letter to Headteachers 
Dear Headteacher  
I am a Registered Osteopath practising in London and possessing a special 
interest in children suffering from Autism. I graduated from the British College of 
Osteopathic Medicine (BCOM) in 2001 and subsequently, the Principal, Dr Ian 
Drysdale, offered me the opportunity to continue with my undergraduate 
research.  
In November 2000 as part of my undergraduate degree I developed a clinical 
trial where I treated autistic children using Osteopathic techniques. The 
treatment consisted of 6 treatment sessions using Osteopathic techniques to the 
children’s abdominal area – essentially a tummy massage. I am now enrolled in 
my second year with BCOM/University of Westminster as an MPhil/ PhD student. 
King’s College Hospital has agreed to support the project and specifically to 
undertake responsibility for the laboratory analysis of the collected samples. 
The purpose of this letter is to enquire whether it would be possible to include the 
children of........... School for the next phase of this study.  
The original study included children aged 3 to 8 years old, who had been 
diagnosed as autistic. To satisfy the inclusion criteria the children also suffered 
from gastrointestinal problems symptoms, impaired social relationship and poor 
communication skills. Each child was given six 30-minute treatments, once a 
week for six weeks, focusing on the abdominal area. 
Parents and teachers were advised how the treatment would work via a brief 
presentation during a school meeting. The trial study was very successful and 
showed some very positive results in terms of the positively changed behaviour 
of the participating children. Parents and teachers were very supportive of the 
research project at the time. 
The second phase of the project is planned to start next year when the plan is to 
start treating autistic children with the same techniques used in the pilot study 
using osteopathic abdominal massage, and to include objective measurements 
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and assessments. The gastrointestinal parameters are to be measured in the 
children before and after osteopathic treatment and include analysis of collected 
faecal/stool material and quantitative assessment of a biochemical marker. 
Neither the treatment nor the stool collection is invasive. The parents will be 
asked to send the children’s stool samples for laboratory analysis to enable 
assessment of the levels of the tissue inflammation biochemical marker. 
I would be delighted to include The.........School in this study if you and the 
parents consider this research project appropriate, and I would be happy to 
discuss this further with you.  
Please do not hesitate to contact me by post at:  
London........ 
or on my mobile 079........... 
I look forward to hearing from you.  
With kind regards,  
Iona Bramati Castellarin BSc (Hons) Ost Med, DO,ND 
Osteopath - MPhil/PhD researcher  
Dr Ian Drysdale BSc, ND, DO, PhD 
Director of Studies  
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Stool Collection Kit information  
1. Write the date and time of the test on the label of the blue top plastic tube. 
Collect one faecal (stool) motion at any time of day from a potty or nappy 
and place several scoops of faeces in the tube using the spoon provided 
in the tube. Seal the tube tightly, place it in the box provided. 
2. Each Safebox™ is numbered. Please use the Box number 1 for the first 
stool collection test and fill the form that is inside with the time and date of 
stool collection. Place the form back into the safe box. Please repeat the 
same procedure for each consecutive stool collection. Each stool 
collection needs to be at least a week apart. Your child needs to be tested 
for 4 calprotectin assays before initiation of the Osteopathic treatment. 
3. Post the sample to the Dept of Clinical Biochemistry, King's College 
Hospital, Denmark Hill, London SE5 9RS. 
4. Please note that I am including a questionnaire that needs to be 
completed up each time you collect a stool sample from your child. Date 
the questionnaire and send it back in the s.a.e provided. Each 
questionnaire is also numbered from 1 to 4. Please use the appropriate 
questionnaire to match the same Safebox™ number.  
4.  
5. Please find attached instructions on how to use the Safebox™. 
 
Thank you very much for being part on this research study. 
 






For voluntary participation in: 
 
Effects of Visceral Osteopathy on the Gastrointestinal and Behavioural Changes 
in Children with Autistic Disorder. 
 
We are inviting you and your child to participate in an investigation that we 
believe to be of potential importance. In order to help you to understand what the 
investigation is about, we are providing you with the Research Proposal – 
Information for Parents. If you agree to participate, please be sure you are 
comfortable with the contents of the Information sheet. If you have any questions 
or concerns regarding the procedures used in this study please do not hesitate to 
contact us for further information. 
 
Contact may be via: 
Mrs Ioná Bramati Castellarin BSc DO, ND, 
Dr Ian Drysdale BSc,PhD,ND,DO or  
Dr Margit Janossa MD,DO at  
BCOM clinic:   
Frazer House 6 Netherhall Gardens 
London NW3 5RR 
Tel:020 7435 7830  
218 
Or  
Mrs Ioná Bramati Castellarin BSc DO, ND, at  
The Notting Hill Osteocare 
26 C…. C…. C….  
London W2 …… 
Tel: 0207 7…….. 
Or by e-mail at: 
research@.............. 
 
Thank you for agreeing to take part in this project. 
Please note that: 
 
 Your child’s participation in this research project is entirely voluntary; 
 You are free to refuse to answer any questions; 
 You are free to withdraw your child from the research at any time; 
 The treatment is a type of massage and there are no known risks associated 
with this; 
 The technique cannot be applied through clothing, therefore your child’s 
abdominal area needs to be exposed; 
 Assessment will be performed via: 
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1. A questionnaire completed by the child’s parents and teacher before and 
after treatment session;  
2. Stool Samples analysis. 
 
There will be complete confidentiality of records  
 No names will be disclosed at any stage of the research; 
 The research will take place at BCOM clinic - no fee will be required.  
 
If you agree to your child taking part in the study please sign and date below to 
indicate that you have read and understood the content of this form and return it 









Date: ______________________________  
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PERMISSION FORM FOR SCHOOLS 
 
TITLE OF INVESTIGATION: An assessment of gastrointestinal inflammation on 




I have read the attached information about the research the School has been 
asked to participate in. I have been given a copy of the Protocol to keep for the 
school record and I have had the opportunity to discuss the details and ask 
questions about this information. 
 
The Investigator has explained the nature and purpose of the research and I 
believe that I understand what is being proposed. 
 
I have been informed what the proposed study involves. I understand that all 
data from this trial will remain strictly confidential. Only researchers involved in 
the investigation will have access to the data. 
 
I hereby fully and freely consent, on behalf of the School Governors, to 
participation in the study which has been fully explained to me. 
 
 














As the Investigator responsible for this investigation, I confirm that I have 
explained to the participant named above the nature and purpose of the research 
to be undertaken. 
INVESTIGATOR'S NAME: Ioná Bramati Castellarin 
INVESTIGATOR'S SIGNATURE:  
DATE: ……./………/……………. 
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Appendix 3 – Example Diagnostic Statement together with the 













Appendix 4 – Recruitment Advertisements 
‘Tummy massage’ for AUTISTIC CHILDREN at Notting Hill Osteocare 
We are inviting children with a diagnosis of Autism between the ages of 3-8 
years of age to take part in osteopathic treatment sessions– tummy massage at 
Notting Hill Osteocare. 
Iona Bramati is a Registered Osteopath practising in London and for the past 10 
years has possessed a special interest in children suffering from Autism. Iona 
graduated from the British College of Osteopathic Medicine (BCOM) in 2001 and 
is currently obtaining an MPhil/ PhD degree. Initial studies that Iona carried out 
looked at the behavioural response of autistic children following tummy 
massage. Due to the positive results, this has led onto a more detailed research 
project studying autism with the University of Westminster/ BCOM in 
collaboration with King’s College Hospital, London. Recently the project has 
been endorsed by the National Autistic Society (NAS). 
Iona is using tummy massage to help improve gut function of children who have 
been diagnosed autistic. Previous studies have shown that manual stimulation of 
the gut may help to decrease inflammatory processes as well as aid a decrease 
in constipation, diarrhoea and bloating suffered by autistic children. It may also 
help to reduce some of the behavioural symptoms characteristic of autism.  
If your child suffers from gut problems such as: diarrhoea, constipation, bloating 
he or she might benefit from this treatment.  
 Please contact research@.............. or call 07---------- for specific details  
or log in at www……..  
 
* There is no cost involved in participating in this study. Any participant may 











Appendix 5 – Questionnaires employed in the study 
 
                                              Admin Number:                 
  
 
Osteopathic treatment of GI symptoms in Autistic Children 
Confidential Health Questionnaire – Screening Questionnaire 
 
 
1. How old were you during your pregnancy? ________ 
 
2. Was your child full term? (please circle)   Yes  
 No 







3. Did you have any problems during pregnancy?  





4. Did you have any problem in delivering you baby? 




        
Child’s Name:______________________________________________________ 
Date of Birth: _________________ 
Age:____________Sex:_____________________________________  








5. Were the following used : ( tick the relevant box) 
 
a) Forceps         • 
b) Ventouse          • 
c) Amniotomy (artificial rupture of the membrane)    • 
d) Pethadine (a potent analgesic drug )      • 







6. Was you labour induced? (please circle)   Yes   
 No 







7. Was your child delivered via caesarian? (please circle) Yes  
  No  






8. Was your child breast fed? (please circle)   Yes 
  No 
If yes, for how long?______________________ 
 
9. Was your child bottle fed? (please circle)   Yes 
  No  
Was he/she fed on: (please tick the relevant box) 
a) Formula (cow’s milk)      •  
 • 
b) Unmodified cow’s milk     •   •
  
c) other (please give details)_______________________  •  
 • 
 
10. At what age were solids first introduced? _______ 
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11. At what age were gluten containing foods introduced?_______ 
 
12. Are there any known food allergies? (please circle)  Yes 
  No 
If yes, what are the associated symptoms? (tick the relevant box) 
a) Skin rash         • 
b) Eczema          • 
c) Diarrohoea          • 
d) Itching          • 
 
13. Has your child been immunised? (please circle)  Yes 
  No 
(see below for list) 
14. Do you remember any side effects post vaccination? 
(please circle)        Yes 
  No 
 
15. If yes, tick on the vaccines that in your view may have caused adverse 
side effects. 
 
a) DTP (Triplice)         • 
b) HIP (Haemophilus influenza)       • 
c) OPV (Oral Polio Vaccine)       • 
d) MMR (measles, mumps, rubella)      • 
  
16. Has your child ever suffered from: (please circle) 
a) Asthma       Yes   No 
b) Diabetes       Yes   No 
c) Bronchitis       Yes   No 
d) Epilepsy       Yes   No 
e) Kidney problems     Yes   No 
f) Bowel problems      Yes   No 
 
 







18. Bowel function - stool characteristics (please give one answer for each of 
the following)  
 
1. Colour      dark   very dark   pale   very 
pale  
  





3. Smell       no smell       light smell  strong        
very strong 
 
4. Frequency      once   twice    three        more  
 (daily) 
 
19. Has your child had any surgery in the past? (please circle)  Yes 
  No 






20. Is your child on any medication? (please circle)  Yes  
 No 






21. Has your child had any accidents? (please circle)  Yes 
  No 





22. Was he/she hospitalised?(please circle)   Yes  
 No 





23. Does your child suffer or has he/she ever suffered from ear, 
nose or throat infections? (Please circle)      
   




24. Is he/she been treated with antibiotics? 
(Please circle)       Yes  
 No 







25. Does your child sleep well at night time?   Yes  
 No 
 
26. When was your child diagnosed with Autism? ____________ 
 
27. Who diagnosed your child? (tick the relevant box) 
a) GP         • 
b) Paediatrician         • 
c) Health visitor         • 





Please sign below and send this questionnaire with the consent form in the 
stamped addressed envelope. 
 
 Parent/guardian name: 
__________________________________(Mother/Father) delete as appropriate 
 
 Parent/guardian signature: _______________________________  
 
























This questionnaire is based on ROME II Integrative Questionnaire: Research Diagnostic 
Questions for Functional Gastrointestinal Disorders  
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Before Treatment/ During Treatment/Post Treatment 
Questionnaire  
Osteopathic Treatment of GI symptoms in Autistic Children 
Child’s Name:  
Child’s Age:  
Date:  
Please rate the child’s behaviour and digestive symptoms using the scale below which 
ranges from: 
     
0= never shows this particular symptom or behaviour 
    1= slight/unobtrusive 
    2 
    3= mild 
    4  
    5=moderate 
    6 
    7=severe 
    8 
    9=extreme/incapacitating 
 
Tick the relevant box to the following: 
Social behaviour and communication. 
 0 1 2 3 4 5 6 7 8 9 
Lack of awareness and 
interaction with parent 
          
Abnormal greeting behaviour           
Abnormal comfort seeking           
Can’t make friends           
Lack of awareness of social 
rules 
          
Lack of spontaneous speech           
Abnormal word utilisation           
Poor compression of verbal 
instructions 
          
Lack of eye contact           
 
Ritual and Repetitive Activities 
 0 1 2 3 4 5 6 7 8 9 
Abnormal repetitive gestures           
Need to maintain sameness           
Need of fixed routine           
 
Digestive Symptoms  
 0 1 2 3 4 5 6 7 8 9 
Diarrhoea           
Constipation           
Poor Appetite           
Bloating           
Flatulence           
Vomiting           
 
General Symptoms  
 0 1 2 3 4 5 6 7 8 9 
Unhappy           
Aggressive           
Destructive           
Spaced out/Non Interactive           
Agitated           
Disagreeable           
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Secretin Outcomes Survey (S.O.S.) Form 
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Appendix 7 – Raw Data Biochemical Markers (Study I-IV) 





















49 100% 0% 
SAMPLE 2 
 
48 95.91% 4.09% 
SAMPLE 3 
 
48 95.91% 4.09% 
SAMPLE 4 
 
46 85.71% 14.29% 
SAMPLE 5 
 
45 89.79% 10.21% 
SAMPLE 6 
 
43 87.75% 10.20% 
SAMPLE 7 
 
44 89.79% 20.21% 
SAMPLE 8 
 
39 79.59% 20.41% 
SAMPLE 9 
 
33 59.18% 40.82% 
Legend to the table: This table represents the number of faecal samples received from 
the total subject number (n=49). 
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Calprotectin (1-4) - Raw Data  
patient initials Calpro 1 Calpro 2 Calpro 3 Calpro 4 
1 EAOD 21 16 108 70 
2 EB  19 10 21 10 
3 YB 42 40 43 16 
4 SC 20 38 40 10 
5 GM 37 13 15 31 
6 MA 46 43 112 10 
7 FM 10 11 56 16 
8 IO 22 37 48 15 
9 RR 13 39 10 39 
10 PW 10 10 10 11 
11 JEW 10 21 10 14 
12 OF 10 13 12 54 
13 BD 164 23 32 56 
14 HH 10 10 10 10 
15 DB 10 10 10 34 
16 SMcA 18 10 10 33 
17 RA 12 31 48 17 
18 JS 10 10 10 10 
19 AD 10 10 10 10 
20 HH2 36 25 43   
21 VS 10 10 10 14 
22 JAW 10 10 10 10 
23 AK 21 Excluded from study 1  
24 CA 10 121 14 11 
25 ZRS 10 10 10 12 
26 NL 10 10 10 10 
27 GN 10 10 70 10 
28 JA 10 10 10 10 
29 ZR 29 51 18 10 
30 NR 30 14 22 13 
241 
31 LB 11 10 15 25 
32 EC 10 11 10 27 
33 NB 24 27 23 14 
34 JB 27 18 14 15 
35 SR 121 30 41 47 
36 AP 10 69 12 34 
37 RO 30 40 14 17 
38 BG 41 36 97 55 
39 FAM 511 89 224 66 
40 OB 14 551 640 40 
41 TO'D 10 12 15 35 
42 N-JF 409 1592 151 391 
43 JB 15 10 22 10 
44 AD 10 34 88 59 
45 MMR 83 234 153 108 
46 RSM 38 14 21   
47 KMK 30 30 59 43 
48 AM 50 18 16 13 
49 SAH 138 195 121 21 




M2-PK (1-4) Raw Data  
patient initials M2PK-1 M2PK-2 M2PK-3 M2PK-4 
1 EAOD 1.65 1.13 2.07 1.16 
2 EB  1.00 1.00 1.00 1.00 
3 YB 1.98 1.00 8.28 1.49 
4 SC 2.16 1.00 3.96 1.00 
5 GM 1.00 1.22 1.00 3.14 
6 MA 20.00 20.00 20.00 17.65 
7 FM 1.66 1.00 12.72 1.00 
8 IO 4.66 2.16 5.44 1.00 
9 RR 2.78 1.00 1.00 1.00 
10 PW 1.00 1.00 1.00 1.00 
11 JEW 1.00 2.10 1.00 1.00 
12 OF 1.00 1.00 1.00 1.00 
13 BD 1.00 1.00 1.00 1.00 
14 HH 1.00 1.00 1.00 1.00 
15 DB 1.00 1.00 1.00 1.86 
16 SMcA 1.00 1.00 1.00 1.00 
17 RA 1.46 12.54 8.40 1.43 
18 JS 1.00 1.00 1.00 1.00 
19 AD 1.00 1.00 1.00 1.00 
20 HH2 1.00 1.00 1.00   
21 VS 1.00 1.00 1.00 3.50 
22 JAW 1.10 2.16 1.31 1.00 
23 AK 1.00 Excluded from study 1 
24 CA 1.04 1.00 1.93 6.24 
25 ZRS 1.00 1.00 1.03 1.97 
26 NL 1.00 1.00 1.00 1.00 
27 GN 1.00 1.00 3.42 1.00 
28 JA 1.00 1.00 1.00 1.00 
29 ZR 3.34 2.19 3.16 1.00 
30 NR 1.00 1.00 1.00 1.00 
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31 LB 1.00 1.14 1.20 2.00 
32 EC 1.00 1.00 1.58 1.00 
33 NB 1.00 1.00 1.00 1.00 
34 JB 1.00 1.00 1.00 1.00 
35 SR 15.37 1.39 3.81 1.00 
36 AP 1.00 1.00 2.02 2.79 
37 RO 1.54 1.00 1.00 1.00 
38 BG 1.00 1.00 4.40 1.21 
39 FAM 20.00 2.60 13.91 1.00 
40 OB 2.89 20.00 20.00 1.00 
41 TO'D 1.00 1.00 1.00 2.69 
42 N-JF 4.05 7.95 3.10 1.00 
43 JB 1.00 1.00 2.86 1.00 
44 AD 1.00 5.32 2.25 3.21 
45 MMR 6.24 2.37 20.00 3.53 
46 RSM 1.00 1.00     
47 KMK 1.00 1.00 1.00 1.00 
48 AM 1.61 1.00 1.00 8.54 
49 SAH 5.66 1.09 1.00 1.00 



















2 EB  
Thrown 
away 62.5 62.5 1,424.1 





4 SC 356.9 1,466.6 
Thrown 
away 62.5 
5 GM 6,045.9 504.0 
Thrown 
away 1,868.1 










8 IO 196.3 229.2 
Thrown 
away 127.8 
9 RR 1,048.2 1,126.3 62.5 260.3 
10 PW 62.5 <62.5 
Thrown 
away 172.8 








































20 HH2 95.7 634.4 1,232.2   

















26 NL 985.0 1,250.0 1,499.0 1,217.2 
27 GN 304.8 111.5 19,805.3 1,711.7 
28 JA 62.5 1,845.4 201.3 4,234.5 
29 ZR 2,497.2 1,637.3 1,342.9 434.4 
30 NR 830.6 587.8 713.6 732.3 
31 LB 1,048.9 173.8 5,542.9 4,999.2 
32 EC 62.5 216.8 434.4 403.8 
33 NB 3,600.0 918.2 4,066.9 1,067.5 
34 JB 598.6 258.1 72.7 98.3 
35 SR 7,030.0 837.4 0.0 886.1 
36 AP 188.9 2,331.7 1,700.0 2,442.6 
37 RO 236.4 623.5 236.4 529.1 
38 BG 558.7 426.9 1,604.8 549.6 
39 FAM 10,000.0 3,624.0 10,000.0 2,973.6 
40 OB 195.0 10,000.0 10,000.0 772.4 
41 TO'D 699.4 650.7 62.5 1,029.8 
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42 N-JF 10,000.0 1,017.8 8,221.4 2,632.2 
43 JB 712.0 62.5 0.0 62.5 
44 AD 62.5 1,022.2 9,260.0 1,266.1 
45 MMR 3,566.2 3,340.8 2,400.0 3,373.6 
46 RSM 1,646.5 <62.5     
47 KMK 0.0 0.0 0.0 911.2 
48 AM 92.6 62.5 0.0 92.6 
49 SAH 7,900.1 2,688.4 559.8 775.6 
















1 EAOD 12 64 37 14 15 
2 EB  17 11 23 19 16 
3 YB 10 24 90 21 135 
4 SC 31 35 96   18 
5 GM 70 73 160 64 284 
6 MA 32 112 40 45 91 
7 FM 10 10 73 32 12 
8 IO 17 11 14 39 10 
9 RR          10 
10 PW 10 47 17 10 10 
11 JEW 10 11 10 50 10 
12 OF 30       20 
13 BD 39 20 31 22 110 
14 HH 10 12 10 10 10 
15 DB 10 10 10 10 10 
16 SMcA 10 10 10   12 
17 RA 43 34 246 114   
18 JS 13 10 10 10 26 
19 AD 10 10 10 10 12 
20 HH2           
21 VS           
22 JAW 10 10 10 10 10 
23 AK 31 104 41     
24 CA 24 10 16 10 13 
25 ZRS 10 10 14 10 10 
26 NL 10 10 10 10 10 
27 GN 10 15 10 10 12 
28 JA 33 10 10 10   
29 ZR 10 14 10 12   
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30 NR 10 34 127     
31 LB 11 26 26   15 
32 EC 14 12 11 10 12 
33 NB 12 10 17 11 41 
34 JB 12 13 36 20 62 
35 SR 63 19 66 17 36 
36 AP 10 10 21 15 82 
37 RO 22 10 18 104 10 
38 BG 18   57 28 108 
39 FAM 123 11 12 40   
40 OB 10 10 59 56 25 
41 TO'D 18 30 21 483 16 
42 N-JF 455   50 323   
43 JB 10 10 10 14 10 
44 AD 35 15 54     
45 MMR 482 44 34 471   
46 RSM   10   103 109 
47 KMK 71 89 99 11 88 
48 AM 21 54 27 30   
49 SAH 129 137 43 124   




M2-PK (5-9) Raw Data 
patient initials M2PK-5 M2PK-6 M2PK-7 M2PK-8 M2PK-9 
1 EAOD 1.00 1.89 1.00 1.00 1.00 
2 EB  1.00 1.00 1.00 1.00 1.00 
3 YB 1.00 1.49 1.00 3.43 1.00 
4 SC 1.00 1.00 11.81   1.4 
5 GM 1.00 1.74 3.71 2.59 1.00 
6 MA 20.00 20.00 4.44 20.00 20.00 
7 FM 1.00 2.05 2.12 1.95 1.00 
8 IO 1.00 1.00 1.00 1.76 1.00 
9 RR         1 
10 PW 1.43 1.22 1.00 1.00 1.00 
11 JEW 3.77 1.00 1.00 1.00 1.00 
12 OF 1.00       1.25 
13 BD 1.00 1.00 1.00 1.00 1.00 
14 HH 1.00 1.00 1.00 1.20 1.30 
15 DB 1.00 1.00 1.33 1.00 3.32 
16 SMcA 1.00 1.00 1.00   1.00 
17 RA 4.08 4.19 3.36 20.00   
18 JS 1.00 1.00 1.00 3.29 1.00 
19 AD 1.00 1.04 1.00 1.23 1.00 
20 HH2 
     21 VS      
22 JAW 1.00 1.00 1.00 1.00 1.24 
23 AK 1.00 1.00 1.00     
24 CA 3.99 1.00 2.45 1.00 2.59 
25 ZRS 2.23 2.09 1.00 1.00 1.00 
26 NL 1.00 1.00 1.00 1.00 1.00 
27 GN 1.00 1.00 1.00 1.00 1.01 
28 JA 12.08 2.48 1.88 1.44   
29 ZR 1.00 1.00 2.62 1.67   
30 NR 1.00 1.00 1.86     
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31 LB 1.00 1.00 1.00   1.31 
32 EC 1.29 5.42 1.68 1.00 1.00 
33 NB 1.00 1.00 1.33 1.00 1.00 
34 JB 1.00 1.00 1.00 1.00 1.79 
35 SR 1.00 1.00 1.00 1.00 10.19 
36 AP 1.00 1.00 2.09 1.00 8.75 
37 RO 2.38 1.49 1.00 1.00 1.99 
38 BG     4.74 2.85 5.68 
39 FAM 10.48 2.75 1.00 4.56   
40 OB 1.00 1.68 2.59 1.00 8.24 
41 TO'D 1.00 1.19 2.04 19.86 1.00 
42 N-JF 6.89   1.00 7.89   
43 JB 1.83 1.00 1.00 1.00 1.52 
44 AD 2.56 3.89 5.43     
45 MMR 20.00 1.68 1.00 20.00   
46 RSM   1.00   4.02 5.94 
47 KMK 8.94 5.64 15.90 1.00 2.67 
48 AM 1.00 2.59 1.00 1.00   
49 SAH 2.69 4.78 1.00 1.00   



































4 SC 879.5 322.0 
Thrown 
away   
Thrown 
away 




















9 RR           
10 PW 62.5 1,241.3 
Thrown 








12 OF 2,160.0       
Thrown 
away 





14 HH 9,773.1 147.8 62.5 62.5 455.2 





16 SMcA 749.0 Thrown 62.5   4,812.9 
252 
away 
17 RA 6,527.1 5,756.5 
Thrown 
away 7,987.7   
18 JS 1,093.8 787.6 1,424.4 
Thrown 
away 331.2 
19 AD 369.3 202.4 
Thrown 
away 221.9 <62.5 
20 HH2           
21 VS           
22 JAW 383.3 62.5 
Thrown 
away 106.5 912.3 
23 AK 1,246.0 10,000.0 1,382.4     










26 NL 2,946.8 715.0 6,421.8 7,344.1 4,096.5 
27 GN 1,030.8 172.8 174.2 1,833.7 1,363.3 
28 JA 7,923.4 5,188.4 3,001.8 1,469.7   
29 ZR 1,881.3 1,731.8 500.7 1,820.4   
30 NR 62.5 732.3 937.8     
31 LB 1,214.6 2,709.7 1,042.8   452.3 
32 EC 836.4 1,749.3 92.8 62.5 790.4 
33 NB 62.5 871.4 2,355.9 62.5 1,044.4 
34 JB 105.9 205.7 1,777.2 675.0 6,752.9 
35 SR 986.0 225.7 0.0 216.3 0.0 
36 AP 1,345.4 62.5 2,435.4 902.3   
37 RO 753.6 62.5 816.9 759.2 62.5 
38 BG     855.0 2,697.4   
39 FAM 10,000.0 3,345.8 1,569.1 3,578.4   
40 OB 62.5 62.5 1,017.8 2,290.6 1,020.3 
41 TO'D 62.5 62.5 62.5 10,000.0 62.5 
42 N-JF 7,429.7   #VALUE! 6,259.2   
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43 JB 1,024.8 921.3 62.5 105.9 959.4 
44 AD 2,596.2 1,368.7 3,974.9     
45 MMR 10,000.0 546.4 95.3 10,000.0   
46 RSM   62.5   1,599.8 2,568.4 
47 KMK 4,563.1 3,591.2 2,569.8 62.5 2,739.3 
48 AM 62.5 1,025.3 556.2 109.8 462.3 




Appendix 8 – Raw Data Questionnaires 1-9 (Study I – IV) 
















Quest 1 48 98% 2% 
Quest 2 47 96% 4% 
Quest 3 44 90% 10% 
Quest 4 44 90% 10% 
Quest 5 46 94% 6% 
Quest 6 43 88% 12% 
Quest 7 44 90% 10% 
Quest 8 42 86% 14% 
Quest 9 29 59% 41% 
Legend to the table: This table represents the number of questionnaire received from 











































































































































































5 1 3 7 9 1 1 4 3 6 5 5 1 0 0 0 2 1 0 1 0 6 2 3 
1 1 7 0 2 7 7 2 2 3 3 7 0 5           8 8 4 4 4 
4 6 3 7 7 9 9 8 3 4 1 2 6 7 5 9   0 4 1   5   3 
3 3 2 3 5 5 5 4 0 1 1 3   5 5 7 5 5 5 2 1 0 6 6 
0 1 5 0 0 0 3 0 5 0 0 1 0 0 7 7 3 0 1 5 7 7 7 7 
  9 9 9 6 9 9 8 8 9 7 9 0 0 0 0 1 0 0 3 7 8 7 6 
0 2 2 6 3 7 9 5 5 5 5 5 0 6 6 0 4 0 1 5 1 3 6 3 
0 1 1 0 5 0 5 0 3 5 5 7 0 7 0 0 0 0 0 3 3   5 3 
0 1 0 0 0 1 1 0 0     0 0 0 0 1 0 0 0 0 0 0 0 1 
3 5 4 6 6 5 5 6 4 7 8 8 0 6 5 5 2 3 3 3 3 2 5 4 
5 7 7 9 9 8 9 7 6 9 5 1 5 2 1 0 3 0 0 1 5 1 5 5 
                        
0 0 1 2 2 1 1 1 3 5 3 3 6 1 5 1 1 0 1 0 0 2 2 2 
0 2 0 0 0 1 1 0 4 0 1 1 1 0 2 1 2 0 0 1 0 0 1 1 
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3       9 9   9 5 5 3 3 1 2 5   1 0 0 0 0   4   
1 2 3 6 6 3 2 5 3 3 4 3 2 1 4 3 3 1 2 3 3 3 3 5 
7 6 8 9 9 9   7 7 8 8 8 0 4 3 1 1 0 2 4 0 0 6 4 
3 5 1 9 7 3 7 6 4 1 6 6 3 5 1 1 0 0 1 0 0 6 3 3 
5 3 5 3 3 3 0 3 3 5 3 3 0 7 0 1 0 0 3 3 0 5 5 5 
3 4 3 NA 3 3 3 7 7 6 9 9 6 9 9 1 9 2 NA 2 2 NA 9 7 
0 0 1 3 2 0   1 0 0 1 0 2 0 0 0 0 0 1 3 0 0 2 2 
3 1 5 1 2 5 1 0 0 0 0 0 0 5 5 5 1 0 5 0 0 2 4 4 
0 0 0 0 0 0 0 0 0 0 0 0   0       9 0 0 0 0 0 0 
7 7 8 8 9 8 9 7 5 7 7 7 5 7 3 8 3 0 7 9 9 3 7 5 
1 3 5 5 6 7 5 2 1 5 3 3 5 8 5 7 7 0 3 0 1 1 1 1 
2 1 1 8 7 3 4 5 3 2 2 1 1 3 5 6 2 1 1 3 4 4 2 1 
5 7 6 9 9 9 9 7 7 2 7 0 9 9 0 7 3 0 0 0 3 5 6 0 
1 1 3 6 7 7 7 7 3 5 5 5 5 7 5 7 7 1 1 3 3 2 3 3 
1 3 3 6 9 5 6 4 6 5 1 1 8 8 6 5 7 0 7 1 1 8 7 1 
                                                
3 8 9 9 9 9 0 3 5 9 8 6 0 7 9 7 0 0 2 3 7 2 8 8 
1 5 1 7 6 3 6 3 2 0 1 1 0 8 0 8 0 0 3 3 1 0 0 1 
3 4 5 5 7 3 4 5 6 7 7 7 3 0 7 5 0 5 5 8 6 2 2 6 
3 5 3 3 5 3 5 5 5 1 3 6 2 6 0 3 3 0 3 6 6 6 6 7 
3 3 4 6 8 9 9 3 5 9 5 4 9 1 5 3 3 1 2 1 3 7 7 7 
1 4 4 9 8 4 3 4 4 6 4 3 3 7 1 7 5 0 2 0 0 3 4 2 
0 0 2 2 3 0 1 0 0 7 7 7 7 6 3 2 4 1 3 1 2 0 5 6 
5 3 3 7 7 9 7 9 5 7 5 5  7 8 1 0 0 1 3 3 3 3 6 
7 7 7 7 7 9 9 8 6 6 7 7 6 0 0 2 2 1 3 7 8 3 6 6 
6 0 7 9 9 9 6 7 6 9 9 9 8 8 6 6 1 1 6 7 6 6 7 6 
2 0 3 7 9 7 7 2 3 3 3 7 7 9   3 3 2 5 7 8 6 8 9 
257 
5 5 5 7 5 5 0 7 1 0 8 8 0 9 7 0 0 0 5 0 0 5 9 9 
3 6 5 5 7 5 7 6 5 6 7 7 4 0 0 4 4 0 0 0 3 3 0 1 
0 4 4 8 7 9 7 4 1 7 5 5 7 3 3 6 7 0 2 1 0 3 0 1 
7 7 7 9 9 9 9 8 5 8 9 8 0 9 0 5 7 0 5 5 7 7 6 8 
4 2 2 1 1 1 1 1 1 7 4 3 0 0 0 0 0 4 6 
 
5 4 5 5 
2 2 0 
 
0 0 2 2 5 3 3 3 4 
 
0 0 3 0 0 1 0 1 3 3 
3 9 
 
9 9 9 
 
9 5 8 8 6 3 8 3 5 
 
4 4 7 9 
  
2 











































































































































































3 5 7 7 9 6 6 4 4 6 5 5 0 0 0 0 0 0 1 0 0 1 3 4 
1 1 1 1 3 2 7 3 1 7 4 4 7 0 0 0 0 0 1 2 2 0 6 6 
4 7 3 8 7 9 9 9 3 3 2 3 2 4 3 8   0 4 1   6   4 
2 3 3 2 3 5 5 5 1 3 2 4 0 5 1 7 5 5             
1 1 5 0 0 0 5 0 3 0 0 0 0 0 3 0 0 0 0 7 3 0 0 7 
9 9 9   3 7 7 7 6 9 8 9 0 0 0 1 1 0 0 3 5 9 5 5 
3 5 3 7 3 5 7 3 3 5 1 2 0 3 0 0   0 0 3 0 0 3 0 
0 3 3 0 3 0 3 0 3 5 5 5 0 7 0 0   0 0 3 3   3 3 
0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 1 0 0 0 0 0 1 1 0 
4 4 3 6 6 6 6 6 5 6 7 7 3 4 3 4 3 2 3 2 2 4 3 4 
5 6 7 7 9 5 7 5 5 6 4 4 4 4 3 2 4 0 1 1 4 2 3 4 
                        
1 0 1 1 2 0 0 1 1 4 6 5 4 1 3 2 0 0 1 1 1 2 1 1 
0 1 0 0 0 3 1 0 1 0 0 0 0 2 1 1 0 0 0 0 0 0 1 1 
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3 3 3 8 9 9 9 9 3 3 3 3   6 6 7 0 0 1 0 0 2 3 0 
1 3 4 6 4 1 4 5 3 3 3 3 4 3 3 4 2 1 2 3 3 3 4 4 
5 5 6 9 9 9 9 6 6 5 5 4 3 1 5 1 1 0 2 3 0 5 4 2 
3 6 3 9 8 7 7 7 5 2 5 5 1 8 3 5 1 0 2 0 0 4 4 2 
3 0 3 3 5 3 0 3 0 3 3 3 0 6 0 3 0 0 3 0 0 3 7 3 
                             
0 1 0 1 1 0 1 1 0 0 1 0 1 0 1 1 1 0 0 0 0 1 1 1 
0 0 0 2 2 3 1 1 1 0 0 0 0 4 1 2 2 0 0 0 0 1 0 0 
3 7 3 9 9 9 9 7 3 7 7 7 9 9 1 1 0 0 2 2 2 2 2 2 
7 6 4 8 7 5 8 6 4 6 7 7 0 9 2 8 8 0 7 9 9 7 7 7 
0 0 5 2 5 5 6 5 0 1 0  6 7 5 7 5 0 1 0 1 0 2 2 
2 1 4 8 7 3 4 4 3 5 2 1 1 4 4 6 3 0 1 4 4 1 1 2 
4 7 8 9 9 9 9 9 7 4 9 3 6 8 0 6 6 0 1 0 2 9 9 6 
1 2 2 4 4 4 5 4 2 3 3 3 0 0 2 3 3   1 1 1 1 1 1 
1 3 3 6 9 4 6 4 7 6 1 1 8 8 8 6 8 0 6 1 1 9 6 1 
6 9 4 9 9 8   5 6 9 6 6 6 0 1 1 6 0 5 7 8 7 8 8 
4 7 7 9 7 0 0 5 5 6 7 6 1 6 8 7 4 0 4 4 5 3 6 6 
1 1 6 6 5 3 6 3 2 0 1 1 0 7 0 8   0 2 4 0 0 1 2 
5 7 7 7 8 5 5 6 6 5 5 6 0 9 9 5 0 6 5 7 7 1 5 9 
3 3 1 3 5 3 1 5 4 1 4 4 1 5 0 3 3 0 3 6 4 4 6 6 
2 3 4 4 2 3 3 2 3 5 3 3 3 1 1 2 1 0 2 2 2 3 4 3 
1 1 4 5 5 2 3 3 4     1 1 5 1 4 4 0 8 3 2     8 
0 0 2 2 3 0 1 0 0 7 7 7 7 6 3 2 4 1 3 1 2 0 5 6 
6 7 5 5 7 7 7 7 5 5 6 7 0 7 6 3 2 0 5 3 3 5 5 5 
6 6 7 6 7 8 8 6 7 7 7 7 7 0 0 1 1 0 5 6 7 7 7 6 
5 7 6 9 8 9 9 8 7 9 8 6 5 5 1 3 2 0 4 6 6 8 8 6 
7 8 9 9 9 5 5 4 7 5 8 8 6 1 9     6 6 8 8 4 7 8 
260 
5 3 3 3 5 5 1 5 6 3 7 7 0 9 8 0 0 0 5 0 0 5 5 5 
3 7 5 3 5 3 5 5 2 5 6 6 2 0 0 2 2 0 0 1 1 2 0 0 
0 3 6 8 6 9 9 7 7 5 5 5 5 5 2 6 6 1 1 1 0 3 0 1 
9 8 8 9 9 9 9 9 7 8 9 9 0 3 0 6 6 0 7 8 8 8 7 9 
3 1 3 1 1 1 1 1 1 7 7 4 1 0 0 0 0 0 2 5 6 6 3 7 
1 2 1 
  
9 9 2 2 2 3 3 4 3 0 1 3 0 1 1 1 1 1 1 
3 9 
 
9 9 9 9 4           8 3 
  
4 4 7 9     2 











































































































































































1 3 5 7 7 6 1  3 7 6 5 1 0 0 2 3 1 0 1 0 2 3 5 
5 1 1 1 5 1 5 1 4 1 1 1   3   3     1 1 1 3 3 3 
4 5 5 8 7 9 9 7 5 2 2 2 0 1 6 7   0 5 1 1 7 3 4 
1 1 2 1 2 2 2 2 0 2 0 1 0 3 0 5 4 2 2 1 1 1 2 3 
3 0 3 5 0 0 0 3 7 0 1 0 0 0 0 0 0 0 5 7 7 5 3 7 
9 9   4 9 9 7 9 6 8 7 9 0 1 0 0 0 0 0 7 7 9 6 5 
                                                
0 3 3 3 3 1 5 3 5 5 5 5 0 7 0 0   0 0 1 3   3 3 
0 0   0 0 1 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 1 0 0 
                                                
5 7 7 7 9 6 7 5 5 7 6 4 1 4 4 0 6 0 1 1 4 0 5 6 
                        
1 1 0 2 3 1 0 0 1 3 4 3 0 6 1 0 0 0 1 2 0 1 2 1 
0 1 0 0 1 2 2 4 0 0 0 0 0 1 2 1 2 0 0 0 0 0 0 0 
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3 5 5 9 9 9 0 7 3 3 5 5 0 2 2 2 0 0 0 0 0   2 0 
1 3 5 6 7 1 3 4 1 3 3 1 4 3 3 3 3 1 2 2 2 1 3 3 
4 4 3 8 8 9   5 4 4 6 6 4 1 5 4   0 0 0 0 4 2   
4 7 3 9 8 7 7 7 6 3 4 4 3 8 4 4 2 0 2 0 1 5 4 3 
7 7 0 5 7 7 0 3 3 7 3 3 0 7 0 0 0 0 3 3 0 7 7 7 
                          
1 0 0 1 1 0 0 1 0 0 0 0 1 0 0 1 1 0 0 0 0 1 1 1 
0 0 0 0 0 2 2 2 1 0 0 1 0 5 0 4 3 0 0 0 0 1 0 0 
                                                
7 7 8 9 8 9 9 6 7 6 8 7 2 8 0 8 8 0 7 4 5 4 7 7 
0 1 3 2 3 7 7 5 1 4 2 2 7 7 6 7 6 0 4 4 4 1 4 4 
1 0 1 8 6 2 4 3 2 3 2 1 1 2 1 2 1 0 1 2 3 1 1 2 
5 5 5 9 9 9 9 7 6 6 6 2 2 8 0 6 5 0 1 0 3 8 8 2 
0 1 1 3 4 7 7 6 0 5 5 5 0 3 0 2 1 0 1 1 1 1 1 1 
1 3 3 8 9 5 5 4 7 6 1 1 8 8 6 5 6 0 3 1 1 5 4 1 
5 8 6 9 8 9 9 4 4 9 6 5 2 6 0 2 7 0 4 7 7 6 5 6 
5 9 9 9 7 9 0 5 4 8 8 7 0 8 9 8 7 0 4 6 8 4 8 8 
1 1 1 6 5 3 6 3 2 0 1 1 0 8 0 7 0 0 1 2 0 0 1 1 
5 5 5 7 7 5 5 4 7 6 6 6 0 8 8 8 0 5 1 5 3 3 2 4 
2 2 3 6 7 0 1 2 4 0 2 4 0 6 0 1 3 0 2 7 6 2 2 6 
1 2 2 2 7 2 2 1 2 5 3 2 3 0 0 2 2 0 1 1 2 3 3 2 
4 3 7 7 5 4 2 2 2 3 2 2 1 7 2 7 3 0 3 2 1 3 5 5 
0 1 1 3 2 0 2 1 0 7 5 5 4 3 1 2 3 0 0 4 3 0 2 5 
5 5 3 6 6 7 7 7 5 5 6 6 0 6 7 2 3 0 5 4 4 6 4 6 
7 7 7 7 7 9 8 8 7 7 7 7 6 0 0 3 3 0 6 6 6 6 5 6 
                                                
8 3 6 8 9 4 7 7 1 5 6 7 4 1 5 0   3 8 7 7 7 8 9 
263 
5 5 8 5 6 5 0 5 6 7 8 9 0 9 8 7   5 5 1 1 5   7 
3 6 1 4 4 1 3 4 3 4 5 5 4 0 0 0 2 0 1 0 2 1 0 0 
1 3 3 7 7 9 9 5 5 7 7 5 7 0 7 7 5 0 3 1 0 1 0 5 
9 9 8 9 9 9 9 9 7 9 9 9 0 8 0 6 6 0 8 9 8 7 7 9 
4 4 4 4 
 
1 1 1 3 1 5 3 0 0 0 0 0 0 1 4 5 1 1 3 
                                                
3 9 
 
9 9 9 
 



















































































































































































2 6 3 7 8 6 5 5 4 2 6 2 1 0 0 0 1 1 1 0 3 4 4 5 
7 3 7 1 7 7 7 3 7 3 3 3 3 3 3         4 4 7 4 4 
2 6 3 9 7 9 9 9 3 3 2 1 0 1 6 5 4 0 0 1 6 5 4 0 
0 1 0 0 2 1 1 2 0 1 1 0 0 5 0 6 5 4 0 1 2 1 2 2 
3 0 3 5 0 0 0 3 7 0 1 0 0 0 0 0 0 0 5 7 7 5 3 7 
9 7 7 6 9 6 9   7 9 9 9 0 0 0 1 1 1 0 3 3 7 5 5 
2 1 1 3 4 7 7 5 3 1 2 3 0 3 0 0 0 0 1 0 0 3 3 1 
0 3 3 3 3 1 5 3 5 5 5 5 0 7 0 0   0 0 1 0   3 3 
0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 
                                                
5 6 7 7 9 6 6 6 5 5 5 3 2 3 5 0 5 0 1 0 1 5 3 3 
                        
1 1 1 2 2 0 0 0 1 4 4 4 3 3 1 1 1 0 1 1 2 0 1 1 
0 1 0 0 0 2 2 5 1 0 0 0 0 2 3 0 1 0 0 0 0 0 0 0 
265 
3 2 2 9 9 9 9 7 2 3 5 5 9 9 3 4 9 9 0 0 0 5 5 5 
1 3 4 5 5 1 3 3 1 3 2 1 3 3 3 4 3 1 1 2 3 2 3 3 
7 6 9 8 8 9 9 6   7 8 5 2 2 7 2   0 1 3 0 0 2 0 
3 3 1 7 5 2 2 5 5 3 3 3 3 5 5 0 0 0 1 1 0 3 1 1 
3 7 7 3 7 3 0 3 5 7 7 3 0 7 0 0 0 0 3 5 0 7 7 5 
            
   
         
0 0 0 1 1 0 0 1 0 1 0 0 2 0 0 0 1 0 0 0 0 0 1 1 
0 0 0 0 0 0 2 2 1 1 1 1 0 3 0 3 2 0 0 0 0 0 0 0 
                                                
7 7 7 7 8 7 6 9 7 7 8 8   8 8 6 7 0 6 6 8 7 8 7 
0 3 3 3 4 7 7 5 0 4 3 1 5 8 5 7 7 0 4 1 1 1 4 4 
2 1 2 6 6 2 3 3 2 2 1 1 3 3 4 2 2 1 1 1 1 1 2 1 
5 6 7 9 9 9 9 7 7 1 6 1 0 5 0 5 5 0 1 0 8 8 8 0 
                                                
1 3 3 8 9 5 5 2 4 4 1 1 6 8 7 7 7 0 3 1 0 5 3 1 
                                                
3 6 8 8 8 0 0 7 6 7 7 7 0 8 9 8 7 0 2 3 4 2 7 8 
1 1 1 6 4 3 5 2 1 0 1 0 0 7 0 6 0 0 1 1 0 0 1 1 
5 6 6 9 8 5 5 5 8 5 5 6 0 9 9 9 0 6 0 6 6 4 5 8 
3 4 1 3 5 1 1 2 4 1 3 3 1 5 0 1 1 0 3 6 5 4 5 5 
3 3 3 3 8 4 2 3 3 7 3 3 1 8 0 3 3 0 6 1 6 1 7 7 
2 3 3 7 7 5 5 3 2 4 1 1 8 1 8 8 4 0 3 2 0 3 7 8 
0 1 2 2 3 0 1 0 0 7 6 5 5 1 0 2 3 0 2 2 3 0 4 7 
4 4 4 7 7 7 6 7 4 6 6 6 0 7 7 4 4 0 3 3 3 6 5 5 
7 7 7 7 7 8 7 7 7 7 7 7 7 0 0 2 2 0 7 7 7 7 7 7 
8 5 8 9 9 9 7 8 7 7 9 9 6 0 9 1 7 9 8 8 1 9 1   
2 1 5 6 8 4 5 4 1 6 4 7 6 6 7     2 3 2 6 2 5 8 
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5 5 5 2 5 5 5 5 6 1 5 7 0 9 7 6 0 0 5 0 0 5 5 5 
6   8 5 8 7 8 7 2 4 7 8 6 0 0 0 0 0 0 0 0 5 5 0 
1 1 3 7 7 9 7 5 3 7 5 7 5 2 8 5 5 0 3 1 0 1 0 1 
8 8 8 9 9 9 1 9 6 8 9 9 0 8 6 6 6 0 6 7 8 9 7 9 
3 3 2 1 1 1 1 1 1 6 6 6 2 1 1 1 1 1 0 6 7 7 7 7 
                                                
3 9 
 
9 9 9 
 
9 4         8 3     4 4   7     2 











































































































































































1 5 5 9 9 7 3 5 3 7 7 6 3 0 0 0 5 0 3 1 0 2 5 3 
1 1 1 1 1 3 6 2 0 1 3 3 5           1 1 1 1 4 4 
3 6 5 9 8 9 9 7 2 3 2 1 0 1 6 7   0 4 2 3 5 3 1 
0 1 2 2 2 2 4 2 0 1 0 0 0 2 0 1 2 0 0 0 0 0 1 3 
5 4 3 7 5 5 4 7 3 7 7 7 0 0 1 0 0 0 1 7 3 3 3 7 
6 7 7 6 9 7 9 9 7 9 9 6 0 0 0 0 2 0 1 4 4 3 6 7 
0 1 2 5 5 4 4 2 1 4 3 4 0 1 0 0 0 0 4 0 0 1 1 0 
0 3 3 3 3 0 4 0 3 3 5 5 0 7 0 0 0 0 0 3 3 1 5 3 
                                                
  4 5 3 5 5 4 4 4 4 7 7 7 1 4 3 4 1 1 1 1 1 5 5 
3 5 6 8 9   5 6 3 5 4 2 1 4 1 0 2 0 0 0 5 0 3 4 
                          
2 1 1 1 2 0 1 3 3 2 3 2 2 1 1 1 1 1 1 1 1 3 2 1 
1 4 0 7 7  4 1 1 0 0 0 1 1 1 1 1 0 0 0 0 1 0 0 
268 
3 3 3 9 9 9 9 9 3 3 1 2 0 3 3 4 0 0 0 0 0 3 3 0 
0 1 0 5 5 3 5 4 3 5 3 1 6 3 4 7 5 1 2 3 2 2 2 3 
3 2 1 8 9 9 9 3 4 5 6 2 0   1 1 0 0 0 0 0 3 4 0 
2 7 2 9 8 7 7 6 5 5 4 3 4 7 2 5 2 0 1 0 0 5 3 3 
0 5 3 0 3 3 0 0 1 3 3 5 0 5 0 5 0 0 1 1 0 3 1 3 
                         
                                                
0 1 0 0 1 2 2 2 1 1 0 0 1 1 0 2 1 1 0 0 0 1 0 0 
1 3 4 9 6 9 9 5 3 5 5 5 4 9 7 7 0 0 2 3 3 3 3 3 
5 6 7 8 7 6 9 7 5 6 7 7 2 6 0 4 3 0 6 6 7 7 6 6 
1 1 0 1 4 7   8 1 2 3 2 7 8 8 8 8 0 3 5 5 0 4 5 
2 2 2 5 4   4 2 1 1 3 2 3 3 4 6 2 0 1 1 2 1 2 2 
5 6 6 9 9 9 9 7 6 6 6 0 2 6 0 4 4 0   1 5 5 6 7 
5 7 7 7 7 7 7 6 3 7 5 5 2 7 3 6 4 1 6 6 6 6 6 6 
1 3 3 8 8 5 5 4 7 4 1 1 7 7 3 4 4 0 4 0 0 8 5 2 
1 4 3 8 9 9 9 2 1 8 6 6 0 2 0 1 1 0 3 7 9 5 7 7 
3 4 7 8 8   5 5 7 7 7 0 8 9 9 9 0 8 4 8 7 7 8 
1 1 1 7 4  3 2 1 0 1 1 0 5 0 5   0 4 1 0 0 0 3 
4 4 3 5 4 3 2 3 5 4 4 4 1 6 7 6 1 3 5 6 6 1 3 6 
1 1 1 3 3 0 0 2 3 0 2 1 0 2 0 5 3 0 1 5 4 1 1 3 
1 1 5 5 6 1 6 2 2 7 2 1 4 1 0 3 1 0 3 3 5 3 6 6 
1 1 6 3 1 1 1 1 1 0 0 0 0 9 3 4 1 8 1 0 0 0 1 1 
0 1 3 2 1 0 3 0 0 8 6 5 5 1 0 2 4 0 2 1 5 0 6 6 
3 3 1 4 7 7 5 8 3 5 7 7 0 7 6 4 4 0 3 5 3 5 5 5 
7 8 8 8 8 9 9 8 8 9 1 1 1 1 3 4 8 8 8 8 8 7 7 7 
5 7 7 7 7 9 9 9 7 7 7 7 3 4 3 7   0 5 6 7 7 9 7 
3 2 2 6 7 3 2 2 3 3 2 6 3 0 5 0 0 0 4 1 2 0 3 6 
269 
5 5 5 5       2 4 6 6 6   1 5   0 0 2 0 0       
3 6 2 4 4 4 5 3 3 4 7 6 5 0 0 4 4 0 0 0 2 2 1 1 
0 3 3 7 7 9 7 6 1 7 5 5 5 3 1 5 5 0 1 3 0 0 3 3 
8 8 8 9 9 8 9 9 6 9 9 9 0 9 3 3 2 0 7 6 7 8 7 9 
2 1 1 1 1 1 1 1 1 5 5 1 0 2 1 1 1 1 3 7 8 7 
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3 3 2 5 5 
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3 6 6 9 8 6 4 4 3 4 3 3 6 0 2 0 4 0 1 0 1 4 3 2 
3 3 5 1 3 3 5 5 1 6 3 3 5               4   4   
3 4 3 9 9 8 9 7 3 2 1 3 0 1 2 4 5 0 2 4 6 6 4 7 
0 0 0 3   2 3 3 1 0 0 0 0 0 0 2 1 0 0 0 0 0 1 1 
3 3 2   3 3 3 4 2 3 3 3 0 0 1 0 0 0 1 1 1 1 1 2 
9 7 7 3 9   6 6 4 7 6 8 1 3 1 1 1 1 2 3 5 7 3 3 
0 1 0 5 3 5 0 0 1 2 2 1 0 2 0 0 0 0 0 0 2 0 3 0 
0 3 3 3 3 0 0 3 5 5 7 7 0 7 0 0 0 0 0 3 3 5 5 5 
                                                
5 4 4 4 3 4 4 4 4 4 4 6 6 0 5 3 2 1 2 2 2 3 3 5 
5 5 7 9 9 7 7 5 2 6 5 1 5 1 3 0 2 0 0 1 5 0 2 2 
                        
2 3 3 2 3 1 3 2 2 6 5 4 7 0 1 1 1 0 1 1 1 1 1 1 
0 1 0 7 5 2 2 1 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 
271 
3 6 6 9 9 9 0 0 3 3 3 3 0 3 1 3 0 0 0 0 0 3 3 0 
1 2 2 5 5 2 3 4 3 5 2 2 3 3 3 5 2 0 2 1 2 2 2 3 
2 2 0 1 8   1     3 3 0 0 1 0 0 0 0 1 1 1 2 0 0 
2 3 3 9 8 6 7 7 6 4 5 5 1 5 1 3 1 0 1 0 0 6 2 2 
5 5 7 5 7 1 0 3 5 7 7 5 0 5 0 7 0 0 1 5 0 7 7 7 
                         
                                                
0 1 0 0 1 1 1 1 0 0 0 0 0 3 0 3 3 0 0 0 0 0 0 0 
2 2 2 2 1 9 9 9 1 9 9 9   5 4   9 9 1 5 0 0 9 9 
6 7 7 8 8 7 9 6 5 5 6 6 2 4 5 2 3 0 5 4 6 7 6 6 
1 2 3 5 4 8 8 5 0 3 5 2 5 3 3 5 5 6 1 2 2 0 1 1 
2 2 2 5 3 5 4 2 1 3 2 2 2 2 3 5 1 0 1 1 1 1 1 1 
3 5 7 9 9 9 9 6 6 5 5 1 3 5 0 4 5 0 1 0 5 6 7 6 
1 3 5 5 5 7 7 4 1 7 6 4 1 1 3 7 7 0 2 2 2 2 2 2 
2 3 3 8 8 7   4 7 4 0 0 7 7 1 3 1 0 4 0 0 9 8 3 
4 9 4 9 9 9 9 3 2 9 7 7 4 1 1 2 2 0 3 6 6 9 7 7 
5 6 7 9  6  5 6 6 6 6 0 6 8 6 5 0 6 3 5 3 7 6 
1 1 1 7 3 2 2 2 1 0 1 1 0 1 0 2   0 5 2 0 0 4 4 
4 5 5 5 5 4 4 4 5 5 5 5 0 4 5 2 2 4 4 6 6 2 3 6 
4 4 1 4 5 3 1 3 4 1 3 3 1 3 1 5 1 0 3 5 4 3 4 4 
4 6 5 5 7 7 6 4 4 7 5 4 3 3 0 2 1 0 5 5 5 4 6 6 
1 1 4 4 4 2 2 2 2 1 1 1 2 5 2 7 5 0 3 0 0 2 4 3 
0 1 1 2 1 0 0 0 0 6 3 3 5 0 0 4 5 0 1 2 3 0 5 6 
                                                
7 7 7 7 7 9 9 6 6 6 7 7 6 0 1 0 0 1 4 7 7 5 6 5 
7 7 7 7 7 7 7 7 7 7 7 7 1 5 5 7 1 3 5 5 7 7 7 5 
1 0 4 5 6 7 3 2 2 2 3 6 0 0 3 0 0 0 3 1 1 0 3 4 
272 
                                                
1 2 2 2 1 1 1 1 1 3 3 2 0 0 0 1 0 0 0 0 0 1 0 0 
1 3 3 9 7 7 7 6 1 5 5 5 5 1 1 5 5 0 0 0 0 0 0 0 
8 8 8 9 9 9 9 9 6 9 9 9 0 8 0 4 4 0 7 7 9 8 8 9 
                                                
3 2 2   6     3 2 3 3 4 4 2 2 2 2 0 1 1 2 3 3 2 
3 9 
 
9 9 9 
 
9 4         8 3     4 4 6 9 
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5 5 7 8 8 5 5 6 3 7 6 6 1 1 0 1 1 0 1 0 0 5 5 4 
3 1 4 4 4 4 4 2 1 1 2 2 3             1 2       
3 4 6 9 8 8 9 8 4 4 2 3 1 1 6 2 1 0 2 3 4 5 4 6 
                                                
3 4 3 3 3 4 3 4 2 5 5 5 0 0 0 0 0 0 3 3 3 3 3 3 
9 9 9 3 9 9 9 4 3 7 7 9 0 0 0 1 1 0 1 4 4 5 6 6 
0 0 1 4 4 5 1 0 1 1 1 1 0 1 0 0 1 0 0 0 0 1 1 0 
0 3 3 3 3 0 3 0 3 5 5 5 0 7 0 0 0 0 0 3 3 0 3 3 
                                                
5                                               
5 3 5 8 9 7 7 7 2 4 2 1 1 1 1 0 5 0 0 0 5 0 2 3 
                        
2 2 1 2 3 1 2 2 2 6 2 2 0 0 0 0 0 0 2 2 1 3 3 2 
0 1 0 2 4 1 1 0 0 0 0 0 0 2 0 0 1 0 0 0 0 0 1 1 
274 
4 3 4 9 9 9 9 9 3 3 3 3 0 2 3 2 0 0 0 0 0 3 3 0 
2 2 2 5 5 2 3 5 3 3 1 1 3 2 3 3 2 0 1 1 2 1 2 2 
5 4 8 8 8 9 3 4 5 5 6 5   8 3 6     4 3 0 0 3 3 
5 7 2 9 8 7 7 5 5 3 3 3 3 6 1 5 0 0 2 1 0 7 5 2 
2 0 3 7 9 3 0 7 7 7 7 7 0 3 0 7 5 0 3 7 7 7 7 7 
                         
                                                
1 0 0 0 1 3 2 1 1 1 0 0 0 2 0 3 3 0 0 0 0 2 0 0 
                           
5 6 6 7 8 6 9 5 5 5 5 5 0 0 5 5 3 0 6 6 6 6 6 6 
1 0 3 3 4 6 7 5 0 3 2 1 5 5 1 5 5 0 4 3 1 0 4 1 
3 4 4 4 4 4 4 4 2 3 3 2 1 4 4 4 6 1 4 1 2 3 4 2 
4 5 4 7 9 8 9 7 6 5 3 3 6 6 0 2 6 0 0 0 5 5 5 0 
2 2 2 5 5 7 7 7 1 4 4 4 1 0 1 2 2 0 1 2 2 1 1 1 
0 1 3 7 8 4 8 4 8 4 1 1 6 6 4 6 6 0 5 0 0 8 5 3 
                                                
4 5 6 2 6 0 0 5 4 5 7 5 0 6 8 6 6 0 2 2 4 4 5 5 
0 1 1 7 3 2 2 2 1 0 1 1 0 1 0 2   0 2 2 0 0 2 1 
5 5 5 6 6 5 4 3 6 5 5 5 2 6 5 6 2 4 4 5 4 2 3 5 
3 1 0 1 4 1 1 3 2 1 1 2 1 3 0 5 1 0 2 5 5 4 5 5 
1 2 3 4 5 1 4 2 2 4 4 2 5 0 0 1 0 0 2 2 2 2 2 2 
1 1 5 6 5 4 4 1 2 2 1 1 1 5 1 6 3 0 1 0 0 0 2 2 
0 1 2 2 1 0 0 0 0 7 5 6 5 0 5 2 5 0 4 2 3 3 7 7 
3 3 4 7 7 7 7 7 4 4 7 7 0 7 7 4 4 0 3 3 2 5 5 5 
6 7 7 6 6 8 8 5 6 6 6 6 2 0 0 0 0 0 5 6 6 6 6 6 
6 6 6 9 7 9 9 9 7 8 8 8 3 6 3 6 6 0 6 2 6 7 7 7 
3 1 5 7 8 3 1 2 3 3 2 5 2 0 7 0 1 0 1 5 5 2 2 5 
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2 3 2 3 3 3 2 3 2 2 4 4 2 0 0 0 0 0 1 0 0 2 0 0 
1 1 1 7 7 7 7 5 1 5 5 7 1 2 0 3 3 0 0 0 0 0 0 0 
7 7 7 9 9 8 9 5 8 9 9 0 8 0 4 4 0 0 5 6 8 8 7 8 
                                                
3 2 3                     2 5       2 4 6   4 4 
3 9 
 
9 9 9 
 



















































































































































































4 6 6 7 7 6 4 5 3 6 6 4 1 1 0 1 4 0 1 0 1 4 1 1 
2 1 4 4 2 2 4 1 1 1 2 2                         
3 6 3 9 9 9 9 7 3 1 0 2 0 9 8 9   0 3 2   8 4 0 
  2 2 2 2 0 2 3 0 1 3 3 0 1 0 1 1 0 1 3 3 2 2 2 
3 3 3 4 4 3 3 3 1 3 3 3 0 0 0 0 0 0 2 3 2 3 3 3 
9 9 9 3 8 9   7 6 7 7 7 0 0 0 0 0 0 0 3 3 3 2 4 
1 0 0 4 2 5 1 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
0 3 3 3 3 0 3 0 3 5 5 5 0 7 0 0 0 0 0 3 3 3 5 5 
                                                
3 4 3 4 3 4 4 4 3 3 3 3 1 2 3 2 1 1 1 1 1 4 4 2 
3 4 5 8 9 6 6 7 2 4 4 3 1 2 1 0 5 0 0 0 4 0 2 2 
                        
1 2 1 1 2 1 3 1 3 6 3 2 0 0 1 0 0 0 1 1 0 1 1 1 
0 0 0 2 2 3 1 0 1 0 0 0 0 4 0 0 1 0 0 0 0 0 0 0 
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3 2 2 9 9 9 9 9 3 3 3 3 0 3 5 2 2 0 0 0 5 4 5 0 
4 4 3 5 5 2 3 3 5 3 1 1 1 1 3 1 3 1 1 1 1 1 1 2 
2 2 5 8 7 9   3 3 5 3 4 0 2 2 3   0 3 4 0 0 4 3 
3 4 4 9 8 5 7 5 6 5 5 5 2 5 0 5 1 0 2 0 1 5 5 5 
5 1 1 3 7 3   3 3 5 5 3 0 5 0 7 0 0 7 7 7 7 7 7 
                           
                                                
0 1 1 1 2 2 2 1 0 1 0 0 2 2 0 2 1 0 0 0 0 2 0 0 
                        5 6 5 8 8 7 9 5 4 5 6 6 0 1 0 5 4 0 4 5 5 5 5 5 
0 0 1 1 2 5 5 1 0 4 1 0 0 3 0 3 1 0 0 0 0 1 1 1 
2 1 0 5 2 2 4 2 1 2 4 2 2 3 5 5 1 0 1 0 2 2 3 1 
4 5 7 9 9 9 9 7 7 3 9 3 0 7 0 3 3 0 6 6 6 9 7 5 
                                                
2 3 3 7 8 5 7 3 5 3 0 0 7 7 1 7 1 0 4 0 0 7 4 0 
                                                
4 5 7 8 7 9 0 5 5 7 8 6 0 7 7 7 7 0 5 5 7 5 6 6 
0 1 0 7 3 2 2 1 0 0 0 0 0 1 0 1   0 2 2 0 0 2 1 
4 5 4 4 4 4 3 3 5 4 4 3 0 3 6 3 2 4 1 4 4 0 4 4 
3 1 1 2 4 1 1 3 2 2 1 2 1 5 0 6 1 0 3 7 5 4 5 6 
1 2 3 2 6 4 4 1 2 5 3 2 3 1 0 0 0 0 2 2 3 2 4 4 
1 1 7 4 2 2 2 1 2 1 1 1 0 1 0 4 7 0 1 0 0 0 0 0 
0 0 1 1 1 0 0 2 0 6 3 4 5 3 7 5 4 5 3 0 0 0 5 5 
3 4 4 7 7 7 5 7 3 5 7 7 0 7 7 3 3 0 3 5 4 4 6 7 
                                                
5 5 5 9 6 8 8 8 8 6 6 6 0 0 7 8 8 0 7 7 7 6 7 7 
2 0 4 5   4 2 2 2 1 1 4 1 0 4 0 0 0 3 2 3 2 3 4 
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2 1 1 0 0 1 0 0 0 0 0 1 2 0 0 0 0 7 0 0 0 0 0 0 
1 3 2 3 2 2 1 1 1 2 4 4 0 0 0 0 0 0 0 0 0 2 0 0 
1 1 5 8 8 8 8 5 1 5 5 5 1 0 0 3 5 0 0 1 0 0 0 0 
8 9 8 9 9 7 8 7 5 8 9 9 0 70 3 4 0 4 6 8 8 7 9 8 
                                                
3               4         2 1         3 3   5 5 
3 9 
 
9 9 9 
 
9 4         8 3 
  
4 4 7 9 
  
2 
4 4 4 4 4 4 4 5 5 4 4 4 4 4 5 5 5 5 3 3 2 2 2 2 
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Appendix 9 – Univariate Analysis Study IV – Step by Step 
analysis 
Variable Value Std.Error p-value  
(Intercept) 22.269808 3.1779737 P<0.001 
parent 2.110164 0.9021045 0.02005 
 
Variable Value Std.Error p-value  
(Intercept) 25.2866675 3.5179010 P<0.001 
greeting 0.7561233 0.8154401 0.35461 
 
Variable Value Std.Error p-value  
(Intercept) 24.3918211 3.505568 P<0.001  
comfort 0.8077814 0.814360 0.32213  
 
Variable Value Std.Error p-value  
(Intercept) 28.2817628 4.1137820 P<0.001  
friends -0.1644126 0.6670985 0.80551  
 
Variable Value Std.Error p-value  
(Intercept) 26.5936344 4.4251636 P<0.001  
social_rules 0.1853427 0.7029702 0.79224  
 
Variable Value Std.Error p-value  
(Intercept) 26.4239013 3.7849563 P<0.001  




Variable Value Std.Error p-value  
(Intercept) 24.4134058 3.8184330 P<0.001  
verbal_instructions 0.7664847 0.7780968 0.32547  
 
Variable Value Std.Error p-value  
(Intercept) 26.044005 3.6641116 P<0.001  
eye 0.518118 0.9218233 0.57454  
 
Variable Value Std.Error p-value  
(Intercept) 17.63134 3.9223333 P<0.001  
repetitive 2.58051 0.7736294 0.97009  
 
Variable Value Std.Error p-value  
(Intercept) 20.156811 3.7824729 P<0.001  
sameness 2.056389 0.7850955 0.00931  
 
Variable Value Std.Error p-value  
(Intercept) 18.202121 3.4942286 P<0.001  
routine 2.905437 0.7995067 0.00033  
 
Variable Value Std.Error p-value  
(Intercept) 27.0713582 2.6718799 P<0.001  
Diarrhoea -0.1301251 0.7815099 0.86789  
 
Variable Value Std.Error p-value  
(Intercept) 31.735587 3.4218727 P<0.001  
Constipation -1.119046 0.6954069 0.10875  
 
281 
Variable Value Std.Error p-value  
(Intercept) 27.0656649 2.9488893 P<0.001  
Appetite 0.3348045 0.7486577 0.65509  
 
Variable Value Std.Error p-value  
(Intercept) 31.940579 3.4610308 P<0.001  
Bloating -1.307219 0.7600441 0.08663  
 
Variable Value Std.Error p-value  
(Intercept) 28.326840 2.8242489 P<0.001  
Flatulence -0.691903 0.8504919 0.41670  
 
Variable Value Std.Error p-value  
(Intercept) 26.757117 2.350903 P<0.001  
Vomiting 1.074328 1.262311 0.39550  
 
Variable Value Std.Error p-value  
(Intercept) 25.6661145 3.015553 P<0.001  
Unhappy 0.9952029 1.070505 0.35339  
 
Variable Value Std.Error p-value  
(Intercept) 24.939714 2.9679088 P<0.001  
Aggressive 1.131391 0.8934463 0.20649  
 
 
Variable Value Std.Error p-value  
(Intercept) 25.4818082 2.9900487 P<0.001  
Destructive 0.7490692 0.8208432 0.36230  
282 
 
Variable Value Std.Error p-value  
(Intercept) 24.009535 3.2516380 P<0.001  
Non_Interactive 1.153383 0.7934077 0.14723  
 
Variable Value Std.Error p-value  
(Intercept) 23.307871 3.9876881 P<0.001  
Agitated 1.102448 0.9121076 0.22786  
 
Variable Value Std.Error p-valuee  
(Intercept) 20.30515 3.6454420 P<0.001  
Disagreeable 2.13007 0.8213322 0.01003  
 
Multivartiate Analysis Study IV – Step by Step analysis 
Variable Value Std.Error p-value  
(Intercept) 22.9931883 4.8535384 P<0.001  
parent 1.2828019 1.1471293 0.26452  
repetitive 1.2848881 1.2489797 0.30459  
sameness -2.4204905 1.6967762 0.15496  
routine 3.6855561 1.5960845 0.02175  
Constipation -1.2326576 0.8615343 0.15374  










Variable Value Std.Error p-valuee  
(Intercept) 22.894636 4.023740 P<0.001  
Routine 3.226851 0.813211 0.00009  
Constipation -1.584028 0.69109  0.02269  
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Appendix 10 – Loss of Samples for Lactoferrin Analysis 
All biochemical analysis of samples was performed by the Department of Clinical 




A large number of lactoferrin samples went missing due to a clerical error at the 
Department of Clinical Biochemistry, King’s College Hospital, London, the 
institution responsible for storing and analysing the samples in this thesis. For 
this reason, the number of subjects included in the lactoferrin analysis was 
smaller than for calprotectin or M2-PK. 
 
 
